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ABSTRACT 
Endosomal sorting complex required for transport (ESCRT) machinery 
responsible for multivesicular body (MVB) biogenesis is essential for receptor 
downregulation, viral budding and cytokinesis. ESCRT-III is a large polymer built from 
related ESCRT-III proteins that is thought to help generate intralumenal vesicles (ILVs) 
within the MVB. How ESCRT-III functions is poorly understood. Although ESCRT-III 
assembles on the endosomal membrane, its components are predominantly soluble in 
the cytoplasm. I found that the transition between these two states is controlled by 
autoinhibitory domains within ESCRT-III proteins, which I identified by structure/ function 
analysis in four human ESCRT-III proteins – Charged multivesicular body protein2A 
(CHMP2A), CHMP3, CHMP4A, and CHMP6. Biochemical and functional assays 
confirmed that the C-terminally located autoinhibitory domains control cycling between a 
“closed” state in which they are soluble monomers and an “open” state in which they 
assemble into membrane associated complexes.  While searching for cellular factor(s) 
that might regulate transition between these states, I found that LIP5, a proposed 
cofactor of the ATPase VPS4, binds efficiently to the autoinhibitory domains of a subset 
of ESCRT-III proteins including CHMP1B, 2A and 3. Because VPS4 disassembles 
ESCRT-III complexes, this direct interaction between its cofactor LIP5 and ESCRT-III 
proteins can enhance VPS4 mediated ESCRT-III disassembly. To ask when and how 
individual ESCRT-III proteins and VPS4 contribute to ILV formation in cultured cells, I 
established reagents to detect and manipulate these proteins including antibodies and 
effective small interfering RNAs. I used these tools to show that representatives of two 
classes of cell surface receptors, epidermal growth factor receptor (EGFR), a tyrosine 
kinase receptor and delta-opioid receptor (DOR), a G-protein coupled receptor, use 
ESCRT-III and VPS4 to undergo downregulation via lysosomal degradation. Taken 
 x
together, the studies in this thesis provide insights into the role and regulation of 
ESCRT-III in MVB biogenesis.  
 
 xi
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CHAPTER ONE 
 
INTRODUCTION 
 2 
1. Membrane trafficking pathways 
1.1 Intracellular compartments 
Eukaryotic cells contain highly specialized membrane-bound compartments (or 
organelles) essential for fundamental cellular processes. These include the nucleus, the 
endoplasmic reticulum (ER), the Golgi apparatus, endosomes, lysosomes, peroxisomes, 
mitochondria, chloroplasts (plant only) and a variety of transport vesicles (1). Each 
membrane-bound organelle has a unique set of proteins and lipids; at the same time, it 
dynamically exchanges materials with other organelles. Therefore, cells have developed 
specific transport mechanisms to selectively transfer materials to different compartments 
while maintaining the identity of the individual organelles (2, 3). Intracellular membrane 
trafficking occurs via two main pathways - the biosynthetic-secretory pathway (outbound) 
and the endocytic pathway (inbound) (Fig. 1-1). Transport at each step of both pathways 
requires highly regulated multi-step processes in which numerous proteins and lipids 
participate. The critical steps include concentrating a specific set of cargo proteins, 
generating transport vesicles by coat proteins, packaging cargo into the vesicles, 
transporting these vesicles between compartments, and fusion between vesicles and 
target membranes (2, 3).  
 
1.2 The secretory pathway 
The secretory pathway is involved in secreting proteins out of cells or and 
delivering newly synthesized proteins to the plasma membrane (Fig. 1-1). Newly 
synthesized proteins from ribosomes are first incorporated into the lumen or membranes 
of the ER and scrutinized by quality control processes. Correctly folded proteins are 
packaged into coat protein complex II (COPII) coated vesicles and delivered to the ER-
Golgi intermediate compartment (ERGIC) (2-4). The COPII coat consists of the small 
GTPase Sar1p and the coatomer complex (Sec23/24 and Sec13/31). Activated Sar1p 
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recruits soluble coat complexes onto the membrane which initiate membrane 
deformation to generate vesicles (5). Proteins leaving the ERGIC are transported 
through the Golgi apparatus (cis, medial and trans Golgi) and finally arrive in the trans-
Golgi network (TGN), where they are sorted into secretory granules targeted to either 
plasma membrane or endosomes (2, 3).  
Resident proteins in the secretory pathway sometimes escape from their own 
compartments but can be retrieved by retrograde transport which is mediated in most 
cases by COPI coated vesicles. Similar to COPII, the COPI coat consists of a coatomer 
complex and the small GTPase, ADP-ribosylation factor (Arf)1. The coatomer complex 
contains !-, "-, "’-, #-, $-, %-, and &- COP. Activated Arf1 binds membranes and recruits 
the coatomer complex which provides a mechanical force for membrane deformation as 
it polymerizes on the membrane surface (6). '
 
1.3 The endocytic pathway  
The endocytic pathway is the inward membrane trafficking pathway from the 
plasma membrane to the lysosome (Fig. 1-1). As endocytic compartments mature, their 
lumenal pH becomes progressively lower. The lysosome, a final destination of the 
endocytic pathway, has the lowest pH (pH 4-5) and contains hydrolytic enzymes that are 
active at the low pH and degrade internalized materials (2, 7).  
Cells internalize material from outside the cell or the cell surface by several 
distinct mechanisms: clathrin-mediated endocytosis (including most receptor mediated 
endocytosis), caveolar endocytosis, clathrin- and caveolin-independent endocytosis, 
macropinocytosis (cell drinking) and phagocytosis (cell eating) (8). The most well 
understood endocytic process is clathrin dependent endocytosis of receptors. In this 
process, a specific receptor on the plasma membrane binds to a ligand and then both 
are internalized via clathrin coated pits, which progress to form clathrin coated vesicles 
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(7, 9). Clathrin is a large protein composed of three heavy and three light chains, and 
self-assembles to form a basket-like clathrin lattice. The clathrin lattice serves as a 
scaffold to generate vesicles from the plasma membrane as well as the TGN and 
endosomes. Clathrin is recruited to the membrane by various adaptor proteins which 
bind to the cytoplasmic domains of transmembrane proteins (e.g. surface receptors). For 
example, clathrin coated vesicles from the plasma membranes are generated by clathrin 
together with adaptor protein 2 (AP2) (10, 11).   
Once clathrin coated vesicles pinch off from the plasma membrane, they lose 
their coats and fuse with early endosomes. Many ligands internalized by receptor-
mediated endocytosis dissociate from their receptors in early endosomes as a 
consequence of the lower pH in these compartments. Once ligands have disassociated, 
unoccupied receptors are often recycled back to the plasma membrane (7, 12). There 
are two distinct subpopulations of early endosomes– the sorting endosome and 
endocytic recycling compartments (ERC). Some molecules are delivered directly back to 
the plasma membrane from the sorting endosome (fast recycling), while others are 
delivered to a long-lived organelle, the ERC, before recycling to the plasma membrane 
(slow recycling) (Fig.1-1). Both the sorting endosome and the ERC can communicate 
with the TGN. Sorting endosomes remove recycling proteins by concentrating them in 
vesicles that bud from their tubular domains. As sorting endosomes mature into late 
endosomes, they move from the cell periphery to the center, and gradually become 
more spherical. Mature late endosomes no longer directly communicate with the plasma 
membrane, but still exchange proteins with the TGN (12, 13). Maturation from early to 
late endosomes is accompanied by the formation of intralumenal vesicles (ILVs), leading 
them to also be called multivesicular bodies (MVBs). Late endosomes/MVBs eventually 
become lysosomes by fusing with preexisting lysosomes (7, 14, 15).  
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1.4 Different routes in the endocytic pathway 
Different proteins take different routes in the endocytic pathway. For example, 
transferrin receptor (TfR) bound to transferrin is endocytosed by receptor-mediated 
endocytosis, releases iron in the early endosome, and returns to the cell surface as a 
transferrin-bound form without iron. Low-density lipoprotein (LDL) receptor dissociates 
from its ligand, LDL, in the endosome and is recycled back to the plasma membrane as 
an unoccupied receptor (7). TGN38, a protein enriched in the TGN, continuously cycles 
between the TGN and the plasma membrane via the ERC. Mannose-6-phosphate 
receptor (M6PR) cycles between the TGN and late endosome, releasing lysosomal 
enzymes in the acidic milieu of the late endosome (7, 13). Some receptors bound to 
ligands are not recycled efficiently, but instead are delivered into ILVs of the MVB and 
eventually to the lysosome where they are degraded. One of the best studied receptors 
in this context is epidermal growth factor receptor (EGFR). EGFR is a receptor tyrosine 
kinase and an important regulator of cell proliferation, angiogenesis, migration and 
tumorigenesis (16). Lysosomal delivery of a signaling receptor functions to terminate 
signaling, thereby preventing cells from inappropriately responding to signal input until 
new receptors are synthesized (7, 17, 18).  
 
2. Molecular mechanism for multivesicular body biogenesis 
2.1 The multivesicular body (MVB) 
The MVB is an intermediate endosome en route to the lysosome which was 
originally identified in early electron microscopy studies in the 1950s as a unique 
membranous structure with internal vesicles (19, 20). The MVB is characterized by 
proteins and lipids including Rab7, CD63 and lysobisphosphatidic acid (LBPA) which 
distinguish it from other organelles with internal membranes such as the autophagic 
body (21, 22). The MVB in yeast is a spherical structure with a diameter of ~200nm filled 
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with ~24nm ILVs (23). In mammalian cells, the MVB with a diameter of 400-500nm 
contains 50-100nm ILVs (15, 24, 25).   
The MVB plays critical roles in various cellular functions. Sorting into the MVBs 
followed by delivery to the lysosome serves as a major mechanism for degrading   
transmembrane proteins and lipids (18, 21). Transmembrane proteins destined for 
lysosomal degradation are first sorted into the limiting membrane of the endosome, 
which is subsequently invaginated into the endosomal lumen to form ILVs. Proteins and 
lipids in the ILVs are eventually degraded by lysosomal hydrolases inside the lysosome.  
Sorting ligand-activated receptors into MVB vesicles function to sequester the 
receptor, thus abgorating signal transduction. Some newly synthesized proteins are also 
sorted into ILVs of the MVB as part of the process delivering them to the lysosome (21, 
26, 27). Finally, in certain cells, the MVB can fuse with the plasma membrane to release 
ILVs into the extracellular space. These secreted vesicles are called exosomes and are 
important for intercellular communication and some aspects of the immune response 
(28).  
An intriguing feature of MVB vesicle formation is the topology of budding. To 
generate MVB vesicles, the limiting membrane must invaginate into the lumen of the 
endosome (21). This process requires generating negative curvature from the 
cytoplasmic side (i.e. budding away from the cytoplasm), which is opposite from the 
curvature involved in COP- and clathrin-mediated vesicle formation. COPs or clathrin 
proteins bind to the cytoplasmic side of the membrane and induce positive membrane 
curvature (i.e. budding towards the cytoplasm) to generate vesicles (29). Therefore, 
MVB vesicle formation requires a budding mechanism distinct from those for formation 
of other cytoplasmic vesicles.  
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2.2 Ubiquitin as a sorting signal to MVB 
The most well-defined signal for sorting transmembrane proteins (cargo) to the 
MVB is ubiquitination (26, 27). Ubiquitin is a 76 amino acid protein which is covalently 
attached to proteins through the formation of an isopeptide bond between the C-
terminus of ubiquitin and the !-amino group of lysine residues on target proteins.  
Ubiquitin itself contains seven lysine residues that can serve as acceptor sites for 
additional ubiquitin molecules (30). Polyubiquitin chains can be generated by attachment 
of the C-terminus of one ubiquitin to lysine 48 or lysine 63 of the adjacent ubiquitin. 
Proteins with polyubiquitin chains linked at lysine 48 are efficiently targeted to 
proteasomes for degradation. Attachment of a single ubiquitin (monoubiquitin), multiple 
monoubiquitins or polyubiquitin linked at lysine 63 acts as a signal for endocytosis and/or 
MVB sorting (26, 27).  
The attachment of ubiquitins to substrate proteins is carried out by the sequential 
activity of three enzyme classes: E1 (ubiquitin-activating enzyme), E2 (ubiquitin-
conjugating enzyme), and E3 (ubiquitin ligase). The E3 ubiquitin ligase provides 
specificity to the reaction by recognizing substrate proteins. The E3 ubiquitin ligases are 
subdivided into two classes containing either a HECT (homologous to E6-AP C-
terminus) domain or a RING (really interesting new gene) finger domain (30). Among 
different E3 ligases, Nedd4 E3 ligases, a subfamily of HECT E3 ligases are notably 
involved in MVB sorting. Rsp5 is the only Nedd4 ligase in yeast and is required for 
sorting of Sna3 and carboxypeptidase S (CPS) into the MVB (31, 32). In mammalian 
cells, AIP4, a Nedd4 ligase, was shown to be essential for lysosomal degradation of the 
chemokine receptor CXCR4, a G protein-coupled receptor (GPCR) (33). RING E3 
ligases also contribute to MVB sorting: c-Cbl in mammalian cells is essential for 
lysosomal degradation of EGFR, whereas Tul1 in yeast is involved in sorting CPS to the 
MVB (34, 35).  
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Deubiquitinating enzymes are proteases that cleave the isopeptide bonds 
between two ubiquitins or between ubiquitin and a substrate protein (30). Several 
deubiquinating enzymes function during cargo sorting into the MVB, presumably 
allowing for recycling of ubiquitin. These include Doa4 in yeast, AMSH (associated-
molecule with the SH3 domain of STAM), and UBPY (ubiquitin specific processing 
protease Y) in mammalian cells (36). Deubiquitinating enzymes are recruited to the 
endosome by interaction with proteins responsible for MVB biogenesis, which will be 
described in the next section.  
 
2.3 Protein machinery responsible for MVB biogenesis 
Elegant genetic screens in S. cerevisiae identified proteins involved in MVB 
biogenesis as a subset of vacuolar protein sorting (Vps) proteins, termed the class E 
Vps proteins (37). Functional loss of any of the class E Vps genes in yeast results in 
accumulation of enlarged prevaculoar compartments lacking internal vesicles, called 
class E compartments, and defects in delivering cargo to the endosomal and ultimately 
vacuolar lumen (38, 39). Class E Vps proteins are conserved throughout eukaryotes 
(Table 1-1). In mammalian cells, these proteins are also important for other topologically 
related budding processes including viral budding and cell abscission during cytokinesis 
(Figure 1-2) (40). Most class E Vps proteins assemble to form four separate protein 
complexes - Endosomal Sorting Complex Required for Transport-0 (ESCRT-0), ESCRT-
I, ESCRT-II and ESCRT-III (Table 1-1 and Fig. 1-3). In the current model, ESCRTs in 
the cytoplasm are thought to be sequentially recruited to the endosomal membrane 
where they act together to sort ubiquitinated cargo and generate ILVs (39, 41) (Figure 1-
3). ESCRT-0, I and II complexes can be purified in vitro with defined stoichiometry, and 
their structures have been mostly described based on high resolution structural studies 
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(22, 40, 42). Less is known about the nature of ESCRT-III complex, which will be 
discussed in more detail in Section 3.   
 
2.4 Roles of lipids in MVB biogenesis 
In addition to protein machinery, some phosphoinositides - phosphorylated 
derivatives of phosphatidylinositol - are important for MVB biogenesis. 
Phosphatidylinositol 3-phosphate (PI(3)P) is concentrated on the early endosome and 
also found on internal MVB membranes. (43, 44). The class III PI 3-kinase, Vps34 
produces PI3P, and functional loss of yeast and human Vps34 results in missorting of 
cargo and impairing formation of internal vesicles in MVBs (45, 46). Another endosomal 
phosphoinositide, phosphatidylinositol 3,5 bisphosphate (PI(3,5)P2), has also been 
implicated in MVB biogenesis. This phosphoinositide is generated through the 
phosphorylation of PI(3)P by the PI(3)P 5-kinase PIKfyve and Fab1 in mammals and 
yeast, respectively. Inhibiting function of these enzymes causes accumulation of 
abnormal MVBs and missorting of cargo (47-50).  
One major contribution of phosphoinositides to MVB biogenesis is recruiting 
ESCRT machinery to endosomes. For example, Hrs/Vps27 (ESCRT-0) contains a FYVE 
domain that specifically binds to PI(3)P, and the GLUE domain in Vps36/Eap45 
(ESCRT-II) can bind to several phospinositides (51-56). Components of ESCRT-III, 
CHMP3 and CHMP4A, were shown to have a weak specificity to PI(3,5)P2 (57, 58).   
Some lipids are proposed to more directly contribute to ILV formation. 
Lysobisphosphatidic acid (LBPA) is an inverted, cone-shaped phospholipid that is 
concentrated on the MVB in mammalian cells and can promote formation of MVB-like 
structures in vitro (59, 60). This lipid, however, has not been found in yeast (38). 
Because MVB biogenesis is highly conserved throughout eukaryotes, LBPA may not be 
a major mechanism facilitating MVB vesicle formation. Ceramide, another cone-shaped 
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lipid, was recently shown to be required for generating ILVs containing proteolipid 
protein (PLP) which are secreted as exosomes (61). Spontaneous formation of ILVs is 
triggered by ceramides which are generated by addition of sphingomyelinase to 
sphingomyelin-containing giant unilamellar vesicles (GUV). Furthermore, inhibition of 
ceramide synthesis in cells blocks sorting of PLP to the endosomal lumen and greatly 
reduces release of PLP-containing exosomes (61).  
 
2.5 Roles of ESCRT machinery in cargo sorting and MVB vesicle formation 
The current model for how the ESCRT machinery operates to sort cargo and 
generate ILVs is depicted in Figure 1-3 (39). In detail, ESCRT-0 is first brought to the 
endosomal membrane through interactions with membranes and ubiquitinated cargo. 
ESCRT-0 recruits both ESCRT-I and ESCRT-II to the endosomal membrane. ESCRT-II 
in turn recruits ESCRT-III, which engages the deubiquitinating enzymes that remove 
ubiquitin from cargo and the ATPase Vps4 that disassembles ESCRTs (39). The ESCRT 
machinery probably dissociates from membranes before MVB vesicles pinch off 
because ESCRT proteins are not present in high copy number in exosomes, viral 
particles or MVB vesicles (62, 63).  
The model assumes that ESCRTs act sequentially; in other words, that ESCRT-0, 
I, II and III assemble in a specific order and hand off ubiquitinated cargo to the next 
ESCRT. For this reason, this model is often called the conveyor belt model (64, 65). 
There are numerous structural and interaction data that support this model. First, 
ESCRTs can interact directly with other ESCRTs. Briefly, Hrs/Vps27 (human name/yeast 
name; ESCRT-0) contains the P(S/T)AP motif that binds to the ubiquitin E2 variant 
(UEV) domain of Tsg101/Vps23 (ESCRT-I) (66-68). The C-terminal domain of 
Vps28/VPS28 (ESCRT-I) interacts with the N-terminus of Vps36/Eap45 (ESCRT-II) 
while Vps25/EAP20 (ESCRT-II) binds to the N-terminus of Vps20/CHMP6 (ESCRT-III) 
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(69-72). These data explain how upstream ESCRT can recruit the next downstream 
ESCRTs.  
Second, components of ESCRTs interact with specific phosphoinositides 
concentrated on the endosomal membrane as described in Section 2.3, explaining how 
the machinery is directed to endosomes. Finally, ESCRTs can interact with ubiquitin on 
cargo (Table 1-1). Vps27/Hrs (ESCRT-0) and Vps23/Tsg101 (ESCRT-I) bind to ubiquitin 
via their ubiquitin interacting motif (UIM) and UEV respectively (73-76). In addition, 
Vps36/Eap45 (ESCRT-II) can interact with ubiquitin via their NZF or GLUE domain (77, 
78) (Fig. 1-3). Unlike upstream ESCRTs, ESCRT-III does not contain ubiquitin binding 
motifs. Therefore, cargo may be fully committed to the MVB sorting pathway by the time 
it arrives at ESCRT-III. The idea of sequential recruitment of ESCRTs in the conveyor 
belt model is largely based on yeast genetic data. Briefly, overexpression of ESCRT-II in 
S. cerevisiae compensates for loss of ESCRT-I while ESCRT-I and II are required for 
appropriate assembly of ESCRT-III (79, 80).  
Although most data available are consistent with this model, there are some data 
that do not agree with it. For example, ESCRT-I can be directly connected to ESCRT-III 
without ESCRT-II, which does not fit the sequential recruitment model. Vps28/VPS28 
(ESCRT-I) binds to Vps20/CHMP6 (ESCRT-III), and Alix, an adaptor protein in 
mammalian cells, may bridge Tsg101 (ESCRT-I) to CHMP4 (ESCRT-III) (81-83). 
Furthermore, although there is evidence for the sorting of ubiquitinated cargo by 
ESCRTs, the data do not necessarily support “sequential transfer” of ubiquitinated cargo. 
Finally, yeast genetic data supporting sequential recruitment of ESCRTs were obtained 
using mutants lacking MVB function, and therefore, whether ESCRTs are sequentially 
recruited under physiological conditions remains unclear. To solve these issues, an 
alternative model has been proposed: ESCRTs could co-assemble around cargo (39, 64, 
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84). However, it should be noted that the current and alternative models are not mutually 
exclusive because ESCRTs might be clustered after they are sequentially recruited.   
Once ESCRTs concentrate ubiquitinated cargo on the microdomain of the 
limiting membrane, they are thought to generate vesicles that contain the cargo. How 
ESCRTs drive ILV formation is one of the important questions yet to be answered in the 
ESCRT field. Current thinking is that ESCRT-III subunits may assemble into an array or 
lattice on the endosomal membrane and thus provide a driving force to generate ILVs 
(39, 41, 85, 86).  
 
2.6 Non-endosomal functions of ESCRT machinery - viral budding and cytokinesis  
At least part of the ESCRT machinery is important for viral budding from the cell 
surface, which is topologically equivalent to MVB vesicle formation (40, 87, 88) (Fig 1-2). 
The most extensively studied virus in this context is human immunodeficiency virus 
(HIV) that causes acquired immunodeficiency syndrome (AIDS). In fact, the involvement 
of the ESCRT machinery in the budding of HIV has been a major motivation for pursuing 
ESCRT research. The sequences in the C-terminal region of Gag protein (a structural 
protein of retroviruses) are required for efficient viral particle release, and these 
sequence motifs were termed the late domain because virus assembly arrested at a late 
stage when mutated (88, 89). The late domain of HIV Gag protein interacts with Tsg101 
(ESCRT-0) and Alix via its PS/TAP motif and LYPXP motif, respectively (82, 90-92). 
Both Tsg101 and Alix likely engage ESCRT-III and Vps4 to complete viral budding. 
ESCRT-I, which contains Tsg101, probably recruits ESCRT-III via ESCRT-II or perhaps 
direct interaction with ESCRT-III (87-89). Virus interaction with Alix can be used to 
recruit ESCRT-III since Alix binds directly to a component of ESCRT-III, (93, 94).  
Viral budding is an attractive therapeutic target distinct from other conventional 
drug targets, and therefore there have been efforts to develop drugs to interfere with 
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interaction between ESCRTs and HIV Gag protein. In fact, a recent report has identified 
a cyclic peptide which disrupts the Gag-Tsg101 interaction, and thereby effectively 
reduces virus release without compromising normal endocytic function in cells (95). 
In mammalian cells, ESCRT machinery is also essential for the abscission step 
during cytokinesis, another budding process topologically equivalent to MVB vesicle 
formation (40) (Fig 1-2). For cytokinesis, ESCRT machinery is recruited through the 
interaction of centrosome protein 55 (Cep55) with Tsg101 or Alix that occurs at 
midbodies (96, 97). Whether Cep55 interacts with Tsg101 or Alix, the final stage 
probably involves recruitment of ESCRT-III and Vps4 to the midbody to achieve 
abscission (40). Recent evidence suggests that Vps2/Vps4 related factors play roles in 
cytokinesis in Archaea, supporting highly conserved roles of ESCRT-III and Vps4 in this 
process (98).  
 
3. ESCRT-III  
3.1 ESCRT-III family 
Subunits of ESCRT-III are structurally related, small (~ 200 – 250 amino acids 
long) proteins with N-terminal basic and C-terminal acidic halves (79, 99). There are six 
ESCRT-III proteins in yeast (Vps2, Vps20, Vps24, Snf7, Did2 and Vps60) and these 
extend to 11 members in humans called charged multivesicular body proteins (CHMPs) 
(39-41) (Table1-1). ESCRT proteins are subdivided into two groups: Vps2, Vps20, 
Vps24 and Snf7 are core ESCRT-III proteins while Did2 and Vps60 are ESCRT-III-like 
proteins (note that these are all yeast names) (79, 99). Core ESCRT-III proteins are 
essential in MVB biogenesis while ESCRT-III-like proteins are proposed regulators of the 
ESCRT pathway. This classification is mostly based on the severity of the mutant 
phenotypes in yeast (79).  
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ESCRT-III proteins consist of a common set of 6 helices (!1 – !6), as will be 
discussed in Chapter 2 (100). Based on the crystal structure of a partial fragment of 
CHMP3, the first two helices (!1 and !2) of the protein form a 70Å long helical hairpin 
that constitutes a four-helical bundle together with two other helices (!3 and !4). The 
ability to bind to membranes and form polymers generally lies in this N-terminal helical 
bundle of the protein (!1-!4). A fifth helical segment (!5) is positioned perpendicularly to 
the helical bundle core. The last helix (!6) and its surrounding linker sequences are 
missing from the crystal structure but appear to extend from one side of the core (101). 
Because ESCRT-III proteins are homologous to each other, the crystal structure of 
CHMP3 is likely to be representative of all ESCRT-III proteins.  
ESCRT-III proteins interact with themselves, other ESCRT-III proteins, upstream 
ESCRTs and a number of other cellular factors. One of the most important interacting 
partners is the AAA ATPase Vps4, which has been shown to bind to most ESCRT-III 
proteins (82, 102-105). This is not surprising because Vps4 is required for disassembly 
of ESCRT-III. Unlike Vps4, many other interactions involving ESCRT-III appears to be 
specific to one or a subset of ESCRT-III proteins. For example, CHMP1B interacts with 
spastin, a microtubule severing enzyme linked to hereditary spastic paraplegia (106). 
AMSH, a mammalian deubiquinating enzyme, shows distinct selectivity for CHMP3 while 
UBPY, another mammalian deubiquitinating enzyme, interacts strongly with CHMP1 and 
CHMP7 (107-110).  Vps4, AMSH, UBPY and spastin all have a Microtubule Interacting 
and Transport (MIT) domain, which is responsible for binding to ESCRT-III proteins (104, 
110-112). Snf7/CHMP4 interacts with Bro1 domain containing proteins including Bro1, 
Alix and HD-PTP (His domain phosphotyrosine phosphatase) (83, 93, 94, 113, 114). In 
yeast, a deubiquinating enzyme, Doa4, is recruited to the endosomal membrane via the 
interaction of Bro1 with Snf7 (115).  
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3.2 Assembly of ESCRT-III polymers on the endosomal membrane 
ESCRT-III proteins cycle on and off endosomal membranes and function as 
membrane-associated polymers. How ESCRT-III proteins are targeted to the endosomal 
membrane is poorly understood. Yeast genetic studies suggest that core ESCRT-III 
consists of two distinct subcomplexes, the Vps20-Snf7 (membrane-proximal 
subcomplex) and the Vps2-Vps24 (soluble subcomplex) (79). The Vps20-Snf7 
subcomplex is thought to bind to the endosomal membrane through binding to ESCRT-II 
and myristolylation of Vps20. The Vps20-Snf7 subcomplex may recruit Vps2-Vps24 
subcomplex which in turn may bring the AAA ATPase Vps4 to endosomes (39).  
ESCRT-III proteins recruited to the endosomal membrane assemble into large 
polymers which may facilitate MVB vesicle formation. While upstream ESCRTs can be 
purified as stable complexes with defined stoichiometry, ESCRT-III polymers were 
originally identified as Triton X-100 insoluble complexes with unknown stoichiometry and 
size in mutant yeast cells lacking Vps4 (79). Recently, Teis et al. have identified a 
~450kDa membrane associated complex containing Snf7 in yeast after crosslinking. 
Whether the complex represents ESCRT-III polymers in cells requires further 
investigation (116).   
Although still largely unknown, several recent studies provide some clues on the 
structure of ESCRT-III polymers. First, our group recently reported deep-etch electron 
microscopy of ESCRT-III polymers formed by human orthologs of Snf7, CHMP4A and 
CHMP4B (86). When CHMP4 proteins were overexpressed in mammalian cells, they 
assembled into 5nm filaments that form circular arrays on the plasma membrane. 
Furthermore, in the presence of the ATPase defective mutant VPS4B, the circular 
scaffolds of the ESCRT polymers turned into buds and tubules emanating from the cell 
surface that could bend the membrane away from the cytoplasm. This data suggests 
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that ESCRT-III proteins may form circular polymers that promote or stabilize negative 
curvature and outward budding.  
Several other studies reconstituted assembly of ESCRT-III polymers in vitro 
using purified ESCRT-III proteins. One study showed that yeast Vps24 could form helical 
filaments with diameters of ~15nm (two stranded) or 20nm (three stranded) in solution 
(117). Vps4 induced curved bundling of two stranded filaments and could disassemble 
the filaments in a nucleotide dependent fashion when the C-terminal region of Vps24 
was replaced by the C-terminal end of Vps2. An alternative structure of ESCRT-III 
polymers, a helical tubule, was also reported. CHMP2A and CHMP3 could be 
assembled into helical tubular structures with ~ 40nm diameter which also could bind to 
liposomes (118). Interestingly, the membrane interaction sites were exposed on the 
outside of the tubule, while the ATPase VPS4 bound on the inside of the tubule. It is 
possible that such helical polymer structures assemble within the neck of a vesicle, 
catalyzing budding reactions under the control of Vps4. 
Two recent studies reconstituted assembly of ESCRT-III polymers on synthetic 
liposomes using four core yeast ESCRT-III proteins, and demonstrated that ESCRT-III 
can induce membrane deformation and vesicle formation in vitro. One study observed 
the invagination about ~40nm in diameter in ~80-100nm liposomes after treating with 
four core ESCRT-III proteins (119). The other showed that ESCRT-III proteins were 
concentrated on the periphery of giant unilamellar liposomes and could induce formation 
of ILVs (120). Among four ESCRT-III proteins, Vps20, Snf7 and Vps24 but not Vps2 
were required for completing vesicle formation and scission of vesicles from the limiting 
membranes.  
All of these data support the idea that ESCRT-III proteins can assemble into 
stable polymers with regular organization and perhaps these polymers may mediate 
vesicle formation. However, these studies were carried out under non-physiological 
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conditions. Therefore, further investigation will be required to determine the extent to 
which of these studies reflects actual ESCRT-III polymers in cells.  
 
3.3 Regulation of ESCRT-III polymer assembly 
Although ESCRT-III proteins function as membrane-associated complexes, they 
exist predominantly as soluble monomers in the cytoplasm. ESCRT-III proteins in the 
cytoplasm are in a closed conformation in which their autoinhibitory domains keep the 
proteins from binding to membranes and forming polymers. ESCRT-III proteins 
assemble on the endosomal membrane when the autoinhibition is relieved (i.e. 
open/activated) (58, 100, 108). A recent study provides structural evidence for these two 
conformations of ESCRT-III proteins. Based on small-angle X-ray scattering data, an 
ESCRT-III protein, CHMP3, can adopt two conformations in solution. A globular form in 
a low salt condition most likely represents the closed state of the ESCRT-III protein 
whereas an extended conformation in a high salt condition may represent the 
open/activated state (121). Conformational changes of Snf7 protein was also examined 
by fluorescence spectroscopy (119). To do this, probes at several different positions of 
Snf7 were monitored spectroscopically in aqueous solution and in the presence of 
different ESCRT-III proteins and membranes. In solution, Snf7 was soluble monomer but 
then oligomerized in the presence of Vps20 and liposomes. Upon membrane binding 
and oligomerization, the loop between !5 and !6 of Snf7 underwent the most dramatic 
changes, presumably representing a conformational transition from a closed to open 
form. Autoinhibition of ESCRT-III proteins will be further discussed in Chapter 2. 
  
3.4 Disassembly of ESCRT-III polymers 
ESCRT-III polymers do not disassemble spontaneously, but require the ATPase 
activity of Vps4. Vps4 is an essential factor in ILV formation and functional loss of Vps4 
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blocks ILV formation and results in accumulation of cargo and other ESCRT proteins in 
class E compartments near vacuoles (79, 80, 122-124). In mammals, there are two 
isoforms, VPS4A and VPS4B (41).  Vps4 belongs to the ATPase family associated with 
various cellular activities (AAA) family that functions in the unfolding and disassembly of 
protein complexes. Members of the AAA ATPase family contain conserved AAA 
domains which oliogomerize to form single or dual hexameric rings required for ATP 
hydrolysis (125).  There are two subtypes in the AAA ATPase family – type I and type II. 
Vps4 is a type I AAA ATPase with a single AAA domain per monomer. Unlike type II 
AAA proteins that form stable rings, Vps4 is oliogermized in an ATP dependent manner 
(125). Additionally, Vta1/LIP5, a proposed cofactor of Vps4, may promote ATPase 
activity of Vps4 in part through promoting or stabilizing Vps4 oligomerization (126, 127). 
Vta1/LIP5 binds to the beta domain of Vps4, beta sheets inserted in the AAA domain of 
Vps4. Vta1/LIP5 can also interact directly with a subset of ESCRT-III proteins, which will 
be discussed in greater detail in Chapter 3.   
Vps4 interacts with ESCRT-III proteins via its N-terminal MIT domain. Structure 
determination of the Vps4 MIT domain revealed a three-helix bundle reminiscent of an 
incomplete tetratricopeptide-like repeat (TPR) (104). The C-terminal regions of many 
ESCRT-III proteins contain motifs called MIT domain interacting motifs (MIMs) 
responsible for binding to the Vps4 MIT domain (102, 103). It is fairly clear that Vps4 
plays a critical role in the dissociation of ESCRT-III from the endosomal membrane, 
considering the phenotypes of cells lacking functional Vps4 (58, 79). More direct 
evidence came from a series of recent studies on ESCRT-III polymers built in vitro 
showing that they could be disassembled by purified Vps4 (117-120).  Whether Vps4 is 
actively required for the budding/fission reaction of ILV formation is still a matter of 
debate in the field. Recent data from an in vitro budding assay, however, favors the idea 
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that Vps4 plays a role in disassembling the machinery after the budding reaction is 
complete (120).  
 
3.6 Implications of ESCRT-III in human diseases 
ESCRT-III proteins are essential in numerous critical cellular processes including 
receptor downregulation and viral budding (39, 40). Dysfunction of ESCRT-III proteins 
may contribute to pathophysiology of cancer because abnormal activity of signaling 
receptors can lead to tumorogenesis (17, 128). Roles of ESCRT-III are also linked to life 
threatening infectious diseases such HIV and Ebola (88, 91). Additionally, it appears that 
disrupting function of ESCRT-III impairs autophagosome formation, which may lead to 
dysfunction and death of neurons (129). In fact, mutations in CHMP2B have been 
associated with frontotemporal dementia (FTD; the second most common form of 
familial dementia after Alzheimer’s disease) and amyotrophic lateral sclerosis (ALS) (130, 
131). Both of these neurodegenerative diseases are characterized by accumulation of 
ubiquitin-positive protein aggregates in the central nervous system, perhaps because of 
impaired autophagocytosis (129, 132, 133).  Finally, mutations in CHMP4B are linked to 
familial cataracts although exactly how the ESCRT machinery contributes to lens 
transparency is not known (134). Note that I contributed to this work which resulted in 
the publication attached as Appendix 1 to this thesis.  
 
4. Summary 
The field has learned much about the structures and interactions of the ESCRT 
machinery, and the mechanism of cargo recruitment by ESCRTs. ESCRT-III still remains 
one of the least understood players in the ESCRT pathway, and the mechanism for MVB 
vesicle formation is still a matter of conjecture. Knowledge about ESCRT-III was far less 
extensive at the time I started my thesis work. In fact, most of the information regarding 
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ESCRT-III described in this introduction came from work carried out over the past four 
years while I was working on this thesis.  
Four years ago, ESCRT-III polymers were defined as Triton X-100 insoluble 
material which could be seen only in cells lacking functional Vps4 (79). Deletion of yeast 
ESCRT-III proteins led to defects in ability to sort cargo to the vacuolar lumen (79, 99). 
Because the size, structure and stoichiometry of ESCRT-III polymers were 
undetermined, it was difficult to understand whether and how ESCRT-III polymers 
contributed to formation of MVB vesicles. While ESCRT-III proteins are expected to 
function as polymers on the endosomal membrane, they exist predominantly as soluble 
monomers in the cytoplasm (79). Precise mechanisms by which ESCRT-III is targeted to 
the endosomal membrane and assembles to polymers on the membrane remain poorly 
understood. 
A hypothesis to explain the transition between soluble monomers and membrane 
associated complexes was that ESCRT-III proteins might have autoinhibitory domains 
that keep the proteins from binding to membranes and forming polymers (58). Based on 
the data from our lab and others with half fragments of CHMP3 and CHMP4A, an 
autoinhibitory domain was thought to be present within the C-terminal half of ESCRT-III 
protein (57, 58). Because ESCRT-III proteins are structurally related to each other, such 
a domain was expected to be present in all ESCRT-III proteins. To determine whether 
this was the case and to identify a common autoinhibitory domain that controls 
conformational changes of ESCRT-III proteins, I performed a structure/function analysis 
of four representative human ESCRT-III proteins (CHMP2A, CHMP3, CHMP4A and 
CHMP6). This work is described in Chapter 2 and was published in Traffic (100).   
While searching for cellular factor(s) that might regulate conformational changes 
in ESCRT-III proteins, I found that LIP5, a proposed cofactor of Vps4, could bind 
efficiently to the autoinhibitory domain of CHMP2A. Through further analyses, I identified 
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novel connections between LIP5 and a subset of ESCRT-III proteins (CHMP1B, 2A and 
3) that have been implicated in Vps4 mediated ESCRT-III disassembly. In Chapter 3, I 
describe these protein interactions as well as their involvement in the disassembly of 
ESCRT-III. This work was published in Molecular Biology of the Cell (135). 
Recent work from our group and others provides insight into structures and 
possible function of ESCRT-III polymers in generating ILVs. Specific roles for individual 
ESCRT-III proteins have emerged from some of the studies. This will be discussed in 
Chapter 5 in greater detail. Overall, however, it has yet to be determined precisely how 
ESCRT-III polymers generate ILVs in cells under physiological conditions and differential 
contributions of each ESCRT-III protein to ILV formation. One of the ultimate goals of my 
thesis is to study the roles of mammalian ESCRT-III in ILV formation. In Chapter 4, I 
describe tools developed for this purpose. Using these tools, I explore the role of 
ESCRT-III and interacting proteins in trafficking of two receptor proteins, epidermal 
growth receptor (EGFR) and !-opioid receptor (DOR).  
In Chapter 5, I discuss remaining questions to be addressed regarding the role 
and regulation of ESCRT-III and describe my preliminary data and future directions.  
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FIGURE LEGENDS 
 
Figure 1-1 Membrane trafficking pathways with particular emphasis on the 
endocytic pathway.  
Secretory pathway (outbound) and endocytic pathway (inbound) are shown. Organelles 
involved in the secretory pathway include the endoplasmic reticulum (ER), Golgi and 
trans-Golgi network (TGN). The endocytic pathway consists of endocytic vesicles, early 
and late endosomes, and lysosomes. A subset of endosomes containing internal 
vesicles is called the multivesicular body (MVB). Transmembrane proteins are 
internalized by endocytosis, and transported to early endosomes. Some proteins are 
recycled back to the plasma membrane, directly (step 1a) or indirectly through the 
recycling endosome (or ERC) (step 1b). Others are sorted to the TGN (step 2). 
Transmembrane proteins on the cell surface (e.g. receptors) are internalized and sorted 
into intralumenal vesicles (ILVs) of the MVB, which are eventually delivered to the 
lysosome lumen (step 3). In contrast, lysosomal membrane proteins remain on the 
limiting membrane of the MVB (step 4) (40).  
 
Figure 1-2 Schematic diagram for MVB biogenesis and other topologically related 
processes.  
Shown are three different cellular processes - MVB vesicle formation, viral budding from 
the cell surface and cell abscission during cytokinesis, all of which involve budding away 
from the cytoplasm.  
 
Table 1-1 Class E Vps proteins and their mammalian orthologs. 
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Figure 1-3 Model for how ESCRT machinery functions in cargo sorting and MVB 
vesicle formation.  
ESCRT-0, I and II complexes are sequentially recruited to the endosomal membrane by 
their interactions with membranes and ubiquitinated cargo. ESCRT-III is in turn recruited 
to the endosomal membrane, and engages deubiquitinating enzymes to remove 
ubiquitin from cargo and the AAA ATPase Vps4 to disassemble ESCRT complexes. 
During this process, the MVB vesicle is formed and cargo is sorted into the vesicle (39).  
PI3P – phosphoinositide-3-phosphate, Ub – ubiquitin  
 
Figure 1-4 Structure of an ESCRT-III protein. 
Partial crystal structure of an ESCRT-III protein, CHMP3 is shown in yellow (Protein 
Data Bank number:2GD5). The C-terminal end missing from the crystal structure is 
shown in gray. An ESCRT-III protein consists of 6 helices. The first four helices form a 
helical bundle responsible for dimerization and membrane binding. The fifth helix is 
positioned perpendicularly to the helical bundle. The last helix in the C-terminal end was 
separately crystallized together with the Vps4 MIT domain (101-103).  
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Figure 1-1 
 
 
 
 
 
 
Adapted from Raiborg and Stenmark, 2009, Nature 
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Figure 1-2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Modified from Hanson et al., Curr Opin Cell Biol, 2009 
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Table 1-1 
 
 
 
Complex 
Sub-
complex 
Yeast  
name 
Mammalian 
name 
Ubiquitin 
binding 
motif 
Selected 
interacting 
proteins 
(mammalian) 
 Vps27 HRS UIM TSG101 
ESCRT-0 
 Hse1 STAM1, 2 UIM AMSH, UBPY 
 Vps23 TSG101 UEV HRS, ALIX 
 Vps28 VPS28  CHMP6 
 Vps37 VPS37A, B, C, D   
ESCRT-I 
 Mvb12 MVB12A, B   
 Vps22 EAP30   
 Vps25 EAP20  CHMP6 ESCRT-II 
 Vps36 EAP45 GLUE/NZF  
Vps2 CHMP2A, B  VPS4, LIP5 
Core,  
Soluble 
Vps24 CHMP3  VPS4, AMSH, LIP5 
Vps20 CHMP6  VPS4, ESCRT-II Core,  
Membrane 
proximal Snf7(Vps32) CHMP4A, B, C  VPS4, ALIX 
Vps60(Mos1) CHMP5  LIP5 
ESCRT-III 
like 
Did2(Vps46) CHMP1A, B  
VPS4, LIP5, 
Spastin 
ESCRT-III 
 - CHMP7  UBPY 
 Vps4 VPS4A, B  LIP5, ESCRT-III 
 Vta1 LIP5  VPS4, ESCRT-III 
 Bro1 ALIX  CHMP4 
Others 
 Ist1 IST1  VPS4, CHMP1 
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Figure 1-3 
 
 
 
 
 
 
 
Modified from Hurley and Emr, Annu Rev Biophys Biomol Struct, 2006 
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Figure 1-4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Modified from Muziol et al., Dev Cell, 2006 
 
  43 
 
 
 
 
 
CHAPTER TWO 
 
Structure/function analysis of four core 
ESCRT-III proteins reveals common 
regulatory role for extreme C-terminal 
domain 
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 INTRODUCTION 
Multivesicular bodies (MVBs) are a subset of late endosomes that contain 
intralumenal vesicles (ILVs) generated by invagination from the endosomal membrane 
(1, 2). The MVB is an intermediate compartment en route to the lysosome; surface 
receptors destined for degradation and some newly synthesized lysosomal proteins are 
sorted into ILVs and delivered to the lysosome (1). In specialized cells, MVBs can 
instead fuse with the plasma membrane to secrete ILVs, also known as exosomes (3).  
Genetic studies of vacuolar protein sorting (Vps) in S. cerevisiae have identified 
~18 proteins specifically involved in creating the MVB, known as class E Vps proteins. 
Functional loss of any of these proteins leads to formation of an aberrant late endosome 
lacking internal vesicles, referred to as the ‘class E compartment’ (4, 5). Class E Vps 
proteins are conserved from yeast to human suggesting that the MVB pathway is 
universal (5, 6). 
Most class E Vps proteins form heteromeric protein complexes called ESCRTs 
(endosomal sorting complexes required for transport) (6). Current thinking is that ESCRT 
complexes are intimately involved in both cargo sorting and ILV formation. In the most 
clearly defined pathway, ubiquitination marks cargo proteins for incorporation into a 
nascent ILV.  Ubiquitinated cargo binds, possibly sequentially, to Vps27-Hse1, ESCRT-I, 
and ESCRT-II. These complexes in turn recruit ESCRT-III proteins to create ESCRT-III 
complex. ESCRT-III engages Bro1 and deubiquitinating enzymes that remove the 
initiating ubiquitin. ESCRT-III also recruits Vps4, which is an AAA+ (ATPases associated 
with a variety of cellular activities) protein that is thought to disassemble ESCRT 
complexes for recycling of the MVB machinery. How the sequential engagement of 
these complexes leads to ILV formation is unclear. 
ESCRT-III appears to play a central coordinating role, bringing upstream 
(ESCRT-I, -II) and downstream (Bro1, deubiquitinating enzymes, and Vps4) factors 
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together. The specific composition, organization, and regulation of ESCRT-III is however 
not well understood. Components of ESCRT-III are related ~200-250 amino acid 
proteins that have characteristic basic N-terminal and acidic C-terminal halves (7). 
ESCRT-III proteins in S. cerevisiae include the core complex components Snf7p, 
Vps20p, Vps2p and Vps24p along with two additional members, Did2p and Vps60p (7, 
8). Of the four core ESCRT-III proteins, two (Vps2p and Vps24p) require the other two 
(Snf7p and Vps20p) for recruitment to the membrane (7). Because of this, these pairs 
are referred to as cytosolic and membrane proximal ESCRT-III subcomplexes (7). The 
family is expanded to 10 proteins in humans (9). Human ESCRT-III proteins are referred 
to as human orthologues of their yeast counterparts or CHMPs (CHarged Multivesicular 
body Proteins) (6).  
The discovery that at least some of the mammalian class E proteins are centrally 
involved in viral budding – a reaction topologically equivalent to ILV formation – has 
added new insight into the function of these proteins (10-12). Structural proteins of 
viruses (i.e. Gag in retrovirus) contain L domains (late assembly domains) in which 
mutations arrest viral release at a late stage (10, 13). Different L domains recruit 
different cellular factors; for example, P[T/S]AP sequences bind to an ESCRT-I protein, 
Tsg101, while YPxL sequences interact with Alix, the mammalian orthologue of Bro1 (9, 
14-16). ATPase deficient VPS4 and ESCRT-III proteins fused to GFP inhibit release of 
viruses involving either type of L-domain (9, 16-18), suggesting a potential role for 
ESCRT-III proteins in the final steps of extracytoplasmic budding.   
ESCRT-III proteins cycle on and off membranes in parallel with their 
incorporation into ESCRT-III complexes (5, 6). Yeast two-hybrid screens and 
biochemical studies have delineated interactions between ESCRT-III proteins in both 
yeast and higher eukaryotes that probably mediate complex assembly (9, 18-21). For a 
subset of these proteins, interactions with membranes as well as their ability to 
  47 
assemble into complexes has been shown to require sequences within their N-terminal 
halves (22-24).  
As a step toward understanding the role of ESCRT-III in MVB biogenesis and 
viral budding, we explored the functional roles of predicted helical domains within 
individual ESCRT-III proteins, including the core complex components hVps2-
1/CHMP2A, hVps24/CHMP3, hVps20/CHMP6 and hSnf7-1/CHMP4A. Removing a short 
C-terminal domain from each protein promoted membrane binding and polymer 
assembly. These truncated ESCRT-III proteins were predominantly localized on 
enlarged vacuoles and potently inhibited both endosomal processing and viral budding. 
Our results suggest a model for ESCRT-III in which each individual protein cycles 
between a default closed and an activated open state under control of sequences at its 
extreme C-terminus. The transition between these states is likely to be controlled by 
other components of the ESCRT pathway.   
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EXPERIMENTAL PROCEDURES 
 
Plasmids 
The following constructs have been previously described (23): pcDNA3.1-FLAG-
CHMP4A full-length (1-222), pcDNA3.1 CHMP4A full-length-myc/His6, pcDNA3.1-
FLAG-CHMP4A 1-116, pcDNA3.1-CHMP3 full-length(1-222)-myc/His6, pHO4d 
VPS4B/SKD1(E235Q)-His6/myc and pGEX 4T-1 CHMP4A full-length. Dr. Lee Ratner 
(Washington University, St. Louis, MO) kindly provided pCMV55 encoding HIV 
Pr55(Gag).  
To construct CHMP4A deletion mutants, DNA fragments corresponding to amino 
acids 1-80, 1-147, 1-181, 1-209, and 60-222 were amplified by polymerase chain 
reaction (PCR) using pcDNA3.1-FLAG-CHMP4A full-length as a template. Each 
fragment was inserted into pcDNA3.1-FLAG (a gift from Dr. Kenneth Johnson, 
Washington University, St. Louis, MO) between BamHI and XhoI sites to generate 
constructs with the FLAG epitope attached at the N-terminus. Additionally, 1-181 and 1-
209 were inserted into pcDNA3.1-myc (a gift from Dr. Kenneth Johnson, Washington 
University, St. Louis, MO) between BamHI and XhoI sites to fuse a myc epitope to the N-
termini.  
To construct CHMP3 deletion mutants, DNA fragments corresponding to amino 
acids 1-119, 1-150 and 1-178 were amplified by PCR from pcDNA3.1 CHMP3-myc-His. 
Each fragment was inserted into pcDNA4/TO-myc (Invitrogen, Carlsbad, CA) via BamHI 
and XhoI sites to attach a myc epitope to the C-terminus.  
cDNAs encoding CHMP6 full-length(1-201) and CHMP2A full-length(1-222) were 
amplified from HeLa cDNA (Clontech, Mountain View, CA). The CHMP6 cDNA and 
CHMP2A cDNA were cloned into pcDNA4/TO-myc.and pcDNA3.1-FLAG, respectively 
both via BamHI and XhoI sites. To make CHMP6 deletion constructs, DNA fragments of 
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CHMP6 corresponding to amino acids 1-115, 1-147 and 1-167 were amplified by PCR 
using pcDNA4/TO-CHMP6-full-length-myc as a template. These fragments were cloned 
into pcDNA4/TO-myc (Invitrogen, Carlsbad, CA) via BamHI and XhoI sites. To generate 
CHMP2A deletion mutants, DNA fragments of CHMP2A corresponding to amino acids 1-
116, 1-144 and 1-180 were amplified by PCR using pcDNA3.1 FLAG-CHMP2A full-
length as template. These fragments were inserted into pcDNA3.1-FLAG via BamHI and 
XhoI sites. All CHMP6 constructs were tagged with myc epitope at the C-termini while 
FLAG epitope was attached to the N-termini of all CHMP2A constructs.   
To express CHMP2A in BL21(DE3) E.coli, DNA fragments of CHMP2A 
corresponding to amino acids 56-222 and 56-180 were amplified by PCR from 
pcDNA3.1 FLAG-CHMP2A and cloned into pGEX 4T-1 via BamHI and XhoI sites. 
DNA fragments corresponding to CHMP2A full-length and amino acids 1-144 were 
obtained by digesting pcDNA3.1 FLAG-CHMP2A full-length and 1-144 with BamHI and 
XhoI and inserted into pGEX 4T-1 between the two restriction sites.   
All constructs were sequenced using ABI big dye reagents at the Nucleic Acid 
Chemistry Laboratory (Washington University, St. Louis, MO).  
 
Immunofluorescence analysis 
COS-7 cells were plated onto glass coverslips and transfected with plasmid(s) 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) following the manufacturer’s 
instructions. 18-24 hrs after transfection, cells were fixed with 3.5% paraformaldehyde in 
phosphate buffered saline (PBS) for 15 min and permeabilized with 0.2% Triton X-100 in 
PBS for 15min. Cells were stained with primary and secondary antibodies in blocking 
buffer (5% goat serum, 100mM NaCl, 30mM HEPES, 2mM CaCl2, pH7.4). To visualize 
nuclei, cells were co-stained with 4'-6-diamidino-2- phenylindole (Molecular Probes, 
Eugene, OR). The following antibodies were used for immunostaining: mouse 
  50 
monoclonal anti-FLAG, M2 (Sigma, St. Louis, MO, 1:2500), rabbit anti-FLAG (Sigma, St. 
Louis, MO, 1:500), mouse monoclonal anti-myc (from the 9E10 hybridoma cell line (40), 
1:500), rabbit anti-myc (Cell Signaling Technology, Danvers, MA, 1:500), mouse 
monoclonal anti-ubiquitin, FK2 (Affiniti Research Products, Plymouth Meeting, PA 
1:1000). Secondary antibodies, goat anti-mouse conjugated to Alexa Fluor 488 or Alexa 
Fluor 555 and goat anti-rabbit conjugated to Alexa Fluor 488 or Alexa Fluor 555 were 
purchased from Molecular Probes (Invitrogen, Carlsbad, CA). Microscopic images were 
obtained using a Leica Diaplan microscope and Zeiss Axiocam camera, processed in 
Adobe Photoshop (Adobe System, San Jose, CA) and assembled into figures in Adobe 
Illustrator (Adobe System, San Jose, CA).   
 
Sedimentation assay  
HEK (Human Embryonic Kidney) 293T cells in 6 cm dishes were transfected with 
the indicated plasmid(s) using Lipofectamine 2000. 18-24 hrs after transfection, cells 
were washed with PBS and solubilized in 350 µL lysis buffer (10mM Tris, 10% sucrose, 
1mM ethylenediaminetetraacetic acid (EDTA), 1% Triton X-100, 0.1mg/ml 
phenylmethylsulfonyl fluoride (PMSF), complete protease inhibitor (Roche Diagnostics, 
Alameda, CA) and 4 µL benzonase (Novagen, San Diego, CA), pH 8.0) on ice for 40 
min. Supernatant and pelletable fractions were separated by centrifuging samples at 
10,000 x g for 15 minutes at 4oC. Pellets were resuspended to the same volume as 
supernatant in lysis buffer. Equal volumes of fractions were analyzed by immunoblotting 
using rabbit anti-FLAG antibody (Sigma, St. Louis, MO, 1:5000), mouse monoclonal anti-
myc (from the 9E10 hybridoma cell line, 1:3000) or rabbit anti-CHMP3 antibody ((23), 
1:20). 
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Membrane flotation  
COS-7 cells in 10 cm dishes were transfected with the indicated plasmid using 
Lipofectamine 2000. 18-24 hrs after transfection, cells were harvested in buffer (10mM 
Tris, 10% sucrose, 1mM EDTA, 0.1mg/ml PMSF and complete protease inhibitor, pH 
8.0). Cells were frozen and thawed once followed by homogenization using a ball 
bearing cell cracker. Homogenate was brought to 73% sucrose (1.5ml) and overlaid with 
65% sucrose (2.5ml) and 10% sucrose (1.5ml). After centrifugation at 34000 rpm in a 
SW55 Ti rotor (Beckman Coulter, Fullerton, CA) for 18 hrs at 4ºC, fractions were 
collected from the top and analyzed by western blotting using rabbit anti-FLAG (Sigma, 
St. Louis, MO, 1:5000), mouse anti-myc antibody (from the 9E10 hybridoma cell line, 
1:3000), rabbit anti-caveolin antibody (BD Transduction Laboratories, San Jose, CA, 
1:2500) or mouse anti-alpha-tubulin antibody (DM 1A, Sigma, St. Louis, MO, 1:5000).  
 
VLP (Virus-like-particle) release assay 
HEK 293T cells in 6 cm dishes were transfected using Lipofectamine 2000. Cells 
were transfected with 4 !g pCMV55 encoding HIV Gag alone or together with 1!g of the 
indicated ESCRT-III construct. These concentrations were chosen to avoid nonspecific 
effects. 18-24 hrs after transfection, media containing VLP was harvested and clarified 
by passing through a 0.45 !m filter. VLPs were pelleted by centrifugation through a 20% 
sucrose cushion at 26,000 rpm in a SW41 Ti rotor (Beckman Coulter, Fullerton, CA) for 
3 hrs. VLPs and cell lysates were resuspended in SDS sample buffer and analyzed by 
immunoblotting using a rabbit antibody against p24, the capsid domain of HIV Gag (a gift 
from Dr. Lee Ratner, Washington University, St. Louis, MO, 1:5000).  
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GST (Glutathione-S-transferase) pull down assay 
To express GST proteins, BL21(DE3) E.coli were transformed with pGEX 4T-1 
constructs, grown at 37 ºC to O.D.600 ~ 0.8 and induced at room temperature for 4 hours 
with 0.5mM isopropyl-!-thiogalactopyranoside. Cells were lysed by sonication in buffer 
(20mM Tris, 250mM NaCl, 5% glycerol and 0.1mg/ml PMSF, pH 7.4) and GST proteins 
in lysates were immobilized on glutathione-Sepharose beads (Amersham Biosciences, 
Piscatawy, NJ). To prepare bacterial lysate containing VPS4B, BL21(DE3) E.coli were 
transformed with pHO4d VPS4B/SKD1(E235Q)-His6/myc, grown and induced as 
described above. The cells were sonicated in lysis buffer (30mM HEPES, 120mM NaCl, 
2mM ATP, 5mM MgCl2, 5% glycerol, 0.1mg/ml PMSF, pH 7.4) and the lysate was 
incubated with GST proteins immobilized on beads for 1 hr at 4 ºC in reaction buffer 
(20mM HEPES, 100mM NaCl, 2mM ATP, 4mM MgCl2 , pH7.4).  Bound and unbound 
VPS4B/SKD1(E235Q) were analyzed by immunoblotting with anti-myc antibody (from 
the 9E10 hybridoma cell line 1:3000) while GST proteins were visualized by 
immunoblotting with a rabbit anti-GST antibody (Invitrogen, Carlsbad, CA, 1:5000).  
 
Tissue Culture 
COS-7 and HEK293T cells were grown in Dulbecco's modified Eagle's medium (Gibco-
BRL, Gaithersburg, MD) containing 5% fetal bovine serum (Gibco-BRL, Gaithersburg, 
MD), 5% supplemented calf serum (Hyclone Laboratories, Logan, UT ) and 2mM 
glutamine (Tissue culture center, Washington University, St. Louis, MO). 
 
Western Blot Analysis 
Samples were separated on SDS-PAGE gels and transferred to nitrocellulose 
membranes. Blots were incubated with indicated primary antibodies followed by 
secondary antibodies conjugated to horse radish peroxidase (HRP) in Tris-buffered 
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saline/0.1% Tween20 (TBST) buffer containing 5% nonfat milk. Proteins were detected 
using Super Signal West Pico (Pierce, Rockford, IL) according to the manufacturer’s 
instruction.  
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RESULTS 
Secondary structure of ESCRT-III proteins 
To generate a framework to guide our structure/function analysis of ESCRT-III 
proteins, we used a neural-net based secondary structure prediction program to identify 
a common set of six predicted !-helices in human isoforms of the four core members of 
the ESCRT-III family, Vps2, Vps24, Vps20, and Snf7 (25).  For Snf7 and Vps2, we 
focused on one each of the closely related human isoforms (CHMP4A/CHMP4a and 
hVps2-1/CHMP2a). Vps20 and Vps24 are present as only one isoform in humans, 
hVps20/CHMP6 and hVps24/CHMP3. As shown in Fig. 2-1, five predicted helices span 
most of the N-terminal two-thirds of each protein and are connected by a relatively long 
linker to a sixth short predicted helix near the C-terminus. The first five predicted helices 
correspond well with helices present in the recently published crystal structure of a 
hVps24/CHMP3 fragment (24). As has been previously noted, the N-terminal halves of 
ESCRT-III proteins are positively charged while the C-terminal halves are negatively 
charged. Correspondingly, !1 – !3 are basic while !4 – !6 are acidic (Fig. 2-1). 
 
Removing C-terminal helices unmasks new properties in ESCRT-III proteins 
Based on earlier proposals from us and others that the C-terminal acidic halves 
of ESCRT-III proteins might function as regulatory domains (6, 22, 23), we deleted one, 
two, or three predicted helices and flanking sequences from the C-terminal end of each 
ESCRT-III protein. To monitor the effects of these deletions, we transiently transfected 
constructs encoding FLAG- or myc-tagged mutant proteins into COS-7 cells and 
compared the distribution of each with that of its full-length counterpart by 
immunostaining and epifluorescence microscopy. Consistent with previous studies (19, 
22, 23, 26-28), full-length CHMP2A and CHMP3 were diffusely distributed throughout 
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the cytosol and nucleus, while CHMP6 was associated with the plasma membrane and 
CHMP4A at least in part with endosomes (Fig. 2-1, column 1).  
Surprisingly, removing only the most C-terminal helix (!6) along with flanking 
sequences dramatically changed the localization of all four proteins (Fig. 2-1, column 2). 
Unlike their full-length counterparts, CHMP2A (!1 – !5) and CHMP3 (!1 – !5) were 
found primarily on enlarged vacuoles. CHMP6 (!1 – !5) coalesced into discrete patches 
on the plasma membrane and internal vacuoles. CHMP4A (!1 – !5) was enriched on 
uniformly sized enlarged vacuoles.  
Deleting additional helices (!5 and !4) from CHMP2A and CHMP3 reduced 
association of the protein fragments with vacuoles (Fig. 2-2, columns 3 & 4). CHMP3 (!1 
– !4) accumulated on the plasma membrane, where it – like the CHMP6 mutants – was 
irregularly distributed in discrete patches. CHMP3 (!1 – !3) as well as both CHMP2A 
(!1 – !4) and CHMP2A (!1 – !3) accumulated primarily in the nucleus, presumably 
because of their positive charge (see Fig. 2-1). All CHMP6 deletion mutants (!1 – !5, !1 
– !4, !1 – !3) formed patches along the plasma membrane. Finally, CHMP4A (!1 – !4) 
and (!1 – !3) were less apparent on vacuoles and instead present along the plasma 
membrane as well as diffusely throughout the cell.   
The fact that removing the C-terminal !6 domain (35-45 amino acids including 
!6 and flanking sequences) changes the distribution of all four core ESCRT-III proteins 
led us to hypothesize that this short region may play a general role in regulating the 
engagement and activity of these proteins. To explore this idea, we compared full-length 
(!1 – !6) and C-terminally truncated (!1 – !5) proteins in more quantitative assays of 
localization and function.  
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Effects of removing ESCRT-III C-termini on membrane association and polymer 
assembly 
To determine whether the striking differences in localization of full-length vs. 
truncated (!1 – !5) ESCRT-III proteins represent changes in their association with 
membranes, we floated cell lysates through sucrose step gradients to separate soluble 
or cytoskeletal proteins from those bound to membranes. Consistent with our 
immunofluorescence experiments (Fig. 2-2), CHMP2A and CHMP3 shifted from soluble 
to membrane-associated fractions following removal of !6 and flanking sequences (Fig. 
2-3A). Full-length CHMP4A was already partially membrane associated (as previously 
shown (23)), but deleting its C-terminus enhanced this interaction such that all of 
CHMP4A (!1 – !5) was recovered in membrane-associated fractions (Fig. 2-3A).  Both 
full-length and truncated CHMP6 cofractionated completely with membranes (Fig. 2-3A), 
presumably because of their myristoylation (19).  Parallel immunoblots confirmed that 
the gradients cleanly separate membrane associated proteins such as caveolin from 
soluble and cytoskeletal proteins including !-tubulin (Fig. 2-3A, bottom). In all of these 
experiments, ESCRT-III proteins are highly overexpressed (>100 fold above 
endogenous levels, data not shown). It is therefore likely that the observed distributions 
reflect direct interactions between individual ESCRT-III proteins and membranes.  
ESCRT-III proteins cycle on and off of membranes, and also assemble 
transiently into large complexes (5, 6). We wondered whether removing the C-terminal 
!6 domain would also enhance assembly into complexes. To detect complexes, we 
used a simple sedimentation assay (Fig. 2-3B). Transfected cells were incubated in 
buffer containing 1% Triton X-100 and then centrifuged at 10,000 x g. Pelleted material 
was resuspended in a volume equal to that of the soluble fraction, and the distribution of 
proteins between the two fractions was monitored by immunoblotting. While full-length 
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CHMP2A and CHMP3 were soluble, their !1 – !5 mutants were mostly (CHMP2A) or 
partially (CHMP3) insoluble (Fig. 2-3B). Full-length CHMP6 was already partially 
insoluble, but again its !1 – !5 mutant was even less soluble (Fig. 2-3B). Both full-length 
and truncated CHMP4A were insoluble (Fig. 2-3B). We conclude that removing !6 and 
flanking sequences promotes complex assembly. Once again, because individual 
proteins are highly overexpressed (>100 fold above endogenous levels), it is unlikely 
that formation of these insoluble protein complexes depends on other cellular proteins.  
 
Requirements for ESCRT-III polymer assembly 
To better understand how ESCRT-III proteins assemble into complexes, we used 
a series of deletion mutants to define the minimal structural requirements needed to form 
them. We chose CHMP4A for these experiments and compared the distribution of 
different fragments following sedimentation. As shown in Fig. 2-4, removing part of !1 or 
!2 (leaving residues 60-222, 1-80) shifted the protein entirely from insoluble to soluble 
fractions. !1 and !2 are therefore required for polymer assembly. A fragment containing 
the first three helices (!1 – !3, 1-116) was present to a small extent in the pellet (Fig. 2-
4). Our earlier finding that adding a lipid modification to the !1 – !3 fragment increases 
its concentration on membranes and enhances its sedimentation (23) suggests that !1 – 
!3 retains the ability to polymerize, but does so only inefficiently without supplemental 
membrane targeting. A fragment also containing !4 (!1 – !4, 1-147) was found mostly 
in the pellet, and one further containing !5 (!1 – !5, 1-181) was entirely in the pellet (Fig. 
2-4). These results show that !1 – !5 contains everything needed to efficiently bring the 
protein to the membrane and build ESCRT-III containing polymeric complexes.  
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Removing C-terminal !6 domains creates inhibitors of MVB biogenesis and viral 
budding: identification of a common regulatory domain?  
To explore and compare the effects of truncating each of these ESCRT-III 
proteins on their function, we asked how expressing full-length (!1 – !6) or truncated 
(!1 – !5) proteins affects endosomes and viral particle release. To monitor protein 
handling on late endosomes, we took advantage of the fact that inhibiting the ESCRT 
pathway causes ubiquitinated proteins to accumulate on the rim of enlarged endosomes 
(23, 29, 30). We immunostained COS-7 cells expressing full-length or C-terminally 
deleted ESCRT-III proteins with an antibody that specifically recognizes conjugated 
ubiquitin (FK2). Cells expressing full-length ESCRT-III proteins had a level and 
distribution of ubiquitin conjugates indistinguishable from that of control cells (Fig. 2-5, 
left panel). In contrast, cells expressing any of the four !1 – !5 truncation mutants 
showed a striking accumulation of ubiquitin conjugates on large vacuoles (Fig. 2-5, left 
panel). In most but not all cases, the mutant ESCRT-III protein was also present on the 
vacuoles (Fig. 2-5, right panel). Note that typical cells expressing full-length CHMP4A 
did not have significantly elevated levels of ubiquitin conjugates, although as previously 
reported, at very high levels of expression, full-length CHMP4A did increase FK2 
reactive proteins on enlarged endosomes (data not shown and (23)).  
To compare the effect of full-length and truncated ESCRT-III proteins on release 
of HIV virus-like-particles (VLPs) from cells, we cotransfected full-length or mutant (!1 – 
!5 and !1 – !4) ESCRT-III proteins with a plasmid encoding Pr55 HIV Gag into 
HEK293T cells. Recovered VLPs were quantitated by immunoblotting with an antibody 
against its p24 capsid domain. Consistent with previous reports (9, 16, 18), expressing 
any of the full-length ESCRT-III proteins with small N- or C-terminal epitope tags had 
little effect on VLP production (Fig. 2-6 A-D). In contrast, deletion mutants (!1 – !5 and 
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!1 – !4) greatly reduced VLP release (Fig. 2-6 A-D). Cell lysates from cells expressing 
inhibitory mutants typically contained increased levels of Gag. All of the ESCRT-III 
proteins were expressed at similar levels (Fig. 2-6 A-D).  
We were initially surprised to find that removing !6 and flanking sequences from 
CHMP4A created a protein that inhibited viral budding while full-length CHMP4A did not 
(Fig. 2-6D) because both forms of CHMP4A efficiently formed membrane associated 
polymeric complexes (Fig. 2-3). To confirm that expressing CHMP4A together with Gag 
did not change its behavior, we carried out a sedimentation assay with cells expressing 
both proteins (Fig. 2-6E). Full-length (!1 – !6) and truncated (!1 – !5) CHMP4A 
pelleted efficiently, indicating that both remained assembled in large complexes. As 
noted above, full-length CHMP4A also had substantially less effect than truncated (!1 – 
!5) protein on the distribution of ubiquitin conjugates in cells (Fig. 2-5). These findings 
suggest that there might be more than one step in the assembly and activation of 
CHMP4A (see Fig. 2-9 below for model).  
 
CHMP4A (!1 – !5) mutant recruits full-length ESCRT-III proteins onto endosomes 
and into detergent insoluble complex 
To determine if ESCRT-III (!1 – !5) mutants interact with full-length ESCRT-III 
proteins, we asked whether a mutant affects the distribution of other full-length ESCRT-
III proteins. Coexpressing CHMP4A 1-181 (!1 – !5 mutant) with CHMP2A, CHMP3 or 
CHMP6 recruited each of these full-length proteins to the enlarged endosomes 
delineated by CHMP4A 1-181 (Fig. 2-7A). Comparable incorporation of cotransfected or 
endogenous CHMP3 into sedimentable complex was also seen (Figs. 2-7B & 7C). This 
ability of CHMP4A (!1 – !5) to bring other full-length ESCRT-III proteins into complexes 
suggests a mechanism for propagating ESCRT-III assembly on endosomes (see Fig. 2-
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9 below for model). In contrast, full-length CHMP4A recruited neither cotransfected nor 
endogenous CHMP3 into its Triton X-100 insoluble complex (Figs. 2-7B & 7C).  
 
Interaction of VPS4 with ESCRT-III C-terminal domain 
From the above analysis, it is clear that removing the C-terminal !6 domain (!6 
and flanking sequences, total of 35-45 residues) causes major changes in association of 
ESCRT-III proteins with membranes and each other. Therefore, anything that binds to 
this region is likely to have a role (positive or negative) in controlling membrane 
association and polymer assembly.  
A number of proteins – including VPS4, Alix/AIP1, EAP20, AMSH and spastin – 
have shown bind to different ESCRT-III proteins (9, 19, 31-34).  While most of these 
interactions are limited to a subset of ESCRT-III proteins, VPS4 has proven to bind all 
four core ESCRT-III proteins as well as CHMP1.  Since our data suggest a general role 
for the C-terminal !6 domain of ESCRT-III proteins, we set out to further examine VPS4 
interactions involving this domain. 
To determine whether VPS4 binding to ESCRT-III proteins involves the C-
terminal !6 domain, we used proteins produced in E. Coli to study interaction of 
VPS4B/SKD1 with an ESCRT-III protein, CHMP2A (Fig. 2-8). We chose to examine 
CHMP2A because its affinity for GST-CHMP2A was higher than that for other GST-
ESCRT-III proteins (data not shown). To localize the VPS4B/SKD1 binding site within an 
ESCRT-III protein, we tested its interaction with a number of GST-CHMP2A deletion 
mutants (Fig. 2-8). Removing the C-terminal !6 domain abolished VPS4B/SKD1 binding 
while removing !1 from the N-terminus had no effect on binding. Together with previous 
work on CHMP1 (31, 33), these results suggest that ESCRT-III proteins bind VPS4 via 
sequences near their C-termini.  
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DISCUSSION 
The interaction of ESCRT-III proteins with each other, membranes, and other 
factors is clearly a highly regulated process. Based on our present work with four 
ESCRT-III proteins, we propose a model to describe the assembly of individual ESCRT-
III proteins into membrane-associated polymers (Fig. 2-9). Each protein has a default 
“closed” conformation in which it is soluble and not associated with other components of 
the ESCRT machinery (Fig. 2-9A). In the model shown, !1 – !4 corresponds to the !-
helical bundle and !5 to the perpendicular helix observed in the recent crystal structure 
of CHMP3/CHMP3 (24). Correct positioning of !6 and surrounding sequences is 
important for maintaining this “closed” state. When the C-terminal !6 domain is removed 
or displaced, the ESCRT-III protein “opens” and moves to the membrane where it 
assembles into polymeric complexes and recruits other ESCRT-III proteins (Fig. 2-9C). 
Our experiments suggest that these complexes can be homo- or hetero-polymeric i.e. 
contain some or all of the ESCRT-III proteins. Finally, a subset of ESCRT-III proteins 
including CHMP4A and CHMP6 may have an intermediate stage of assembly in which 
they form “closed” polymers that do not recruit other ESCRT-III proteins (Fig. 2-9B).  
 
Deletion of C-terminal !6 domain brings out common properties of membrane 
association and polymer assembly  
There are clear differences in the way in which ESCRT-III proteins associate with 
other proteins and membranes and are regulated (5, 6).  These differences include 
unique binding partners, i.e. CHMP6/CHMP6 binds to the ESCRT-II subunit EAP20 (19) 
and hSnf7 binds to Alix (9, 16), and distinct post-translational modifications, i.e. only 
CHMP6/CHMP6 is N-myristoylated (7, 19). In our experiments, differences between 
ESCRT-III proteins were apparent in the behavior of overexpressed full-length proteins, 
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with CHMP6 and hSnf7 assembled at least partially into membrane-associated 
complexes and hVps2 and CHMP3 entirely soluble. However, all four proteins were 
similarly incorporated into membrane-bound complexes after removing their C-terminal 
~40 amino acid !6 domain, demonstrating that they share an underlying ability to 
assemble into complexes and associate with membranes.  
We believe that the efficient localization of each !1 – !5 ESCRT-III mutant to 
membranes indicates that each of the core ESCRT-III proteins interacts directly with 
membranes, arguing against the idea that some (soluble) require others (membrane 
proximal) for this link. Binding of !1 – !5 fragments to the membrane may be mediated 
by different determinants than the spontaneous association of “closed” hSnf7 and 
CHMP6 with membranes. Because !1 – !5 mutants of CHMP3, CHMP2A, and 
CHMP4A localize to swollen endosomes more efficiently than do !1 – !4 mutants (Fig. 
2-2), sequences within and around !5 may be particularly important for directing the 
proteins to endosomal membranes. The presence of one vs. two ways to interact with 
membranes might explain the difference between soluble (Vps2 and Vps24) and 
membrane-proximal (Vps20 and Snf7) ESCRT-III subcomplexes (7).  
Intertwined with the accumulation of ESCRT-III proteins on membranes is their 
assembly into large Triton X-100 insoluble complexes (Fig. 2-3B). How closely these 
complexes resemble bona fide ESCRT-III complex will require a more precise 
understanding of native ESCRT-III complex than is currently available. (ESCRT-III 
complex has so far only been characterized in yeast cells lacking Vps4 activity and does 
not have a specifically defined size (7)). We believe that the detergent insoluble 
complexes formed by the individual overexpressed ESCRT-III proteins studied here 
represent specific polymers rather than aggregates for the following reasons: (1) the 
polymerized !1 – !5 fragments accumulate selectively on endosomal membranes (Fig. 
  63 
2-2); (2) CHMP4A !1 – !5 recruits soluble full-length CHMP3 into the complexes it 
forms (Fig.2-7 B&C); (3) endogenous ESCRT-III proteins accumulate in similar 
complexes when Vps4 is inactivated (7, 23); and (4) the proteins can be seen in highly 
organized filaments along the membrane when examined by quick-freeze deep-etch 
electron microscopy (P.I. Hanson et al., unpublished data).  
 
Inhibiting function: all truncated ESCRT-IIIs are potent inhibitors of both MVB and 
viral budding pathways 
Despite variations in the intracellular distribution of different full-length ESCRT-III 
proteins, none of them have much effect on either the MVB pathway or viral budding 
(Figs. 2-5 & 6) indicating that overexpressed full-length proteins retain normal regulation 
and function. In contrast, removing the C-terminal !6 domain converted each protein into 
a potent inhibitor of both pathways (Figs. 2-5 & 6). These data add to existing evidence 
implicating ESCRT-III and associated proteins in ILV formation (7, 19, 22, 23, 35, 36) 
and viral budding (9, 16, 18). We do not know whether the effects of !1 – !5 mutant 
ESCRT-III proteins on these pathways are direct or indirect. Sorting this out will require 
reconstituting ESCRT-III function on membranes in vitro.   
The inhibitory effects of removing C-terminal !6 domains from ESCRT-III 
proteins are similar to previously described effects of fusing bulky GFP tags to the C-
termini of the same proteins (9, 16, 18). This leads us to propose that disrupting the 
normal disposition of the !6 domain is what “opens” or activates ESCRT-III proteins.  
Proteins that bind to the C-terminal !6 domains are therefore likely to play critical roles 
in regulating these transitions.  
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Putative regulatory factors 
It has been shown that deleting the extreme N-termini (~ 60 amino acids) of 
CHMP1 and CHMP2A did not disrupt interaction with Vps4 (31, 32).  We found that 
CHMP2A bound well to VPS4B/SKD1 in an interaction that required the C-terminal !6 
domain. Precisely how different ESCRT-III proteins engage the three helix structure of 
the VPS4 MIT domain remains to be determined (31, 37, 38). Reconstituting the 
disassembly of ESCRT-III containing complex(es) by VPS4 will be required to establish 
the precise relationship between this reaction and ESCRT-III function in vesicle 
biogenesis. 
While this study was under revision, Gottlinger and coworkers (39) described 
inhibitory effects of truncated (!1 – !4) CHMP3/CHMP3 and hSnf7-2/CHMP4B on viral 
budding, proposing that the C-terminal acidic halves of ESCRT-III proteins are 
autoinhibitory domains. They further reported that CHMP3 is activated by binding to 
AMSH, and consistent with our results with CHMP2A found that CHMP3 binds to VPS4 
via sequences near its C-terminus.   
What do transient membrane associated ESCRT-III complexes contribute to ILV 
formation and viral budding? So far, it is clear that ESCRT-III serves as an 
organizational scaffold to bring up- and down-stream factors together presumably for the 
common purpose of generating a vesicle. Whether and if so how they contribute to 
actual vesicle biogenesis remains to be established. Understanding how ESCRT-III 
polymers affect membrane structure will be an important next step forward, as will 
establishment of an in vitro assay for ILV formation. 
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FIGURE LEGENDS 
 
Figure 2-1 Secondary structure of human ESCRT-III proteins. 
Schematic aligned representations of predicted secondary structures of (A) CHMP2A, 
(B) CHMP3, (C) CHMP6 and (D) CHMP4A obtained using a neural network based 
algorithm (http://www.compbio.dundee.ac.uk/~www-jpred/submit.html). (E) Secondary 
structure of CHMP3 fragment (9 -183) based on the recently published crystal structure 
(24). The regions missing from the crystal structure (1 - 8 and 184 - 222) are indicated 
as light grey lines. Boxes correspond to predicted helices. Blue and red boxes represent 
helices with pI higher than 8 and lower than 6, respectively. A lighter blue or lighter red 
box indicates a helix with approximately neutral pI.  
 
Figure 2-2 Subcellular localization of full-length and C-terminally deleted ESCRT-III 
proteins. 
COS-7 cells expressing indicated constructs of FLAG-CHMP2A, CHMP3-myc, CHMP6-
myc and FLAG-CHMP4A were immunostained using anti-FLAG or myc antibody and 
visualized by epifluorescence microscopy. FLAG or myc staining is shown in red, DAPI 
in blue. The images shown are representative of cells expressing each ESCRT-III 
construct.  
 
Figure 2-3 ESCRT-III (!1-"!5) mutants lacking !6 and flanking sequences form 
membrane-associated complexes.  
(A) Flotation though sucrose step gradient of full-length and !1 – !5 ESCRT-III proteins. 
COS-7 cells were transfected with full-length and !1 – !5 mutants of FLAG-CHMP2A, 
CHMP3-myc, CHMP6-myc and FLAG-CHMP4A. Cell lysate in 73% sucrose was loaded 
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at bottom and overlaid with 65% and 10% sucrose. Protein distribution was visualized by 
immunoblotting.  
(B) Sedimentation analysis of full-length and !1 – !5 ESCRT-III proteins. HEK293T cells 
transfected with full-length and !1 – !5 mutants of FLAG-CHMP2A, CHMP3-myc, 
CHMP6-myc and FLAG-CHMP4A were solubilized in 1% Triton X-100 and fractionated 
by centrifugation at 10,000 x g.  The distribution of ESCRT-III proteins in the resulting 
supernatant (S) and pellet (P) was analyzed by immunoblotting. The data shown here 
are representative of three independent experiments.  
 
Figure 2-4 Core domain required for CHMP4A polymer assembly. 
293T cells transfected with indicated FLAG-CHMP4A constructs were analyzed by 
sedimentation as described in Fig. 2-3B (solubilization in 1% Triton X-100 and 
centrifugation at 10,000 x g). The CHMP4A mutants were visualized in the resulting 
supernatant (S) and pellet (P) by immunoblotting. The data shown here are 
representative of three independent experiments.  
 
Figure 2-5 Cells expressing ESCRT-III (!1 – !5) mutants accumulate ubiquitin 
conjugates on enlarged endosomes. 
COS-7 cells transfected with full-length and !1 – !5 mutants of FLAG-CHMP2A, 
CHMP3-myc, CHMP6-myc and FLAG-CHMP4A were analyzed by epifluorescence 
microscopy. The cells were co-stained with FK2 antibody for conjugated ubiquitin (left 
panel) and anti-FLAG or anti-myc antibody for ESCRT-III constructs (right panel). The 
images shown are representative cells expressing each ESCRT-III construct.  
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Figure 2-6 Expressing C-terminally deleted ESCRT-III mutants reduces VLP (virus-
like-particle) production.  
(A-D) Effect of full-length and C-terminally deleted ESCRT-III mutants (!1 – !4 and !1 – 
!5) on VLP release. VLPs were collected from culture media of HEK293T cells 
transfected with a plasmid encoding HIV Pr55 (Gag) and indicated ESCRT-III constructs 
including (A) FLAG-CHMP2A, (B) CHMP3-myc, (C) CHMP6-myc and (D) FLAG-
CHMP4A. Gag protein (55KDa) in VLPs and cell lysates was visualized by 
immunoblotting using a polyclonal antibody against p24 capsid domain of Gag. ESCRT-
III proteins in cell lysates were visualized by immunoblotting with anti-FLAG or anti-myc 
antibody. All bands in each panel were from one exposure of a single blot. Where 
necessary, lanes were rearranged as indicated by white lines.  FL= full-length. 
(E) Effect of co-expressing Gag on sedimentation of full-length CHMP4A and CHMP4A 
(!1 – !5) mutant. HEK293T cells transfected with a plasmid encoding HIV Pr55 (Gag) 
and FLAG-CHMP4A full-length or 1-181 were subjected to sedimentation analysis as 
described in Fig. 2-3B (solubilization in 1% Triton X-100 and centrifugation at 10,000 x 
g). The distribution of protein in the resulting supernatant (S) and pellet (P) were 
visualized by immunoblotting.   
 
Figure 2-7 CHMP4A (!1 – !5) mutant recruits other ESCRT III proteins. 
(A) Left panel: Subcellular localization of individual full-length ESCRT-III proteins. COS-7 
cells transfected with CHMP6-myc, CHMP3-myc or FLAG-CHMP2A were 
immunostained with anti-FLAG or anti-myc antibody and visualized by epifluorescence 
microscopy.  
Right panel: Changed distribution of full-length ESCRT-III proteins in the presence of 
CHMP4A(!1 – !5) mutant. FLAG-CHMP4A 1-181 or myc-CHMP4A 1-181 was co-
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transfected with CHMP6-myc, CHMP3-myc or FLAG-CHMP2A into COS-7 cells. Cells 
were co-stained with anti-myc and anti-FLAG antibody and visualized by epifluorescence 
microscopy. CHMP4A 1-181 is shown in green while full-length CHMP6, CHMP3 and 
CHMP2A are in red.  
(B) Differential recruitment of cotransfected full-length CHMP3 into detergent-insoluble 
complex formed by full-length and !1 – !5 mutant of CHMP4A. HEK293T cells 
transfected with CHMP3-myc alone or together with FLAG-CHMP4A full-length or 1-181 
were subjected to sedimentation analysis as described in Fig. 2-3B (solubilized in 1% 
Triton X-100, centrifuged at 10,000 x g). The resulting supernatant (S) and pellet (P) 
were analyzed by immunoblotting with anti-myc antibody. 
(C) Differential recruitment of endogenous CHMP3 into detergent-insoluble complex 
formed by full-length and !1 – !5 mutant of CHMP4A. Samples of HEK293T cells 
transfected with FLAG-CHMP4A full-length or 1-181 were prepared as in (B) and the 
distribution of endogenous CHMP3 analyzed by immunblotting with anti-CHMP3 
antibody (23). 
 
Figure 2-8 A candidate binding site for VPS4B/SKD1 in CHMP2A. 
GST and GST-CHMP2A constructs immobilized on glutathione-Sepharose beads were 
incubated with E.coli lysate containing VPS4B/SKD1(E235Q)-His6/myc. Bound and 
unbound VPS4B/SKD1(E235Q) were detected by immunoblotting with anti-myc antibody. 
Unbound material loaded corresponds to 5% of bound. GST and GST-Vps2-1 proteins 
were detected by immunoblotting using anti-GST antibody.  
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 Figure 2-9 Model of regulated ESCRT-III polymer assembly 
(A) Representative monomeric ESCRT-III proteins in their closed conformation. The C-
terminal region including !6 and flanking sequences (~40 amino acids) is responsible for 
maintaining this closed state.   
(B) Intermediate assembly into “closed” ESCRT-III polymers. At high concentration, 
membrane proximal (CHMP4A and CHMP6) ESCRT-III proteins assemble into the 
noninhibitory polymers shown here. This state may be an intermediate in assembling 
fully activated ESCRT-III complex. 
(C) “Open” ESCRT-III proteins assemble into polymeric complexes on the membrane. 
Polymer assembly can propagate by recruitment (and coincident opening) of additional 
ESCRT-III proteins. Opening may be regulated by proteins that bind to the C-terminal!!!!!! !6 
domain.  
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CHAPTER THREE 
 
Novel interactions of ESCRT-III with LIP5 and 
VPS4 and their implications for ESCRT-III 
disassembly 
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INTRODUCTION 
Multivesicular bodies (MVBs) are a subset of late endosomes morphologically 
characterized by the presence of intralumenal vesicles (ILVs) (1, 2). Signalling receptors 
destined for degradation as well as certain lysosomal proteins are sorted into ILVs en 
route to the lysosome (3). Protein machinery involved in MVB biogenesis was 
discovered in studies of protein sorting to the vacuole in Saccharomyces cerevisiae. 
Functional loss of what are termed the class E Vps (vacuolar protein sorting) proteins 
prevents delivery of cargo into the vacuole. Cargo accumulates instead on the limiting 
membrane of the vacuole and in an adjacent abnormal compartment referred to as the 
“class E compartment” (4). 18 class E Vps proteins have been identified in yeast and 
these proteins are highly conserved throughout evolution (5-7). Interestingly, several 
mammalian class E Vps proteins are also involved in viral budding and cytokinesis, 
demonstrating a conserved role in topologically similar membrane budding and fission 
reactions (8-12). 
A majority of class E Vps proteins are components of four complexes that include 
Vps27/Hse (sometimes referred to as ESCRT-0), ESCRT-I, ESCRT-II and ESCRT-III 
where ESCRT is an acronym for Endosomal Sorting Complex Required for Transport. 
These complexes are recruited (possibly sequentially) to endosomal membranes where 
they function in sorting cargo and generating ILVs. The AAA+ ATPase Vps4 is recruited 
by ESCRT-III to disassemble and recycle the ESCRT machinery (5, 6, 13).  
ESCRT-III components are small (200-250 amino acid) structurally related 
proteins. All have basic N-terminal and acidic C-terminal halves, and are thought to 
share a common set of six !-helices (14, 15). There are six ESCRT-III related proteins in 
yeast (Vps2, Vps24, Vps20, Snf7 – core members – and Did2/Vps46, Vps60 – proposed 
regulatory members) and these are extended to 11 proteins in humans (5, 16, 17). 
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Mammalian ESCRT-III proteins are referred to either as orthologs of their yeast 
counterparts or as CHMPs (charged multivesicular body proteins). To standardize our 
discussion of the large group of mammalian ESCRT-III proteins, we will primarily use the 
CHMP nomenclature in this paper.  
Unlike ESCRT-I and -II that are stable heteropolymeric complexes, ESCRT-III 
proteins are monomers in the cytoplasm and only assemble into complex on the 
endosomal membrane (16). In current models, ESCRT-III proteins are maintained in a 
metastable “closed” conformation in the cytoplasm and  “open” when they bind to the 
membrane and assemble into polymers (5, 6, 13, 15). These polymers may deform the 
membrane and participate in forming ILVs  (18). Previously we defined ~40 amino acids 
at the extreme C-terminus of each core ESCRT-III protein as an autoregulatory domain 
that controls transition between these states (15). These 40 amino acids include a short 
C-terminal !-helix and a linker that connects it to the rest of the protein.  
ESCRT-III does not spontaneously disassemble, but instead requires energy 
input from the AAA+ (ATPases associated with a variety of cellular activities) protein 
Vps4 (19), of which there are two isoforms in mammalian cells, VPS4A and 
VPS4B/SKD1. We will use VPS4 to refer generically to the different forms of this enzyme. 
VPS4 has recently been shown to bind via its N-terminal Microtubule Interacting and 
Trafficking (MIT) domain to a short motif present in a subset of ESCRT-III proteins, 
including CHMP1 (Did2 in yeast), CHMP2 (Vps2 in yeast), and CHMP3 (Vps24 in yeast) 
(20, 21). This VPS4 binding motif is in a short C-terminal !-helix and is referred to as the 
MIT domain interacting motif (MIM) (20). The C-termini of the remaining ESCRT-III 
proteins (CHMP4 (Snf7 in yeast), CHMP5 (Vps60 in yeast) and CHMP6 (Vps20 in 
yeast)) do not contain the conserved MIM despite the fact that some of them have 
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previously been shown to bind to VPS4 (22-24). How VPS4 interacts with these proteins 
remains to be determined.  
Although VPS4 activity is essential for MVB biogenesis, little is known about how 
it works. The AAA+ domain of VPS4 is similar to other AAA+ domains with the exception 
of an inserted !-sheet motif (referred to as the ! domain) and a C-terminal "-helix (24, 
25). Like other AAA+ ATPases, VPS4 is thought to function as an oligomeric ring. VPS4 
is primarily a monomer or dimer in the cytoplasm, and its assembly into a ring is 
enhanced by interaction of its ! domain with the cofactor LIP5 (Vta1 in yeast)  (25-29).  
LIP5/Vta1 is a ~300 amino acid long highly charged protein. Deletion of Vta1 in 
yeast leads to defects in cargo sorting and vacuolar morphology (30) and knockdown of 
LIP5 in mammalian cells significantly impairs receptor downregulation and viral budding 
(31).   A conserved domain at the C-terminus of LIP5 (the “VSL (Vta1/SBP1/LIP5) 
domain”) mediates LIP5 dimerization and interaction with Vps4 (26).  
In addition to binding to VPS4, LIP5/Vta1 has been found to interact with 
CHMP5/Vps60, one of the proposed regulatory ESCRT-III proteins (26, 30-32). This 
interaction is robust and has been documented in many systems. Less well explored 
connections between Vta1 and a few other ESCRT-III related proteins have been 
reported, primarily in yeast. In particular, Vta1 binds to Did2/Vps46 (yeast ortholog of 
CHMP1) (33) and the name Vta1 (Vps twenty (Vps20) associated 1) was originally 
derived from a connection between Vps20 and Vta1 although this interaction has not 
been reproduced (23, 26).  
In the present study, we directly examine the ability of LIP5 to bind each of the 
six classes of ESCRT-III related proteins in order to determine whether ternary 
interactions between LIP5, VPS4 and ESCRT-III might play a role in ESCRT-III 
disassembly. We confirm that LIP5 binds to CHMP5, but also find that it binds to 
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CHMP1B, CHMP2A, and CHMP3 but not to CHMP4A or CHMP6. Mapping the binding 
sites reveals that LIP5 binds to the extreme C-terminal region of CHMP1B and CHMP2A 
and instead to an internal sequence in CHMP5. Complexes of LIP5 with CHMP5 are 
preferentially soluble, while those between LIP5 and CHMP2A are polymeric and 
insoluble. The C-terminal binding site for LIP5 in CHMP1B and CHMP2A overlaps with 
the previously defined “MIT interacting motif” or MIM responsible for recruiting Vps4. 
Surprisingly, we find evidence of a second binding site for VPS4 within these ESCRT-III 
proteins that may allow them to simultaneously interact with VPS4 and LIP5. These 
studies suggest that LIP5 is deeply intertwined with ESCRT-III and VPS4 in the pathway 
leading to multivesicular body formation.  
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EXPERIMENTAL PROCEDURES 
Plasmids 
The following ESCRT-III and VPS4 constructs have been previously described: 
pGEX4T-1 CHMP4A residues 1-222, pHO4d VPS4B(E235Q)-His6/myc, pEGFP C1 
VPS4B(E235Q), pcDNA3.1 FLAG-CHMP4A 1-222, 1-181, 1-147 and pGEX4T-1-
CHMP2A 1-222, 1-180, and 1-144 (15, 34). ESCRT-III and VPS4 constructs prepared 
for this study include: pGEX4T-1-CHMP6 1-201; pGEX4T-1-CHMP3 1-222; pGEX4T-1-
CHMP2A 1-219, 1-216, 1-203, 1-193, pGEX4T-1-CHMP1B 1-199, 1-181, 106-199, 106-
181, 169-199; pGEX4T-1-CHMP5 1-219, 121-149, 121-158, 121-175, 121-219, 149-175, 
149-183; pcDNA3.1-FLAG-CHMP2A 1-219, 1-206, 1-193; pcDNA3.1-FLAG-CHMP1B 1-
199, 1-181, 1-168, 1-136; pcDNA3.1-FLAG-CHMP5 1-219; pcDNA4TO-CHMP5 1-219 
His6myc; pET28a-VPS4A MIT domain (1-75); pGEX4T-1-VPS4B(E235Q) and pGEX4T-
1-VPS4B(E235Q, !GAI deletion of 390-396). cDNAs used to create these constructs 
were either from the Mammalian Genome Collection (human CHMP1B, CHMP2B, and 
CHMP5; IMAGE ID: 6165059, 3460712, and 4094210, respectively) or previously 
described (CHMP2A, CHMP3, CHMP4A, CHMP6) (15, 34). For insertion into pGEX4T-1, 
pcDNA3.1-FLAG, pcDNA4/TO- His6myc or pET28a, BamHI and XhoI sites were added 
to the fragments as they were amplified by PCR. Quikchange (Stratagene, La Jolla CA) 
site directed mutagenesis was used to introduce point mutations into CHMP2A and 
CHMP1B as indicated in the text.  
pEGFP C1-LIP5 was a kind gift from Dr. Jerry Kaplan (University of Utah, Salk 
Lake City, UT). For bacterial expression of His6-LIP5, PCR amplified cDNA was inserted 
into pET28a between NdeI and XhoI sites. GFP-LIP5 !N contains residues 76-307 in 
pEGFP C1 between BglII and HindIII sites. All constructs were sequenced using ABI big 
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dye reagents at the Nucleic Acid Chemistry Laboratory (Washington University, St. Louis, 
MO).  
 
Protein expression and purification 
BL21(DE3) E. coli transformed with the indicated constructs were grown at 37 ºC 
to a 600nm optical density of ~1, transferred to room temperature, and brought to 0.4 !M 
IPTG for 3 hrs to induce expression. Pelleted bacteria were resuspended in buffer A 
(20mM Tris, 250mM NaCl, 5% glycerol, 1mM DTT, 1mM PMSF, pH 7.4) and lysed by 
sonication. Bacterial lysates were centrifuged at 66,000 x g for 20 minutes. Clarified 
lysates were bound to glutathione sepharose (Amersham Biosciences, Piscataway NJ) 
or Ni2+-NTA agarose (Qiagen, Valencia CA) for 1 hr at 4ºC. Unbound material was 
removed by washes in buffer A, and proteins were eluted in buffer A containing either 
glutathione (50mM) or imidazole (160mM). Purified protein was quantitated using 
Bradford reagent with BSA as a standard. Proteins were snap frozen in liquid nitrogen 
and stored at -80°C. 
 
GST pull down assays 
Where indicated, GST proteins immobilized on beads were combined with 
clarified bacterial lysate containing His6-LIP5. This lysate was prepared from BL21(DE3) 
E.coli  expressing pET28a-LIP5 grown as above. Bacteria were lysed in buffer B (30mM 
HEPES, 120mM NaCl, 5% glycerol, 1mM PMSF, pH 7.4), brought to 0.5% Triton X-100, 
and centrifuged at 66,000 x g for 20 min. Clarified bacterial lysate was incubated with 
immobilized GST fusion proteins for 1 hr at 4 ºC in buffer B. Beads were washed, and 
bound material was analyzed by SDS-PAGE and staining with Coomassie brilliant blue. 
For the experiment shown in Fig. 3-6B, GST proteins were combined with mammalian 
cell lysate containing GFP-LIP5.  This was prepared from HEK293T cells transfected 
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with pEGFP C1-LIP5 solubilized in buffer B containing 0.5% Triton X-100 and 
centrifuged at 15,000 x g for 15min. After the binding reaction, bound and unbound 
material was detected by SDS-PAGE and immunoblotting with rabbit anti-GFP antibody 
((34) (1:2500)).  
 To assess competition between LIP5 and the VPS4A MIT domain, GST proteins 
immobilized on glutathione sepharose were blocked in buffer C (20mm Tris pH 7.8, 
100mM NaCl, 2mM MgCl2, 2mM CaCl2, 5mM DTT, 5% glycerol) also containing 1% 
casein for 1 hr. Beads were incubated with His6-LIP5 (0.4 to 12.8 !M) with or without 
300 !M His6-VPS4A MIT domain (CHMP2A) and with or without 500 !M MIT domain 
(CHMP1B) for 1hr at 4 ºC. Control experiments were carried out with or without 300 !M 
ribonuclease A. Beads were then washed three times in buffer C. Bound proteins were 
analysed by SDS-PAGE. Gels were stained with colloidal Coomassie (G Biosciences, 
St. Louis MO) and visualized using an Odyssey Infrared imager (LiCor Biosciences, 
Lincoln NE). Bands were quantified with Odyssey 2.1 software and were within the 
experimentally determined linear range of detection. 
 
Solid phase LIP5 binding assay 
 Microtiter plate wells containing immobilized antibody against GST (Pierce, 
Rockford IL or EMD Biosciences, Gibbstown NM) were incubated with 100 !l of the 
indicated GST-ESCRT-III or GST-VPS4B protein at 10 !g/ml for 1 hr in buffer D (20 mm 
Tris pH 7.4, 150 mM NaCl, pH7.4) (estimated to be ~60-100 times the binding capacity 
of the plate as per manufacturer data). For VPS4 binding assays, buffer D contained 100 
mM KOAc in place of NaCl, 5 mM MgCl2, and 1 mM ATP. Plates were washed three 
times in buffer D with 0.05% Tween-20 and blocked for 1 hr in buffer containing 1% 
casein (Pierce plates) or 1% casein + 0.5% BSA (EMD plates). Plates were then 
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washed, and 100 !l of His6-LIP5 at the indicated concentration in buffer D was added 
and incubated for 1 hr. Plates were again washed with buffer D, and 100 !l of a 1:2000 
dilution of NTA-HRP (Qiagen) was bound for 1 hr. After washing, 100 !l of TMB-Ultra 
(Pierce) was added to wells for ~3 min. Absorbance was read at 652 nm on a Bio-Tek 
plate reader. Background signal arising from non-specifically bound His6-LIP5 
(measured in parallel wells containing no GST protein or GST alone) was subtracted 
from each value. The background was concentration dependent and in a typical assay 
ranged from ABS of 0.1 for 4 nM His6-LIP5 to 0.23 for 3 !M His6-LIP5. Corrected 
absorbance data were analyzed using Prism (GraphPad, San Diego CA) to define an 
EC50 by nonlinear regression analysis using the formula ABS= (ABSmax*X)/(EC50+X).  
 
Tissue Culture and transfection 
HEK293T cells were grown in Dulbecco's modified Eagle's medium (Gibco-BRL, 
Gaithersburg MD) containing 5% fetal bovine serum (Gibco-BRL), 5% supplemented calf 
serum (Hyclone Laboratories, Logan UT) and 2mM glutamine. Cells were transfected 
with the indicated plasmid(s) using Lipofectamine 2000 (Invitrogen, Carlsbad CA) 
following the manufacturer’s instructions and then used for experiments 18-24 hrs after 
transfection.  
 
Sedimentation assay  
Sedimentation assays were performed as described previously (15). Briefly, 
transiently transfected HEK293T cells in 6 cm dishes were solubilized in 1% Triton X-
100 and centrifuged at 10,000 x g for 15 minutes at 4oC. Pellets were resuspended to 
the same volume as supernatant in lysis buffer and equal volumes of the fractions were 
analyzed by immunoblotting with rabbit anti-FLAG antibody (Sigma, St. Louis MO, 
  95 
1:2500) or rabbit anti-GFP.  
 
Immunoprecipitation 
Transiently transfected HEK293T cells in 6 cm dishes were solubilized in 500!l buffer E 
(0.5% Triton X-100, 30mM HEPES, 120mM NaCl, 1mM PMSF and complete protease 
inhibitor (Roche Diagnostics, Alameda, CA)). Insoluble material was removed by 
centrifugation at 15,000 x g for 15 minutes. Soluble lysate was incubated with 20!l of 
protein A-sepharoseTM CL-4B (GE Healthcare, Piscataway, NJ) for 25 min to remove 
nonspecifically interacting material, then with 6!l of rabbit anti-GFP antibody for 2 hour, 
and finally with 30!l of protein A sepharose for 1 hour, all at 4oC.  Bound protein and 
lysate were analyzed by immunoblotting using mouse monoclonal anti-myc 
(Developmental Studies Hybridoma Bank, Iowa City IA, 1:2500) and rabbit anti-GFP. 
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RESULTS 
LIP5 binds tightly to several ESCRT-III proteins in addition to CHMP5 
The AAA+ ATPase VPS4 plays a key role in MVB biogenesis  (19, 35-37), but 
precisely what it does and how this is regulated remains unclear. To gain new insight 
into this reaction, we explored connections between ESCRT-III and a known cofactor of 
VPS4, LIP5. A previous study demonstrated that LIP5 bound efficiently but apparently 
uniquely to the ESCRT-III like protein CHMP5 (31); this interaction was also found in a 
reciprocal immunoprecipitation of proteins that bind to CHMP5 (38). In yeast, Vta1p, the 
LIP5 orthologue, binds both to Vps60p (CHMP5 ortholog) (26, 30, 32) and to 
Did2p/Vps46p (CHMP1 ortholog) (33). Based on this, we asked whether LIP5 also 
interacts with other human ESCRT-III proteins. We expressed ESCRT-III proteins 
representing each of the ESCRT-III subfamilies as GST-fusion proteins in E. coli and 
carried out in vitro binding experiments. In a survey GST pulldown, we found that 
CHMP1B, CHMP2A/hVps2-1, and CHMP3/hVps24 all bound to His6-LIP5 while 
CHMP4A/hSnf7-1 and CHMP6/hVps20 did not (Fig. 3-1A).  
To quantitatively compare binding of LIP5 to these different proteins, we 
immobilized each GST-CHMP fusion protein on microtiter plates using anti-GST 
antibodies and measured binding of His6-LIP5 across a range of concentrations using 
Ni2+-NTA conjugated to horseradish peroxidase and a colored substrate to detect bound 
His6-LIP5. EC50 values for LIP5 binding ranged from 10 - 20 nM for binding to GST-
CHMP1B to 0.3 - 1 !M for binding to GST-CHMP3 (Fig. 3-1B). There was no binding 
above background to immobilized GST, GST-CHMP4A, or GST-CHMP6 (data not 
shown).   
For comparison, we also quantitated the interaction of LIP5 with VPS4B. These 
two proteins have previously been shown to bind each other with an EC50 of 53 nM in 
  97 
surface plasmon resonance experiments (39). We found that His6-LIP5 bound to 
immobilized GST-VPS4B(E235Q) with an EC50 of 60 nM (Fig. 3-1C), and that this 
binding was abolished by a short deletion within the VPS4B ! domain ("390-396) known 
to block interaction of yeast Vps4 and Vta1 (27) (Fig. 3-1C). We conclude that LIP5 
binds with sub-micromolar affinity to both a subset of ESCRT-III proteins and to VPS4B. 
As will be described below, we confirmed in parallel studies that LIP5 also binds to 
CHMP5 with comparable or even higher affinity (see Fig. 3-8). The interaction of LIP5 
with CHMP1B might have been anticipated based on earlier studies in yeast (33), but 
the association of LIP5 with the core ESCRT-III proteins CHMP2A and CHMP3 was 
unexpected and raises the possibility of a more intimate relationship between LIP5 and 
ESCRT-III than previously appreciated. 
 
LIP5 binding to CHMP2A and CHMP1B is mediated by C-terminal sequences  
To understand how LIP5 binds to ESCRT-III proteins, we began by looking for its 
binding site in the core ESCRT-III protein CHMP2A. We examined interaction between 
LIP5 and a series of CHMP2A deletion proteins that lack one or more of the protein’s 
predicted six #-helices (Fig. 3-2A), as previously described (15). Because even the 
shortest deletion from the C-terminus (leaving an #1 – #5 protein, residues 1-180) 
abolished binding, we generated a series of smaller deletions from the C-terminus to 
determine whether binding required #6 or sequences within the long linker between #5 
and #6. GST-CHMP2A fusion proteins were purified from E. coli and combined with 
His6-LIP5 to assess their interaction (Fig. 3-2B). Removing three amino acids from the 
C-terminus of CHMP2A (leaving residues 1-219) was not expected to significantly affect 
#6, and did not change binding of LIP5. On the other hand, removing six or more amino 
acids (thus perturbing or removing #6) abolished interaction of CHMP2A with LIP5. 
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Deleting !1 from CHMP2A (leaving residues 56-222) did not perturb LIP5 binding, 
demonstrating that the interaction is independent of CHMP2A’s N-terminus.  
In further experiments, we found the same requirement for extreme C-terminal 
sequences for interaction of CHMP1B with LIP5 (Fig. 3-2C). Removing the predicted !6 
from CHMP1B’s C-terminus disrupted LIP5 binding while deleting the N-terminal half of 
the protein had no effect (Fig. 3-2D). These experiments demonstrate that sequences 
within !6 are needed for CHMP2A and CHMP1B to bind LIP5.  
Because deleting sequences from ESCRT-III proteins significantly changes their 
conformation (15), there remained the possibility of deletions indirectly impairing binding 
to a site or sites located elsewhere in the protein. To rule this out, we carried out 
additional experiments. We started by changing a single conserved residue within !6 of 
CHMP2A from leucine to alanine (L216A). This mutation significantly decreased binding 
to LIP5 (Fig. 3-3A). A comparable leucine residue in other ESCRT-III proteins has 
previously been shown to be important for binding of VPS4B to CHMP1B (21) and 
binding of Alix to CHMP4 (22), pointing to a likely common role for the surface of !6 in 
binding between ESCRT-III proteins and other factors.  
To ask whether the C-terminal region is by itself sufficient for interaction of these 
ESCRT-III proteins with LIP5, we expressed !6 and surrounding linker sequences from 
CHMP1B (169-199) as a GST fusion protein and asked if it could bind to LIP5. Indeed, 
LIP5 bound to this 31 amino acid fragment (Fig. 3-3B) with an EC50 of 25 nM (Fig. 3-3C), 
similar to what we observed above for full-length CHMP1B. These results argue that all 
of the determinants needed for LIP5 binding are encoded within the C-terminal regions 
of these ESCRT-III proteins.   
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Studies in mammalian cells suggest that ESCRT-III interaction with LIP5 may be 
regulated by ESCRT-III assembly status 
As mentioned above, the high affinity binding of LIP5 to the core ESCRT-III 
protein CHMP2A was entirely unexpected. Indeed, this finding is at first glance 
inconsistent with a published report in which endogenous LIP5 was not immunoisolated 
with overexpressed CHMP2A from transfected mammalian cells (31). We therefore 
examined interaction of LIP5 with CHMP2A in HEK293T cells transiently transfected with 
tagged versions of each protein. When we immunoprecipitated FLAG-CHMP2A from the 
solubilized lysate of doubly transfected cells, we also did not recover significant amounts 
of LIP5 (data not shown). However, we noticed that overexpressed FLAG-CHMP2A had 
a strong tendency to form large complexes or aggregates that were insoluble in Triton X-
100 and therefore pelleted during preparation of the solubilized lysate. Although LIP5-
GFP expressed alone is soluble, we found that when coexpressed with CHMP2A it 
associated with this insoluble material (Fig.3-4A). LIP5 remained soluble when 
coexpressed with CHMP2A fragments lacking their !6 region despite the fact that the 
CHMP2A proteins still sedimented. In addition, LIP5 only associated with pelleted 
CHMP2A when its N-terminus – previously shown in yeast to mediate interaction with 
the ESCRT-III related protein Vps60 – was intact.  
Parallel studies with cells transfected with CHMP1B and LIP5-GFP demonstrated 
that CHMP1B similarly recruited LIP5 to sedimentable complexes only when its !6 
region was intact (Fig. 3-4B). These results are consistent with our analysis of 
recombinant proteins above and confirm that LIP5 binds to extreme C-terminal 
sequences in CHMP2A and CHMP1B. Based on our earlier study of ESCRT-III 
homopolymers (15), the preferential association of LIP5 with pelleted CHMP2A and 
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CHMP1B suggests that LIP5 may bind to these proteins in their “open” conformation and 
tend to stabilize this state.  
 
 LIP5 and VPS4 MIT binding sites overlap in CHMP2A and CHMP1B 
Interestingly, the extreme C-terminal regions of CHMP2A and CHMP1B were 
recently shown to contain a short !-helix that binds to VPS4 via a twelve residue 
sequence referred to as the MIT interaction motif (MIM) (20, 21). The MIM helix largely 
coincides with the sequence we defined as !6 by secondary structure prediction (15). 
We found above (Fig. 3-3A) that mutating a conserved hydrophobic residue in this helix 
reduced binding of LIP5 to CHMP2A. This impairment is in accordance with the reported 
ten fold decrease in VPS4 binding when the equivalent change was made in CHMP1B 
(21). VPS4 and LIP5 may therefore share elements of a common binding site in these 
ESCRT-III proteins.  
To determine if this is the case, we asked whether the VPS4 MIT domain 
competes with LIP5 for binding to CHMP2A and CHMP1B. We expressed and purified 
the His6-tagged MIT domain of VPS4A from E. coli and added it to GST pulldown 
experiments (Fig. 3-5A). We found that high concentrations of the MIT domain reduced 
but did not abolish binding between LIP5 and both CHMP2A and CHMP1B (Fig. 3-5B). 
Parallel control experiments demonstrated that adding 300 "M ribonuclease A had no 
effect on LIP5 binding (Fig. 3-5A & C).  
Given this apparent overlap in binding sites, the question of how the affinity of 
these ESCRT-III proteins for LIP5 compares to that for VPS4 becomes important.  We 
were unable to quantitate VPS4B (full-length or MIT domain) binding to immobilized 
GST-ESCRT-III proteins because of high background in the microtiter plates. In recent 
studies of VPS4 MIT domain binding to ESCRT-III MIM fragments the observed EC50 
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values were significantly higher (i.e. lower affinity) than those we measured between 
LIP5 and full-length ESCRT-III proteins (20, 21). For a first assessment of the relative 
ability of VPS4 and LIP5 to bind to their shared binding site, we compared binding of full-
length proteins to GST-CHMP1B(169-199) (Fig. 3-5D). After incubating this !6 fragment 
with 5 "M His6-VPS4B(E235Q) or His6-LIP5, we recovered similar amounts of bound 
protein, suggesting that full-length VPS4B and LIP5 may have similar affinity for the 
MIM-containing ESCRT-III proteins.  
 
A second binding site for VPS4 in ESCRT-III proteins 
If VPS4 and LIP5 have overlapping binding sites in this subset of ESCRT-III 
proteins, how do they function together? One possibility is that the C-terminal !6 
sequences, preferentially exposed when the proteins assemble into ESCRT-III complex, 
cooperate to bring VPS4 and LIP5 together. Another, not mutually exclusive, possibility 
is that the interaction between !6 sequences and these proteins is only one step in the 
reaction leading to ESCRT-III disassembly, with additional steps and interactions 
required.  Based on what is known about other AAA+ proteins, we wondered whether 
there might be a second, yet unidentified, binding site for VPS4 within ESCRT-III 
proteins. If so, this might also enable simultaneous interaction of ESCRT-III with VPS4 
and LIP5.  
To search for such a binding site, we took advantage of the fact that the 
detergent insoluble polymers formed when CHMP proteins are overexpressed in 
mammalian cells (see Fig. 3-4) create a high avidity matrix for their binding partners. We 
carried out sedimentation assays using HEK293T cells coexpressing CHMP2A deletion 
mutants and VPS4B(E235Q). Similar to what we saw with LIP5, coexpressed 
VPS4B(E235Q) sedimented with full-length CHMP2A (Fig. 3-6A). Interestingly, however, 
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small C-terminal deletions (including the MIMs) that eliminated interaction between 
CHMP2A and LIP5 did not affect association of VPS4B(E235Q) with CHMP2A. On the 
other hand, further deleting !5 and surrounding sequences abolished the CHMP2A 
dependent recruitment of VPS4B(E235Q). Note that the basal association of 
VPS4B(E235Q) with the insoluble fraction is somewhat higher than that of LIP5, 
presumably because VPS4B(E235Q) traps and binds to polymerized endogenous 
ESCRT proteins (34). Similar results were obtained with CHMP1B and VPS4B(E235Q) 
(Fig. 3-6B), suggesting that there might be a secondary binding site for VPS4 around or 
within the predicted !5 helix of both proteins. The orthogonal and exposed position of !5 
in the currently available crystal structure of CHMP3 (14) suggests that this helix may 
move as a function of ESCRT-III conformation, making it an attractive candidate for 
engaging VPS4. Our initial attempts to define this potential binding site more precisely 
using purified proteins in GST pulldown experiments failed, both because the affinity of 
this interaction appears to be low and because the nonspecific binding of VPS4B to 
truncated ESCRT-III proteins was variable and relatively high.  
To gain additional insight into the nature of this binding site, we instead turned to 
site-directed mutagenesis in our cell-based sedimentation assay. We noted that the 
region within and around !5 is highly acidic in all ESCRT-III proteins, and contains a 
glutamic acid that is the only residue conserved among all ESCRT-III proteins (14) (Fig. 
3-7A). To determine if this region is involved in the secondary association of VPS4B with 
ESCRT-III proteins, we replaced pairs of acidic residues within and around !5 in 
CHMP2A with alanines. One pair included the conserved glutamic acid (mut a) while the 
others (mut b and mut c) were nearby but less conserved pairs. We also replaced the 
conserved pair of acidic residues (mut a) in CHMP1B. We made these mutations in both 
full-length and !6-deleted proteins, with the prediction that association of VPS4B with 
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the full-length proteins would be mediated largely by their MIM and would therefore be 
independent of a secondary binding site, while association of VPS4B with the truncated 
(!6-deleted) proteins would instead be fully dependent on the secondary binding site. 
Strikingly, we found that mut a eliminated recruitment of VPS4B(E235Q) to !6-deleted 
but not full-length CHMP2A (Fig. 3-7B). Mut b and mut c had no effect. The fact that mut 
a did not affect recruitment of VPS4B to polymers of full-length CHMP2A confirms that 
the alanine replacements did not induce significant protein misfolding. In support of 
these results, we found the same effect of mut a replacements on the recruitment of 
VPS4B(E235Q) to CHMP1B (Fig. 3-7C). We conclude that conserved acidic residues at 
the center of !5 are an important component of the secondary VPS4 binding site. 
Because these experiments were carried out in cells that highly overexpress VPS4B and 
the ESCRT-III protein in question, we consider it unlikely but cannot exclude that an 
intermediate protein such as Ist1 (40) mediates this secondary interaction between 
VPS4 and the acidic !5 residues in ESCRT-III proteins.  
 
LIP5 complex with CHMP5 is unique 
Finally, we wondered how the previously described interaction between LIP5 and 
CHMP5 (31) compares to its binding to the MIM-containing ESCRT-III proteins studied 
above. The fact that LIP5 and CHMP5 have been reciprocally identified as binding 
partners in unbiased pulldowns from cultured mammalian cell cytosol (31, 38) while 
none of the other complexes have been detected suggests that there could be important 
differences. CHMP5 does not have a MIM, and in fact its predicted secondary structure 
does not include strong indication of a C-terminal helix comparable to !6 in the other 
ESCRT-III proteins (Fig. 3-8A). To characterize the interaction between LIP5 and 
CHMP5, we began by performing in vitro binding experiments. Our initial attempts to use 
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full-length GST-CHMP5 purified from E. coli were unsuccessful because the protein was 
not well behaved, forming aggregates that did not consistently bind to LIP5 (data not 
shown). The C-terminal half of the protein (GST-CHMP5 121-219), however, was readily 
soluble and reproducibly bound to LIP5 (Fig. 3-8B & C). In solid phase binding assays, 
we found that LIP5 bound to this C-terminal fragment with an EC50 of 1 - 2 nM (Fig. 3-
8D), confirming an even tighter interaction between CHMP5 and LIP5 than between 
LIP5 and the other ESCRT-III proteins.  
To define the structural requirements for interaction of CHMP5 with LIP5, we 
made a series of GST-CHMP5 fragments and tested their ability to bind to GFP-LIP5 
present in a transfected cell extract (Fig. 3-8B). Deleting sequences C-terminal to the 
predicted !5 helix (GST-CHMP5 121-175) had little effect on binding while removing the 
predicted !5 region (GST CHMP5 121-158 and 121-149) abolished LIP5 binding, 
suggesting an important role for !5. Indeed, a 27 residue fragment containing only linker 
sequences and !5 (GST CHMP5 149-175) bound to LIP5 as efficiently as the longer 
fragments.  Sequences within and around !5 are thus both necessary and sufficient for 
binding of LIP5. To confirm this result with purified proteins, we examined binding of 
His6-LIP5 expressed in E. coli to the CHMP5 !4 +"!5 or !5 fragments. As was the case 
with GFP-LIP5 from mammalian cell extracts, both fragments were able to bind 
efficiently to LIP5 confirming that sequences within and around !5 are responsible for 
high affinity binding between these two proteins (Fig. 3-8C).  
To further compare the interaction of LIP5 with CHMP5 to that with CHMP1B or 
2A, we again carried out a sedimentation assay in cotransfected HEK293T cells. As 
seen previously for CHMPs 1B and 2A, a substantial portion of overexpressed CHMP5 
formed complexes or aggregates and ended up in the pellet. Interestingly, however, this 
insoluble material did not recruit LIP5, which was exclusively found in the soluble fraction 
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(Fig. 3-8E). To confirm that soluble CHMP5 actually interacts with LIP5 in these cells, we 
immunoprecipitated GFP-LIP5 and found that, as expected, FLAG-CHMP5 was 
efficiently recovered (Fig. 3-8F).  Deleting the N-terminal 75 residues from LIP5 
(LIP5!N) abolished this binding as it has been reported to do with the comparable 
proteins in yeast (26). Together, our data suggest that LIP5 interacts with CHMP5 in a 
distinct manner that may or may not be compatible with ESCRT-III polymer assembly.  
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DISCUSSION 
LIP5 (Vta1 in yeast) emerged in recent years as a protein involved in late stages 
of MVB formation and viral budding. It participates in these events at least in part by 
binding via its C-terminal “VSL domain” to the AAA ATPase VPS4 to enhance 
oligomerization and ATPase activity (25-27, 33). At the same time, LIP5 also binds via 
its N-terminus to the ESCRT-III related protein CHMP5 (Vps60 in yeast) (30-32), and in 
yeast Vta1 has been shown to bind to Vps46, another ESCRT-III related protein (33). 
Whether, and if so how, these interactions affect VPS4 activity toward ESCRT-III 
complexes has been unclear. Here, we define new and unexpected relationships among 
these proteins, including a high affinity connection between LIP5 and the C-termini of a 
subset of ESCRT-III proteins and a second binding site for VPS4 further inside these 
proteins. In addition, comparison of LIP5’s interaction with CHMP5 and the other 
ESCRT-III proteins revealed important differences in where and how the proteins bind to 
each other, suggesting the possibility of a unique role for CHMP5. These findings lead 
us to propose that there are at least two ways in which LIP5 is involved in ESCRT-III 
disassembly.  
LIP5 has been clearly shown to be a positive modulator of the MVB sorting 
pathway. Reducing its expression by RNAi decreases degradation of the EGF receptor 
and blocks HIV viral particle release, while overexpressing it has no effect (31). In yeast, 
mutations in VTA1 impair membrane protein degradation and create a weak class E 
phenotype, the severity of which may depend on the flux of cargo through the 
endosomal pathway (26, 30, 32). While LIP5’s known role in VPS4 oligomerization might 
explain these effects, our results reveal that LIP5 also directly and efficiently engages a 
number of ESCRT-III proteins including in particular those that contain the C-terminal 
MIT interacting motif (MIM) known to bind VPS4 (Figs. 3-1 & 2) (20, 21).  
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How might LIP5 bound to ESCRT-III proteins modulate progress through the 
MVB pathway? Because LIP5 and ESCRT-III are already thought to be cofactor and 
substrate of VPS4, respectively, it is logical to think that their interaction will affect VPS4 
function. This idea is supported by the fact that the same ESCRT-III proteins that bind 
well to VPS4 (CHMP1, CHMP2 and CHMP3) bind well to LIP5  (20, 21, 41-43). One 
possibility is that the extra link between LIP5 and ESCRT-III complex ensures that VPS4 
oligomerizes only where it is needed. In the simplest scenario, this would predict that 
interactions between these three proteins would reinforce each other. Indeed, VPS4 
interacts with ESCRT-III and LIP5/Vta1 via separate domains (26, 27). Similarly, 
LIP5/Vta1 binds to VPS4 and the ESCRT-III like protein CHMP5/Vps60 via its C-
terminus and N-terminus, respectively (26).  However, we found that the VPS4 MIT 
domain reduces LIP5 binding to both CHMP2A and CHMP1B, indicating that everything 
cannot happen simultaneously (Fig. 3-5).  
At the same time, we found evidence for a second, more internal, binding site for 
VPS4 in these ESCRT-III proteins (Figs. 3-6 & 7), leading us to suggest that the 
interaction of VPS4 with the MIM motifs in !6 may represent only one step in ESCRT-III 
disassembly. Although we were unable to precisely define the second VPS4 binding 
motif in vitro, deletion and alanine scanning studies in both CHMP2A and CHMP1B 
indicated that this interaction depends on conserved sequences within these proteins’ !5 
helix and in particular on two acidic residues that are conserved across all ESCRT-III 
proteins. Interestingly, !5 occupies an exposed position in the crystal structure of 
CHMP3 (14), which probably represents the “open” form of these proteins (5). We 
propose that interaction of VPS4 – using its MIT domain, elements within its AAA+ 
domain such as the “pore loops” known to be important for its function (25), or possibly 
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an associated cofactor such as the recently described Ist1 (40) – with !5 in all ESCRT-III 
proteins is likely to be an important additional step in ESCRT-III complex disassembly.    
While LIP5 is clearly established as a positive modulator of the MVB sorting 
pathway, the role played by CHMP5 (Vps60 in yeast) is less clear. CHMP5 binds with 
high affinity to LIP5 (Fig. 3-8), and deleting these two proteins in yeast has overlapping 
rather than additive effects (32). However, reducing or eliminating CHMP5 expression in 
mammalian tissues or cells does not prevent formation of MVBs (nor incorporation of 
TGF-" receptors into the internal vesicles) (44) and in fact enhances HIV budding from 
cells (31). These effects, together with the fact that LIP5’s interaction with CHMP5 is 
fundamentally different from its interaction with the other ESCRT-III proteins, lead us to 
suggest that CHMP5 bound to LIP5 might negatively regulate LIP5 for engagement with 
other ESCRT-III proteins and VPS4. This possibility remains to be further explored. 
A model that summarizes our results and how they impact thinking about the 
cooperation between LIP5 and VPS4 in regulating ESCRT-III is shown in Fig. 3-9. 
Binding sites for LIP5 (!5 in CHMP5, !6 in CHMP1B and CHMP2A) and for VPS4B 
(previously described primary site in !6, secondary binding site in !5) are shown in Fig. 
3-9A. The relationship between ESCRT-III subunits, ESCRT-III complex, and LIP5 and 
VPS4 is depicted in Fig. 3-9B. ESCRT-III proteins are closed monomers in the cytosol. 
In this state, our results suggest that only CHMP5 binds to LIP5. When ESCRT-III 
proteins polymerize into complexes on the endosomal membrane (presumably 
nucleated by upstream factors that are connected to cargo) the subunits open, exposing 
sequences at their C-termini for binding to LIP5 and/or VPS4. How these two proteins 
share their overlapping binding sites remains to be determined, but their separate ability 
to bind each other (via domains that are not engaged with the ESCRT-III proteins, the " 
domain in VPS4 (25, 27) and the VSL domain in LIP5 (Azmi et al., 2006)) is likely to 
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reinforce their association. Once some threshold is reached (perhaps full assembly of a 
VPS4 oligomer (28, 29), we hypothesize that VPS4 engages its secondary contact site. 
This in turn may allow VPS4 to unfold individual ESCRT-III subunits and release them 
into the cytoplasm, where they revert to their closed and monomeric states. While 
aspects of this model remain to be confirmed, and importantly any ESCRT-III 
disassembly reaction has yet to be reconstituted, the intricacies of this important step in 
MVB biogenesis are finally starting to come into focus.   
While this paper was being reviewed and revised, two papers examining the 
structure and interactions of Vta1 (the yeast equivalent of LIP5) were published (45, 46). 
In one, the high-resolution crystal structure of the Vta1 N-terminus revealed two MIT-like 
domains, each consisting of three !-helices (46). This structure strongly supports our 
finding of a high affinity interaction between LIP5 and the MIM-containing ESCRT-III 
proteins CHMP1B and CHMP2A and suggests that one or both of LIP5’s MIT domains 
binds to these proteins. In the second paper, the interaction between Vta1 and Vps60 
(yeast CHMP5) was explored in more detail with results that largely agree with what we 
report here for mammalian proteins (45). Significant differences are the failure to see a 
high affinity interaction between Vta1 and Vps2 in the yeast system and mapping of the 
Vta1 binding site in Vps60 to !4 instead of !5 as found here for CHMP5 and LIP5. 
Whether these differences reflect differences in the protein interactions or in the 
conditions used to study them remains to be established.  
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FIGURE LEGENDS 
 
Figure 3-1 LIP5 binds to ESCRT-III proteins. 
(A) Interaction of LIP5 with a subset of ESCRT-III proteins. GST and GST-ESCRT-III 
proteins immobilized on glutathione-sepharose beads were incubated with E.coli lysate 
containing His6-LIP5. Bound material was separated on a SDS-PAGE gel and stained 
with Coomassie Blue. Where necessary, lanes were rearranged as indicated by white 
lines. Immunoblotting with an anti-His6 antibody confirmed that no His6-LIP5 bound to 
GST-CHMP4A or GST-CHMP6 (not shown). 
(B) Solid phase assay of LIP5 binding to GST-CHMP1B, 2A and 3. His6-LIP5 bound to 
immobilized GST-CHMP proteins was detected with NTA-HRP and TMB colorimetric 
substrate. EC50 values determined by non-linear regression analysis ranged from 10-20 
nM for CHMP1B (triangles, solid line), from 49-60nM for CHMP2A (open circles, dotted 
line), and from 0.3-1!M for CHMP3 (asterixes, alternating dashed line) in several 
independent experiments. Error bars show the SD from one experiment run in duplicate. 
Absorbance data was normalized to the Bmax for CHMP1B. 
(C) Binding of His6-LIP5 to GST-VPS4B(E235Q) and GST-VPS4B(E235Q, "GAI) # 
domain mutant. EC50 for VPS4B(E235Q) (boxes, solid line) was 60nM. LIP5 binding to 
VPS4B(E235Q, "GAI) did not change as a function of LIP5 added (pyramids, dotted 
line). Error bars again show the SD from one experiment run in duplicate, and the 
absorbance data was normalized to the Bmax for VPS4B(E235Q). 
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Figure 3-2 C-terminal sequences in CHMP2A and CHMP1B are required for LIP5 
binding.  
(A) Predicted CHMP2A secondary structure obtained using a neural network based 
algorithm (http://www.compbio.dundee.ac.uk/~www-jpred/submit.html). Pink and blue 
boxes correspond to predicted !-helices with pI higher than 8 and lower than 6, 
respectively.  
(B) Effects of deleting N- and C-terminal sequences from CHMP2A on LIP5 binding. 
GST and GST-CHMP2A proteins with the indicated sequences immobilized on beads 
were incubated with E.coli lysate containing His6-LIP5. Bound material was analyzed by 
staining with Coomassie Blue.  
(C) Predicted CHMP1B secondary structure. 
(D) Effects of deleting N- and C-terminal sequences from CHMP1B on LIP5 binding. 
GST and GST-CHMP1B proteins with the indicated sequences immobilized on beads 
were incubated with E.coli lysate containing His6-LIP5. Bound material was analyzed by 
staining with Coomassie Blue (upper panel) and by immunoblotting with an anti-His6 
antibody (lower panel). Immunoblotting was needed because His6-LIP5 migrates 
similarly to GST-CHMP1B(106-199).  
 
Figure 3-3 CHMP2A and CHMP1B !6 region is responsible for LIP5 binding. 
(A) Effect of CHMP2A L216A mutation on interaction with LIP5. GST and GST-CHMP2A 
proteins immobilized on beads were incubated with E.coli lysate containing His6-LIP5. 
Bound material was analyzed by staining with Coomassie Blue. Where necessary, gel 
lanes were rearranged as shown by a white line. 
(B) Binding of His6-LIP5 to GST-CHMP1B(169-199). This CHMP1B fragment contains 
!6 and surrounding sequences but does not include !5.  
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(C) Solid phase assay of His6-LIP5 binding to GST-CHMP1B(169-199) carried out as 
described in Fig. 3-1. The EC50 of 25 nM is similar to that of His6-LIP5 for full-length 
CHMP1B. Absorbance data was normalized to the Bmax for full-length CHMP1B 
measured in parallel. 
 
Figure 3-4 LIP5 associates preferentially with polymerized CHMP2A and CHMP1B 
in transfected mammalian cells. 
(A) Cosedimentation of LIP5 with CHMP2A. HEK293T cells cotransfected with GFP-
LIP5 or GFP-LIP5!N and the indicated FLAG-CHMP2A constructs were solubilized in 
1% Triton X-100 and centrifuged. The distribution of CHMP2A and LIP5 in the resulting 
supernatant (S) and pellet (P) was visualized by immunoblotting. LIP5!N is equivalent to 
a deletion in Vta1 that impairs binding to Vps60 (26). Experiments with LIP5!N were 
performed separately from those with full-length LIP5 and are therefore shown in a 
separate box. 
(B) Cosedimentation of LIP5 with CHMP1B. The same experiments performed with 
FLAG-CHMP1B constructs.  
 
Figure 3-5 Binding sites for VPS4 and LIP5 in CHMP2A and CHMP1B overlap.   
(A) VPS4A MIT domain reduces LIP5 binding to GST-CHMP2A. GST-CHMP2A was 
incubated with His6-LIP5 alone or together with 300"M His6-VPS4A MIT domain or 
ribonuclease A as indicated. Bound LIP5 was visualized by staining with colloidal 
Coomassie blue and quantified by infrared fluorescence scanning. The bound MIT 
domain can be seen as an increased intensity in the dye front. 
(B) Quantitation of the effect of MIT domain on binding of 3.2 "M LIP5 to CHMP2A or (in 
parallel experiments) CHMP1B.  
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(C) Quantitation of lack of effect of the same concentration (300 !M) of ribonuclease A 
on binding of 1.6 !M LIP5 to GST-CHMP2A.  
(D) LIP5 and VPS4B(E235Q) bind similarly to GST-CHMP1B(169-199). Material 
retained on GST or GST-CHMP1B(169-199) after incubation with 5 !M of the indicated 
protein is shown on a gel stained with Coomassie Blue.  
 
Figure 3-6 Effects of C-terminal deletions suggest existence of secondary binding 
site for VPS4B in CHMP2A and CHMP1B.  
(A) HEK293T cells co-transfected with VPS4B(E235Q)-GFP and indicated FLAG-
CHMP2A constructs were solubilized in 1% Triton X-100 and centrifuged. The resulting 
distribution of VPS4B(E235Q) and CHMP2A between supernatant (S) and pellet (P) was 
visualized by immunoblotting.  
(B) Same experiment but with FLAG-CHMP1B constructs.  
 
Figure 3-7 Conserved acidic residues in "5 are part of secondary VPS4 binding 
site.  
(A) Sequences of predicted "5 and surrounding sequences in CHMP2 and CHMP1 
proteins. Highly conserved acidic residues near the center of the helix are colored red, 
less conserved pairs of acidic residues in CHMP2A are colored blue. Pairs of alanine 
replacements in CHMP2A studied below are designated mut a, mut b, and mut c as 
indicated. The conserved central pair of acidic residues was also mutated in CHMP1B 
and designated as mut a. 
(B) Effect of double alanine mutants on co-sedimentation of VPS4B(E235Q) with full-
length (1-222) or "6-deleted (1-206) CHMP2A in cotransfected HEK293 cells. Cells were 
solubilized in 1% Triton X-100 and centrifuged. The resulting distribution of 
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VPS4B(E235Q) and CHMP2A between supernatant (S) and pellet (P) was visualized by 
immunoblotting.  
(C) Effect of mut a on cosedimentation of VPS4B(E235Q) with full length (1-199) or !6-
deleted !1 – !5 (1-181) CHMP1B.  
 
Figure 3-8 Unique properties of CHMP5-LIP5 complex: LIP5 binds to CHMP5 !5 
preferentially in the soluble fraction. 
(A) Predicted secondary structure of CHMP5.  
(B) GST and GST-CHMP5 proteins immobilized on beads were incubated with 
HEK293T cell lysate containing GFP-LIP5. Bound and unbound fractions were analyzed 
by immunoblotting with anti-GFP antibody. GST proteins were visualized by staining the 
immunoblot with Ponceau red.  
(C) GST and GST-CHMP5 proteins on beads were incubated with E.coli lysate 
containing His6-LIP5 and the bound material was analyzed by staining with Coomassie 
Blue. Where necessary, lanes were rearranged as indicated by white lines. 
(D) Binding of His6-LIP5 to immobilized GST-CHMP5(121-219), detected and analyzed 
as in Fig. 3-1B. EC50 values ranged from 1-2 nM. Error bars show SD from one 
experiment performed in duplicate. 
(E) LIP5 does not cosediment with CHMP5. HEK293T cells co-transfected with GFP-
LIP5 and FLAG-CHMP5 were solubilizated in 1% Triton X-100 and centrifuged. The 
resulting supernatant (S) and pellet (P) were analyzed by immunoblotting.   
(F) Coimmunoprecipitation of CHMP5-myc with LIP5-GFP from co-transfected HEK293T 
cells. LIP5-GFP or LIP5"N-GFP was immunoprecipitated from the soluble lysate of 
cotransfected cells. Bound proteins and lysate were analyzed by immunoblotting.  
 
  120 
Figure 3-9 Model showing proposed engagement of LIP5 with ESCRT-III proteins 
and VPS4.  
(A) Binding sites for LIP5 and Vps4 in individual ESCRT-III subunits. Sites defined in this 
study in CHMP2A and CHMP1B are shown at left and in CHMP5 at right. The schematic 
structure of the ESCRT-III subunits is based on the crystal structure of CHMP3 (14).  
(B) Proposed model of ESCRT-III assembly, disassembly, and interaction with LIP5 and 
VPS4. Most ESCRT-III proteins are closed monomers in the cytoplasm and do not bind 
to LIP5, although CHMP5 interacts differently with LIP5 and can bind in the cytoplasm. 
As ESCRT-III complexes assemble on the endosomal membrane, individual subunits 
open and expose sequences at their C-termini for binding to LIP5 and/or VPS4. How 
these two proteins share their overlapping binding sites remains to be determined, but 
their separate ability to bind each other (via domains that are not engaged with the 
ESCRT-III proteins, the ! domain in VPS4 (Scott et al., 2005a; Vajjhala et al., 2006) and 
the VSL domain in LIP5 (Azmi et al., 2006)) is likely to reinforce their association. Once 
some threshold is reached (perhaps assembly of VPS4 rings), we propose that VPS4 
engages its secondary contact site in "5 of the ESCRT-III proteins. Based on analogy to 
other AAA+ proteins, this may allow VPS4 to unfold individual ESCRT-III subunits and 
release them into the cytoplasm where they revert to their closed and monomeric state. 
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Figure 3-9 
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INTRODUCTION 
 One goal of my thesis is to better understand the role of ESCRT-III in mammalian 
cells. Recent studies from our lab and others provide some clues about the structure of 
ESCRT-III polymers and their effects on the membranes with which they associate. 
However, it is yet to be determined whether and precisely how such polymers play roles 
in ILV formation. The first in vitro reconstitution of intralumenal vesicle (ILV) formation by 
ESCRT-III and VPS4 was recently reported using giant unilamellar vesicles (GUVs) and 
a minimal set of yeast proteins (1). The next step will be reconstitution using endosomes 
containing cargo proteins in order to answer the questions of when and how individual 
ESCRT-III proteins and VPS4 contribute to ILV formation under more physiological 
conditions. To do this, we need to define relevant cargo that utilizes ESCRT-III 
machinery for entry into the MVB and establish reagents for manipulating and detecting 
endogenous components of the machinery. These tools and functional assays are 
described in this chapter.   
To monitor incorporation of transmembrane protein cargo into the MVB and 
subsequent degradation in the lysosome, one typically follows the fate of specific 
signaling receptors destined for lysosomal degradation. Epidermal growth factor receptor 
(EGFR) has been extensively studied in this context (2-4). EGFR is a receptor tyrosine 
kinase that dimerizes upon ligand binding, inducing kinase activation and 
phosphorylation of tyrosine residues in the cytoplasmic tail. The phophorylated tyrosine 
resides interact with adaptors and effectors that activate various kinases including 
Ras/MAP kinase, phospholipase C!/protein kinase C and phosphatidylinositol 3-kinase 
(PI3-kinase)/Akt. Signal transduction pathways activated by these kinases lead to gene 
expression responsible for cellular responses including cell proliferation, adhesion and 
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migration (2, 5). Dysregulation of EGFR by overexpression or failure in downregulation is 
frequently associated with cancer, in particular carcinoma (6).  
One functional assay using receptors is measurement of the degradation of the 
receptors or sometimes ligands after stimulation (7). A limitation of this assay is that 
lysosomal degradation of receptors is several steps away from sorting into ILVs within 
the MVB. A more direct assay is to monitor cargo sorting into the MVB vesicles. When 
the plasma membrane is disrupted, the cytoplasmic domain of a receptor on the limiting 
membrane of the endosome will be degraded by proteases (8). The receptor internalized 
into ILVs will be protected from protease treatment. Cargo sorting into the MVB can also 
be reconstituted and monitored in vitro using this protease protection assay (9). Finally, 
quantitative electron microscopy has also been used to observe ILV formation and 
EGFR sorting into ILVs (10). 
In the current model, a receptor destined for lysosomal degradation engages 
ESCRT machinery via the interaction with ubiquitin at its cytoplasmic tail (11-13). EGFR 
destined for lysosomal degradation is ubiquitinated by the E3 ubiquitin ligase c-Cbl, and 
many components of the ESCRT machinery were shown to be involved in the 
degradation of EGFR (7-9, 14-18). Similar to EGFR, a number of surface receptors are 
efficiently degraded in the lysosome upon activation and ubiquitination of their 
cytoplasmic tails (11, 19). However, the involvement of the ESCRT machinery has been 
studied only in a small number of receptors with a subset of ESCRT components. 
Protease-activated receptor2 (PAR2), a G protein-coupled receptor (GPCR), is 
ubiquitinated by c-Cbl and subsequently degraded in the lysosome (20). Hrs (ESCRT-0) 
overexpression or knockdown resulted in formation of enlarged endosomes containing 
PAR2 and c-Cbl (21). The chemokine receptor CXCR4, another GPCR, is ubiquitinated 
by AIP4, an E3 Ub ligase, and also degraded in the lysosome. Its degradation is 
inhibited by overexpression of Hrs (ESCRT-0) and ATP hydrolysis defective VPS4 (22). 
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Finally, ferroportin, an iron transporter which is activated by binding to hepcidin, is 
similarly ubiquitinated and degraded in the lysosome. Its degradation was inhibited by 
knockdown of several components of ESCRTs (23, 24).  
Interestingly, however, recent reports suggest that lysosomal degradation of 
some receptors does not require ubiquitin modification and may be independent of at 
least part of the ESCRT machinery. These include Protease-activated receptor1 (PAR1), 
!"opioid receptor (DOR) and Calcitonin receptor-like receptor (CLR), all of which belong 
to the GPCR family.  Mutating all lysine residues in their cytoplasmic tails prevents them 
from being ubiquitinated but does not inhibit their degradation, indicating that 
ubiquitination of the receptors themselves is not necessary (25, 26). Lysosomal 
degradation of PAR1 was not affected by depletion of Hrs (ESCRT-0) and Tsg101 
(ESCRT-I), leading to a proposal that PAR1 undergoes lysosomal degradation via an 
ESCRT-independent pathway (19, 27). CLR and DOR appeared to depend on Hrs 
(ESCRT-0), but DOR was not affected by Tsg101 (ESCRT-I) knockdown (21, 28). For 
the most part, the involvement of ESCRT-III and VPS4 has not been studied.  
Because the ESCRT machinery engages cargo via the interaction with ubiquitin 
on cargo, it is possible that delivery of these receptors to the lysosome bypasses the 
ESCRT machinery. However, alternative routes have not been clearly identified. 
ESCRT-III and VPS4 do not have ubiquitin binding motifs, unlike upstream ESCRTs 
(ESCRT-0, I and II). Yet, ESCRT-III and VPS4 have been the most conserved ESCRT 
machinery throughout evolution, and are also required for other topologically related 
budding processes - viral budding and cytokinesis. Thus, I hypothesize that ESCRT-III 
and VPS4 are necessary for lysosomal degradation of all receptors whether or not the 
process requires upstream ESCRTs and ubiquitination.  
I test this hypothesis using DOR as a model system. Although lysosomal 
degradation of DOR may be ESCRT-I-independent, dominant negative VPS4 can inhibit 
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its degradation, suggesting that ESCRT-III and VPS4 are likely involved in lysosomal 
degradation of DOR (28). DOR is a receptor expressed in neurons, and plays a role in 
opioid-mediated analgesia and opioid tolerance (29). Agonists of DOR were also shown 
to modulate T cell proliferation and cytokine production, suggesting that at least a subset 
of T cells may have DOR (30). Thus, studying the mechanisms for lysosomal 
degradation of DOR will provide insight into DOR mediated pain regulation and some 
aspects of the immune response. In summary, I test whether ESCRT-III and VPS4 are 
required for lysosomal degradation of DOR in order to provide evidence for their 
conserved roles in the lysosomal degradation of receptors. I also discuss how DOR 
together with EGFR can be used to determine the specific roles of individual ESCRT-III 
proteins and VPS4 in ILV formation.  
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EXPERIMENTAL PROCEDURES 
Plasmids and siRNAs 
The following plasmids are previously described: pcDNA4TO VPS4B wild type-
GFP, pcDNA4TO VPS4B(E235Q)-GFP, pcDNA3.1 FLAG-CHMP2A full-length, 
pcDNA3.1 FLAG-CHMP2A 1-180 (Chapter 2 and (31)). FLAG-DOR plasmid was a gift 
from Dr. von Zastrow (UCSF, San Francisco, CA). pLKO shRNA plasmids were obtained 
from the Washington University Genome Sequencing Center (St. Louis, MO). siRNAs for 
Tsg101, VPS4A and VPS4B were purchased from Thermo Scientific (Chicago, IL). 
Sequences for shRNAs and siRNAs are listed in Table 4-2. Control siRNA is Accell Non-
targeting siRNA #1 (Thermo Scientific, IL).  
To make pcDNA4TO Myc-CHMP2A full-length or pcDNA4TO Myc-CHMP2A 1-
180, CHMP2A, cDNAs for CHMP2A were cut from pcDNA3.1 FLAG-CHMP2A full-length 
and 1-180, and inserted into pcDNA 4TO -myc vector between BamHI and XhoI site. 
This generated constructs tagged with Myc at their N-termini.  To make pcDNA4TO 
EGFR-GFP, cDNA for EGFR-GFP were cut from pEGFP-EGFR (a gift from Dr. Linda 
Pike Washington University, MO) and digested with XhoI and NotI. XhoI site was filled 
using Klenow (New England Biolabs, Ipswich, MA) to make a blunt end. The cDNA were 
subsequently ligated into pcDNA4TO vector (Invitrogen, Carlsbad, CA) between EcoRV 
and NotI sites.  
 
Tissue culture 
HEK293T and HeLa cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) (Invitrogen-BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum 
(FBS) (Invitrogen –BRL or Atlanta Biologicals, Lawrenceville, GA) and 2mL glutamine 
(Washington University Tissue Culture Center, St. Louis, MO). HEK293 and HeLa cells 
stably expressing FLAG-DOR were obtained from Dr. Von Zastrow (UCSF) and 
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maintained in DMEM supplemented 10% FBS together with 2mL glutamine and 
250!g/mL of G418 (Sigma, MO). TRexTM-HEK293 cells (Invitrogen, CA) expressing 
tetracycline repressor were grown in DMEM supplemented with 10% tet-free FBS 
(Atlanta Biologicals), 2mL glutamine and 5!g/mL blasticidin (Invitrogen, CA). All cells 
were grown in a 5% CO2 incubator at 37 °C. 
 
Establishing stable cell lines  
TRex-HEK293 cells stably expressing EGFR-GFP were generated as described 
previously (32). Briefly, TRex-HEK293 cells were transfected with pcDNA4TO EGFR-
GFP and selected in 125!g/mL Zeocin (Invitrogen, CA) containing media. One of the 
zeocin resistant clones was chosen and used for further analysis. 10ng/mL tetracycline 
was added to cells overnight to induce a low level of EGFR-GFP protein expression that 
can be degraded upon EGF treatment.  
To establish TREx-HEK293 cell lines expressing FLAG-DOR together with 
VPS4B or CHMP2A, TRex-HEK293 cells were first transfected with FLAG-DOR and 
selected in 250!g G418 (Sigma, St. Louis, MO). One of G418 resistant clones was 
transfected again with pcDNA4TO VPS4B wild type-GFP, pcDNA4TO VPS4B(E235Q)-
GFP, pcDNA4TO Myc-CHMP2A full-length or pcDNA4TO Myc-CHMP2A 1-180. 
Population cell lines were obtained by selection in 125!g/mL zeocin. These cell lines 
express FLAG tagged DOR constitutively but express VPS4 or CHMP2A in a 
tetracycline inducible manner. To express VPS4 and CHMP2A proteins, 1!g/mL 
tetracycline was added to cells overnight (Fig. 4-7B and 4-9B) or for 6 hours (Fig. 4-7C 
and 4-9C).  
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Transfection  
For plasmid transfection, cells were transfected with indicated plasmids using 
Lipofectamine 2000 (Invitrogen, CA) following the manufacturer’s instruction and 
typically assayed 18-24 hours after transfection. Cells transfected with shRNA 
expressing plasmids were assayed about 48 hours after transfection. For siRNA 
transfection, HEK293 derived cells and HeLa derived cells were seeded at 2x105 
cells/well and 8x104 cells/well respectively in a 12 well plate. Next day, cells were 
transfected with indicated siRNAs using Dharmafect #1 (Thermo Scientific, IL), following 
the manufacturer’s instruction, and assayed about 48 hours after transfection.  
 
Transduction  
8x105 HEK293T cells were plated in a 6cm dish a day before transfection, and 
were transfected with 1!g shRNA constructs together with 0.9!g pCMV 8.2 delta R 
(packaging construct) and 0.15!g pCMV VSV-G (envelope construct) (gifts from Dr. 
Sheila Stewart, Washington University in St. Louis, MO). Next morning, media was 
changed to DMEM containing 30% heat inactivated FBS and 2mL glutamine.  About 26-
28 hours later, media containing recombinant lentiviruses was collected by passing the 
media through a 0.45!m filter to remove cell debris, and was added to target cells 
together with 10!g/mL protamine sulfate. Target cells are typically prepared in a 6 well 
plate a day before transduction: 2.5x105 cells/well and 8x104 cells/well were seed for 
HEK293 derived cells and HeLa derived cells respectively. Production and transduction 
of recombinant lentiviruses were carried out in BL2+ facility in the Dept of Cell Biology 
and Physiology at Washington University in St. Louis, following BL2+ bio-safety criteria.  
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EGFR degradation assay  
TRex-HEK293;EGFR-GFP cells were incubated with 10ng/mL tetracycline 
overnight. After incubating in tetracycline free media for 5 hours, cells were stimulated 
with 100ng/mL EGF for 0, 1 and 2 hours. Cells were then lyzed in sodium dodecyl 
sulfate (SDS) sample buffer and analyzed by immunoblotting with anti-GFP antibody 
(1:2500). HeLa cells were starved in serum free DMEM for 3 hours before stimulation 
with 100ng/mL EGF for 0, 1 and 2 hours. Treatment of 10!g/mL cycloheximide did not 
make noticeable differences in the level of EGFR and its degradation rate at least in this 
assay setting. The experiments presented in this chapter were carried out without 
cycloheximide. Cells stimulated with EGF were analyzed by immunoblotting with rabbit 
anti-EGFR antibody (Santa Cruz;1:500) after lysis in SDS sample buffer. Equal loading 
of proteins was confirmed by mouse anti-"-tubulin antibody (Sigma; 1:5000).   
 
DOR degradation assay 
HEK293 and HeLa cell lines expressing FLAG-DOR (HEK293;FLAG-DOR and 
HeLa;FLAG-DOR) were incubated with 10!M DADLE (enkephalin, D-Ala2, D-Leu5) 
(Sigma, MO) for 0, 2 and 4 hours. 10mg/mL cycloheximide was added to HeLa;FLAG-
DOR cells 1 hour prior to treatment with DADLE and maintained during stimulation. 
HEK293;FLAG-DOR cells were not treated with cyloheximide. Stimulated cells were 
lyzed in SDS sample buffer and analyzed by immunoblotting with rabbit anti-FLAG 
antibody (Sigma; 1:5000). Equal loading of proteins was confirmed by mouse anti-"-
tubulin antibody.   
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Immunofluorescence analysis  
Cells grown on coverslips were fixed in 3.5% paraformaldehyde in PBS and 
permeabilized with 0.2% Triton X-100 in PBS. HeLa derived cell lines were grown on 
plain glass coverslips while HEK293 based cell lines were grown on poly-lysine coated 
coverslips. After blocking in 5% goat serum, cells were stained with indicated primary 
antibodies followed by secondary antibodies. To visualize nuclei, cells were costained 
with 4’-6’-diamidino-2-phenlindole (DAPI; 1:10000; Molecular Probes. Eugene, OR). The 
following antibodies were used for immunofluorescence analysis: rabbit anti-FLAG 
antibody (Sigma, MO, 1:500), mouse anti-myc ascities (1:500), anti-CD63 
(Developmental Studies Hybridoma Bank, University of Iowa, IA; 1:1000), anti-early 
endosomal antigen1 (EEA1) (Developmental Studies Hybridoma Bank, 1:500). Staining 
conditions for CHMP2B, CHMP4A, CHMP4B and CHMP6 are described in Table 4-1.  
For epifluorescence microscopy, images were obtained using a Leica Diaplan 
microscope and Zeiss Axiocam camera. For confocal microscopy, images were obtained 
using Zeiss Axioplan2 microscope coupled to a Radiance plus confocal laser system 
(Bio-Rad), and Zeiss Axioskop upright microscope coupled to Zeiss 2Photon LSM510 
NLO system (Carl Zeiss, Maple Grove, MN) in the Bakewell NeuroImaging Laboratory at 
Washington University in St. Louis. Images are obtained using Laser and Images were 
processed using Image J (NIH image, Bethesda, MD) and Adobe Photoshop (Adobe, 
CA).   
 
Fluorescence EGF uptake assay 
HeLa cells grown on coverslips were starved in serum free DMEM for 3 hours 
and incubated with 200ng/mL of Alexa-555 EGF (Invitrogen, CA) in HEPES buffered 
DMEM containing 0.2% bovine serum albumin (BSA) for 30min on ice. After washing 3 
times with ice-cold PBS, cells were incubated with pre-warm DMEM containing 10% 
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FBS in a 37ºC humidified incubator for 15min and 5 hours. Cells were then fixed and 
stained with DAPI and analyzed by epifluorescence microscopy. 
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RESULTS 
Antibodies recognizing ESCRT-III proteins and other proteins in the ESCRT 
pathway 
As a step towards studying the function of endogenous ESCRT-III proteins in 
mammalian cells, I first characterized antibodies that recognize human ESCRT-III 
proteins and other proteins in the ESCRT pathway. As shown in Fig. 4-1A and B, I was 
able to detect a number of ESCRT-III proteins (CHMP1A, CHMP2A, CHMP2B, CHMP3, 
CHMP4A, CHMP4B, CHMP5 and CHMP6), two VPS4 isoforms (VPS4A and VPS4B), 
Tsg101 (ESCRT-I), and LIP5 in HEK293 based cell lines by immunoblotting (Fig. 4-1A 
and B). Most antibodies visualized proteins of interest as specific bands near expected 
sizes. For CHMP2A, two bands appeared near the expected size, ~30 – 35 KDa (left 
lane). To determine which one of them represents endogenous CHMP2A, I took 
advantage of the fact that CHMP2A co-sediments with dominant negative mutant VPS4 
following solubilization in Trinton X-100 (Fig. 3-4). When VPS4B(E235Q) was expressed, 
only the lower band appeared in the insoluble fraction, thereby identifying it as 
endogenous CHMP2A. The specificity of several antibodies including CHMP2A was 
confirmed by knockdown as shown in Fig. 4-2. The sources of antibodies and staining 
conditions are listed in Table 4-1. To further determine how specific the antibodies are, I 
tested antibodies for CHMP2, CHMP4 and VPS4 in HEK293T cells transiently 
transfected with isoforms of these proteins. Antibodies for CHMP2A, CHMP2B, 
CHMP4A, CHMP4B and VPS4B recognized their own proteins well but did not detect 
the related isoforms. VPS4A antibody cross-reacted with VPS4B at low efficiency (Table 
4-1 and data not shown).  
Importantly, several of these antibodies also detected endogenous proteins by 
immunofluorescence (Figure 4-1C and Table 4-1). Because ESCRT-III proteins are 
predominantly soluble in the cytoplasm, it is difficult to distinguish specific cytoplasmic 
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staining from non-specific staining. Thus, I tested antibodies in cells expressing 
dominant negative mutant VPS4B(E235Q). Because this mutant VPS4 interferes with 
ESCRT-III disassembly, one would expect ESCRT-III proteins to accumulate on the 
endosomal membrane. Our lab previously generated the TRex-HEK293 cell line that 
expresses VPS4B(E235Q)) following addition of tetracycline (33). The cells induced to 
express mutant VPS4B were stained for endogenous ESCRT-III proteins. CHMP4A is 
shown as an example (Fig. 4-1C). In a cell that did not express VPS4B (right), CHMP4A 
was present diffusely throughout the cell. In contrast, in a cell expressing 
VPS4B(E235Q) (left), enlarged endosomes were coated with both mutant VPS4B and 
CHMP4A. This different pattern of antibody staining confirms that the CHMP4A antibody 
specifically stains for endogenous CHMP4A. Similar staining patterns were observed 
with CHMP2B, CHMP4B and CHMP6 antibodies (Table 4-1 and data not shown). The 
differential distribution of ESCRT-III proteins with and without dominant negative mutant 
VPS4 indicates that endogenous ESCRT-III proteins indeed cycle between the 
endosomal membrane and cytoplasm, and that this dynamic transition can be inhibited 
by functional loss of VPS4.  
 
Knockdown of ESCRT-III proteins and other proteins in the ESCRT pathway  
To knock down ESCRT-III proteins and other proteins in the ESCRT pathway, I 
used two different approaches. The first was to express small hairpin RNA (shRNA) in 
cells. shRNA is a RNA molecule that forms a tight hairpin structure, which is cleaved by 
cellular machinery into a double stranded small interfering RNA (siRNA). This is then 
bound to the RNA-induced silencing complex (RISC) which cleaves its target mRNA and 
thereby reduces expression of a target protein (34). Another approach is to directly 
introduce synthesized siRNA into cells.    
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To express shRNAs, I obtained lentiviral constructs (pLKO) containing shRNAs 
targeting various ESCRT proteins from The RNAi Consortium (TRC) through 
Washington University Genome Sequencing Center. I screened 5 hairpins for each 
protein, and the most effective shRNAs are presented in Figure 4-2A. To produce 
recombinant virus to express shRNAs, I trasnsfected individual pLKO shRNA constructs 
into HEK293T cells with packaging and envelope constructs. It should be noted that 
some components of the ESCRT machinery are involved in lentiviral budding (35, 36). 
Thus, expressing shRNAs for those proteins may compromise production of 
recombinant virus. Because knockdown of Tsg101 and LIP5 has been shown to reduce 
viral budding, I transiently transfected shRNA constructs in HEK293T cells (Fig. 4-2A) 
(37, 38). Expression of Tsg101 and LIP5 was greatly reduced 48 hours after transfecting 
shRNAs. I tested the efficiency of knockdown of several ESCRT-III proteins by 
transducing cells with recombinant virus stocks containing shRNAs. 48-72 hours after 
transduction, ESCRT-III protein levels were decreased by more than 50%, implying that 
lentviruses were present in these stocks. Because shRNAs can be stably expressed in 
cell lines, I attempted to generate such knockdown cell lines for CHMP2A, CHMP6 and 
LIP5. However, expressing shRNAs for these proteins was toxic to cells and therefore I 
was not able to make the cell lines. Cells died 3 - 5 days after transduction. Because our 
lab had no problem generating comparable knockdown cell lines for unrelated proteins 
(Torsin A and LULL1) using the same system, the toxicity I encountered is likely to be a 
specific effect of knocking down the ESCRT proteins. It is conceivable that knocking 
down the ESCRT proteins could compromise cytokinesis, although I cannot completely 
rule out off-target effects of these shRNAs. 
As a second knockdown approach, I transiently transfected siRNAs for VPS4A, 
VPS4B, and Tsg101. siRNA may be a better tool than viral packaged shRNAs for 
knocking down these proteins, which is clearly known to inhibit viral budding (23, 37). 
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The sequences for these siRNAs were all obtained from previous publications (23, 37) 
(Table 4-2). 48 hours after transfection of siRNAs, all three proteins were efficiently 
knocked down in HeLa cells (over 90%) and less efficiently in HEK293 derived cells (Fig. 
4-2B).   
 
EGFR/EGF degradation  
To examine the effects of manipulating the ESCRT machinery on trafficking of a 
previously well studied cargo protein, EGFR, I monitored lysosomal degradation of 
EGFR. I first examined endogenous EGFR in HeLa cells before and at several time 
points after adding 100ng/mL EGF, and the level of undegraded EGFR was determined 
by immunoblotting. As expected, endogenous EGFR was efficiently degraded within 2 
hours after EGF treatment (Fig. 4-3A). I also generated a TRex-HEK293 cell line 
expressing EGFR tagged with GFP in a tetracycline inducible manner. When I induced 
the expression of EGFR-GFP by treating a low concentration (10ng/mL) of tetracycline 
overnight, EGFR-GFP was efficiently degraded within 2 hours of 100ng/mL EGF 
treatment (Fig. 4-3B). Trafficking and degradation of EGFR-GFP was also analyzed by 
directly imaging the GFP signal with epifluorescence microscopy (Fig. 4-3C); EGFR-
GFP was internalized upon 100ng/mL EGF treatment and most receptors disappeared 2 
hours after stimulation. It should be noted that treating the EGFR-GFP cell line with a 
high concentration (1!g/mL) of tetracycline overnight resulted in a higher level of EGFR-
GFP expression, which was not decreased by EGF treatment (data not shown). This 
suggests that something in the pathway, perhaps the ESCRT machinery, is saturated, 
and therefore maintaining expression of EGFR at a proper level is critical for targeting 
the receptor to the lysosome. Another way to detect EGFR degradation is measuring 
undegraded EGF bound to EGFR. Alexa-555 conjugated EGF bound to the surface of 
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HeLa cells on ice was internalized upon incubating at 37ºC and was mostly degraded 5 
hours later (Fig. 4-3D).  
To confirm a role for the ESCRT machinery in the lysosomal degradation of 
EGFR, I tested how manipulation of an upstream ESCRT component, Tsg101 (ESCRT-
I), and a downstream ESCRT protein, VPS4, affects degradation of EGFR.  When I 
expressed dominant negative mutant VPS4 (VPS4B (E235Q)) or knocked down Tsg101, 
EGFR degradation was greatly reduced as expected (Figure 4-4). This data confirms 
that lysosomal degradation of EGFR requires ESCRT machinery, and that EGFR is a 
good cargo for studying the roles of ESCRT-III and VPS4.  
 
Requirement of ESCRT machinery for lysosomal degradation of DOR 
To determine the involvement of the ESCRT machinery on DOR trafficking and 
delivery to the lysosome, I first examined DOR degradation in cell lines stably 
expressing FLAG tagged DOR before and after 10!M DADLE (D-Ala2, D-Leu5) treatment 
by immunoblotting. In both HEK and HeLa derived cell lines, most DOR was degraded 
within 4 hours after stimulation with DADLE (Fig. 4-5A and B). Trafficking and 
degradation of DOR were also analyzed by immunofluorescence and confocal 
microscopy. DOR in the HEK293 cell line was mostly present on the cell surface; 
however, the receptor was internalized upon agonist treatment and disappeared mostly 
4 hours after stimulation (Fig. 4-5C). The internalized DOR colocalized well with CD63 
30 min after stimulation, suggesting that DOR transits through late endosomes/MVBs, 
the compartment I am interested in (Fig. 4-6). 
To test whether VPS4 is required for lysosomal degradation of DOR, I examined 
the effect of functional loss of VPS4 on DOR degradation. To do this, I transiently 
transfected the ATP hydrolysis defective mutant VPS4B (VPS4B(E235Q)) in the 
HEK293 derived DOR cell line. Similar to previously reported data, mutant VPS4B 
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greatly inhibited degradation of DOR while wild type VPS4B did not affect degradation 
(Fig.4-7A) (28). This inhibition was even greater in the cell line stably expressing mutant 
VPS4B in addition to DOR, presumably because VPS4B was expressed in all cells, 
unlike the transient transfection setting (Fig. 4-7B). I then used this cell line to determine 
colocalization of DOR and mutant VPS4B by immunofluorescence and confocal 
microscopy. As shown in Fig. 4-7C, DOR accumulated on enlarged endosomes 
generated by mutant VPS4B 1 hour after DADLE treatment, suggesting that DOR 
degradation was specifically inhibited by mutant VPS4B. Note that VPS4B(E235Q) 
protein was expressed in a tetracycline inducible manner because the sustained 
expression of this protein is toxic to cells. To further confirm whether DOR degradation is 
VPS4 dependent, I knocked down both VPS4A and VPS4B. Depleting both VPS4 
isoforms reduced DOR degradation to some extent in both HEK and HeLa derived cell 
lines (Fig. 4-8). Incomplete knockdown of VPS4A may account for the smaller effect on 
DOR degradation by knockdown than that by expressing mutant VPS4. Nevertheless, 
this data further supports the requirement of VPS4 for lysosomal degradation of DOR.  
Next, I tested whether ESCRT-III is also involved in DOR degradation. C-
terminally deleted ESCRT-III proteins behave as inhibitors of MVB function and viral 
budding (Fig. 2-5 and 2-6). To examine the effect of manipulating the function of 
ESCRT-III proteins on DOR degradation, I transiently transfected C-terminally truncated 
and wild type CHMP2A or CHMP4A in the HEK293 derived DOR cell line and monitored 
the level of DOR. Interestingly, mutant ESCRT-III proteins inhibited DOR degradation 
while wild type ESCRT-III proteins had little effect (Fig. 4-9A and data not shown). 
Furthermore, stable expression of mutant CHMP2A inhibited DOR degradation to a 
greater extent, similar to that seen with the cell line expressing mutant VPS4 (Fig. 4-9B). 
Localization of DOR in the cell line expressing mutant CHMP2A was also examined by 
immunofluorescence followed by confocal microscopy. Similar to that seen in cells 
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expressing mutant VPS4, DOR and mutant CHMP2A co-accumulated on enlarged 
endosomes (Fig. 4-9C). Together, these data suggest that lysosomal degradation of 
DOR requires ESCRT-III. To further confirm this, I knocked down several ESCRT-III 
proteins. My first pass analyses suggest that knockdown of CHMP3 inhibits degradation 
of DOR but knockdown of CHMP2A and CHMP6 does not (data not shown). It is 
possible that certain ESCRT-III proteins (perhaps CHMP6) may not be required for 
lysosomal degradation of DOR, and the functions of CHMP2 isoforms (CHMP2A and 
CHMP2B) may be redundant. However, any conclusions should await further 
experiments. 
Finally, I examined whether DOR degradation requires Tsg101. Surprisingly, 
knocking down Tsg101 inhibited DOR degradation, contrary to a previous report (28) 
(Fig. 4-10). Efficiency of knockdown could account for the discrepancy between these 
results. In fact, my knockdown appears to be more efficient than that previously reported 
based on the immunoblots for endogenous Tsg101 after knockdown. In conclusion, 
lysosomal degradation of DOR is required for Tsg101 (ESCRT-I), and therefore, DOR 
may be delivered to the lysosome via a pathway involving both upstream and 
downstream ESCRT machinery, similar to that seen with EGFR.   
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DISCUSSION 
Precisely how ESCRT-III contributes to MVB biogenesis remains unclear. As a 
step toward understanding this process, I have described reagents to detect and 
manipulate ESCRT-III proteins and other proteins in the ESCRT pathway. I also showed 
that two different receptors, EGFR and DOR, use ESCRT machinery to undergo 
lysosomal degradation. These reagents and defined cargo will be used to study the 
specific roles of ESCRT-III proteins and VPS4 in ILV formation and cargo sorting into 
ILVs.  
 
Detecting and knocking down ESCRT-III proteins 
Using antibodies, I was able to detect a number of human ESCRT-III proteins, 
VPS4 and other proteins in the ESCRT pathway (CHMP1A, CHMP2A, CHMP2B, 
CHMP3, CHMP4A, CHMP4B, CHMP5 and CHMP6, VPS4A, VPS4B, LIP5 and Tsg101) 
by immunoblotting and some of them (CHMP2B, CHMP4A, CHMP4B and CHMP6) by 
immunofluorescence (Fig. 4-1 and Table 4-1). I also knocked down several of these 
proteins using shRNAs (for CHMP2A, CHMP2B, CHMP3, CHMP6, Tsg101 and LIP5) or 
siRNAs (for Tsg101, VSP4A and VPS4B) (Fig. 4-2 and Table 4-2). These tools were 
used to show the role of ESCRT machinery in lysosomal degradation of EGFR and DOR. 
I also attempted to generate cell lines expressing shRNAs for CHMP2A, CHMP6 and 
LIP5. However, these attempts were unsuccessful due to toxicity of the shRNAs. 
shRNAs for these proteins will need to be expressed transiently or expressed stably in 
an inducible manner.  
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Both upstream and downstream ESCRT machinery is required for lysosomal 
degradation of DOR 
I found that degradation of DOR was inhibited by expressing mutant VPS4 and 
ESCRT-III proteins, and DOR co-accumulated on the endosomes with mutant VPS4 and 
mutant CHMP2A (Fig 4-7 and 4-9). Additionally, knocking down VPS4 and CHMP3 also 
decreased DOR degradation (Fig 4-8 and data not shown). These data suggest that 
lysosomal degradation of DOR requires ESCRT-III and VPS4. Surprisingly, Tsg101 
knockdown did inhibit DOR degradation, contrary to a previous report (28). Taken 
together, I conclude that lysosomal degradation of DOR is mediated by both upstream 
(Hrs based on another report (28), and Tsg101) and downstream ESCRTs (ESCRT-III 
and VPS4) similar to that seen in lysosomal degradation of EGFR here and elsewhere 
(7-9, 15-17) (Fig. 4-4). Supporting this, my preliminary data indicates that trafficking of 
DOR is not noticeably different from that of the well characterized ESCRT-dependent 
EGFR. In fact, internalized DOR colocalized with EGFR 15min or 30min after treatment 
with both enkephalin (DADLE) and EGF (data not shown). Nevertheless, how DOR 
engages the ESCRT machinery without itself being ubiquitinated remains unclear. DOR 
could interact with ESCRT machinery via protein-protein interactions or by ubiquitin 
attached to a cellular factor binding to DOR.  
One would be concerned that expressing dominant negative mutants or knocking 
down ESCRT proteins could block lysosomal targeting of transmembrane proteins 
nonspecifically by interfering with normal maturation of endosomes. However, there are 
situations in which compromising the ESCRT pathway does not affect ILV formation and 
sorting of transmembrane proteins into MVB vesicles. First, delivery of Pmel17 into the 
melamosome, a lysosome-related oraganelle, occurs via an MVB-like intermediate but 
distribution of Pmel17 is not affected by mutant VPS4, overexpressed Hrs and Tsg101, 
nor depletion of Hrs (39). Secondly, sorting of proteolipid protein (PLP) into the MVB and 
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release of PLP-containing exosomes (secreted ILVs) are not compromised by mutant 
VPS4 and overexpressed Tsg101, nor knockdown of Hrs and Tsg101 (40). These 
ESCRT independent pathways might have evolved for generation of special MVBs 
distinct from MVBs en route to the lysosome.  
 
Requirement of ESCRT-III and VPS4 in lysosomal degradation of receptors 
independent of upstream ESCRTs  
Because DOR appears to depend on upstream ESCRTs in addition to ESCRT-III 
and VPS4, my original hypothesis – that ESCRT-III and VPS4 are required for lysosomal 
degradation of receptors regardless of requirement of upstream ESCRTs or ubiquitin 
modification - should be tested using other receptors. PAR1 may be a good receptor on 
which to test this hypothesis since lysosomal degradation of PAR1 appears to be 
independent of Tsg101 and Hrs, yet the involvement of ESCRT-III and VPS4 has not 
been determined. If PAR1 degradation does not require ESCRT-III and VPS4, PAR1 
may be delivered to the lysosome via an alternative route which deserves further 
investigation. If lysosomal degradation of PAR1 depends on ESCRT-III and VPS4, this 
will support my hypothesis, and PAR1 can be used as an additional cargo protein to 
study the roles of ESCRT-III and VPS4, complementing EGFR and DOR.    
 
Studying specific roles of individual ESCRT-III proteins and VPS4  
Growing evidence suggests that individual ESCRT-III proteins contribute 
differentially to ILV formation. For example, CHMP6/Vps20 is thought to connect 
ESCRT-III to ESCRT-II and initiate ESCRT-III polymer assembly (41-44). CHMP4/Snf7 
is a main constituent of ESCRT-III polymers and might play a major role in generating 
ILVs (45, 46). CHMP2/Vps2 seems to be particularly critical for recruiting VPS4 
disassembly machinery (1, 41, 47, 48). When each ESCRT-III protein is recruited to the 
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endosome may at least partly contribute to its specific function. Based on yeast genetic 
studies, a specific order of recruitment of core ESCRT-III proteins has been proposed 
(CHMP6/Vps20 ! CHMP4/Snf7 ! CHMP3/Vps24 ! CHMP2/Vps2) (41, 45). In general, 
this order fits well with proposed roles of individual ESCRT-III proteins, although further 
investigation is required to determine whether and how this ordered ESCRT-III assembly 
occurs in mammalian cells.  
To better understand specific roles of individual ESCRT-III proteins and VPS4 in 
ILV formation, it will be ideal to watch when and where these proteins are recruited to 
cargo (e.g. EGFR and DOR) on the endosome. However, if the machinery only stays on 
endosomes transiently, it may be difficult to observe such events in fixed samples 
stained for endogenous proteins. Alternatively, specific effects of manipulating ESCRT-
III proteins and VPS4 can be analyzed. The phenotypes of knocking down a few 
ESCRT-III proteins and VPS4A/B have been previously reported. Briefly, knocking down 
CHMP3 inhibits EGFR degradation and resulted in smaller MVBs with fewer ILVs (15). 
Knockdown of CHMP4B or CHMP3 leads to accumulation of autophagosomes (49, 50). 
CHMP6 knockdown inhibits degradation of EGFR and ferroportin but do not inhibit viral 
budding (17, 23). Knocking down VPS4A/B greatly reduces viral budding and EGF 
degradation but how it affects ILV formation has not been analyzed (16, 23).  While 
these variable phenotypes support the idea of specific roles for individual ESCRT-III 
proteins and VPS4, the studies do not provide direct insight into the order of recruitment 
or how each protein functions at different stage of ILV formation and cargo sorting into 
ILVs. Such questions may be better answered by analyzing where the receptors 
accumulate, and how much and which ESCRT-III proteins and VPS4 colocalize after 
manipulating each protein. This can be examined by light and electron microscopic 
analyses of cells stained for endogenous ESCRT-III proteins, VPS4 and receptors after 
knocking down each protein followed by stimulating with ligands for the receptors. Such 
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analyses require good antibodies, efficient knockdown, defined cargo to engage the 
machinery and optimized times when most of the machinery is recruited to receptors, 
which are in part described in this chapter.  
Based on the current model of sequential recruitment, knockdown of one 
ESCRT-III protein could result in more accumulation of some ESCRT-III proteins than 
others. For example, knockdown CHMP3 may lead to accumulation of CHMP4 and 
CHMP6 but not of CHMP2. Knockdown of VPS4 may result in accumulation of all core 
ESCRT-III proteins. It will be also interesting to determine where individual proteins 
accumulate relative to receptors and each other. In fact, such different localization of 
ESCRT-III proteins was observed in cells expressing VPS4B(E235Q); endogenous 
CHMP4A and CHMP2B accumulated on the rims of VPS4B containing endosomes (Fig. 
4-1C and data not shown). Under a higher magnification, colocalization of CHMP2B with 
VPS4B on endosomes appeared to be better than that with CHMP4A supporting close 
relationship between CHMP2 and VPS4. 
To learn about how individual ESCRT-III proteins and VPS4 contributes to 
specific stages of ILV formation, MVB morphology should be carefully analyzed in cells 
lacking one or more of these proteins by electron microscopy. It is conceivable that 
depleting different proteins may result in accumulation of ILVs at different stages of 
budding. ILV formation of cells lacking CHMP4 proteins is of particular interest because 
of their proposed roles in ESCRT-III polymer assembly and ILV formation (44, 46). It is 
possible that depleting all CHMP4 proteins in cells might almost completely block vesicle 
formation unlike that seen with CHMP3 knockdown (15). A challenge to study roles of 
CHMP4 in mammalian cells is the fact that there are three isoforms, and CHMP4C 
antibody is not available yet.  
Several ESCRT-III proteins and VPS4 in mammalian cells have isoforms, and it 
is important to understand whether individual isoforms function redundantly or 
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specifically. In particular, studying CHMP2 proteins in this regard may provide insight for 
understanding pathophysiology of certain neurodegenerative diseases associated with 
mutations in CHMP2B (51, 52). It will be also interesting to examine specific roles of 
each isoform in different budding reactions. Recently, dominant negative mutant 
CHMP4C was shown to inhibit cytokinesis more than mutants of other CHMP4 proteins 
(53). To determine specific functions of CHMP4 proteins in different budding processes, 
effects of knockdown of each CHMP protein can be examined by various functional 
assays including receptor degradation assays, the virus-like particle (VLP) release assay, 
and counting multinucleated cells to measure interference with cell abscission during 
cytokinesis (Fig. 2-6, 4-4 and 4-5 and (54, 55)).  
Finally, mechanisms for cargo sorting into ILVs by ESCRT machinery could vary 
for different cargo proteins. Unlike that seen in EGFR, ubiquitination of DOR is 
dispensable for its lysosomal degradation, and therefore it is possible that DOR might 
engage a different subset of ESCRT-III components. My preliminary data showed that 
CHMP6 and CHMP2A did not affect DOR degradation while CHMP3 inhibited 
degradation to some degree (data not shown). For CHMP2, CHMP2A and CHMP2B are 
likely to compensate for each others’ function, because knocking down CHMP2B alone 
does not appear to have obvious effects on cells (49).  Although further experiments are 
required to make a conclusion, it is tempting to think that CHMP6 may not be necessary 
for lysosomal degradation of DOR similar to that seen in viral budding. HIV budding is 
not affected by knockdown Eap20, a component of ESCRT-II and CHMP6 which is 
proposed to connect ESCRT-II and ESCRT-III (17). In fact, both viral Gag proteins and 
Cep55 which is important for midbody formation during cytokinesis can interact with 
CHMP4 proteins via their interaction with Alix (53, 55, 56). Whether CHMP4 proteins can 
assemble polymers without CHMP6 in cells, and whether DOR, Gag and Cep55 could 
engage such polymers deserve further investigation.  
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Assays to monitor ILV formation and receptor sorting into ILV 
To study the roles of ESCRT machinery, I mostly used a functional assay to 
measure lysosomal degradation of EGFR and DOR, which allow for indirect monitoring 
of MVB biogenesis. For a more direct analysis, one can use the protease protection 
assay described in the Introduction. In this assay, the cytoplasmic domain of a receptor 
on the limiting membrane of the endosome will be degraded by proteases while the 
receptor internalized into ILVs will be protected from protease treatment. Thus, it will be 
useful to have a cell line expressing a receptor with an epitope tag at the cytoplasmic 
domain. I generated a HEK293 derived cell line expressing EGFR with GFP attached to 
the cytoplasmic domain. EGFR-GFP in this cell line was degraded efficiently upon EGF 
treatment (Fig. 4-3A and C). The DOR cell lines used here express DOR with a FLAG 
tag attached to the extracellular domain. Therefore, I have recently generated a HEK293 
derived cell line expressing DOR with GFP at the cytoplasmic domain in addition to a 
FLAG at the extracellular domain. I confirmed that the double tagged DOR was 
efficiently degraded 4 hours after agonist treatment (data not shown). These EGFR and 
DOR cell lines will be used to directly monitor ILV formation and receptor sorting into ILV, 
and ultimately to establish an in vitro reconstitution using isolated endosomes (9).  
In summary, tools and assays described here allow dissecting specific roles of 
ESCRT-III proteins and VPS4 in ILV formation, and sorting different receptors into ILVs. 
This will help understand mechanisms for this unusual budding process and 
downregulating receptors involved in critical cellular processes and pathological 
conditions.  
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FIGURE LEGENDS  
 
Figure 4-1 Antibodies recognizing ESCRT-III proteins and other proteins in the 
ESCRT pathway.  
(A-B) Endogenous ESCRT-III proteins (A) and other proteins in the ESCRT pathway (B) 
in HEK293 derived cell lines were visualized by immunoblotting with antibodies for 
indicated proteins. Samples shown here were prepared by lysis in 1% Triton X-100 or 
SDS sample buffer. Arrows point to the bands representing proteins of interest around 
expected sizes. For CHMP2A, there are two bands near the expected size, ~30 - 35KDa 
(left lane). The lower band in the pellet (P) likely represents endogenous CHMP2A 
protein. Supernatant (S) and pellet (P) were obtained by solubilizing HEK293 cells 
expressing the dominant negative mutant VPS4B (VPS4B(E235Q)) in 1% Triton X-100. 
(C) HEK293 cell line expressing VPS4B(E235Q)-GFP was immunostained with 
CHMP4A antibody and analyzed by confocal microscopy. GFP signal was visualized 
without staining. VPS4B(E235Q)-GFP and CHMP4A are shown in green and red 
respectively.  
 
Table 4-1 List of antibodies for ESCRT-III proteins and other proteins in the ESCRT 
pathway. 
 
Figure 4-2 Knockdown of ESCRT-III proteins and other proteins in the ESCRT 
pathway.  
(A) Efficiency of knockdown by shRNAs. ESCRT-III proteins were knocked down by 
transduction with recombinant lentivirus expressing shRNAs while Tsg101 and LIP5 
were knocked down by transfection with shRNA expressing plasmids. shRNAs were 
transduced in various HEK293 derived cell lines, and knockdown efficiency was 
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analyzed by visualizing endogenous proteins by immunoblotting. For CHMP6, 
knockdown by two different shRNAs was shown. Note that in the case of CHMP3, 
knockdown efficiency was tested against overexpressed CHMP3. To do this, cells 
transduced with CHMP3 shRNA were transfected with myc tagged CHMP3 construct a 
day before analysis. Con: cells expressing LacZ shRNA or no shRNAs, K/D: cells 
expressing with indicated shRNAs. (B) Efficiency of knockdown by siRNAs. Cells were 
transfected with 20nM siRNA for Tsg101, VPS4A or VPS4B, and knockdown efficiency 
was analyzed by immunoblotting for endogenous proteins. Con: untransfected control, 
K/D: cells transfected with indicated siRNAs.  
 
Table 4-2 List of shRNAs and siRNAs to knock down ESCRT-III proteins and other 
proteins in the ESCRT pathway.  
 
Figure 4-3 Trafficking and degradation of EGFR and EGF upon EGF treatment.  
(A) A stable HEK293 cell line expressing EGFR-GFP in a tetracyclin inducible manner 
(TRex-HEK293;EGFR-GFP) was incubated with 10ng/mL of tetracycline overnight to 
induce EGFR-GFP expression. Cells were stimulated with 100ng/mL EGF for 0, 1 or 2 
hours. EGFR-GFP protein was visualized by immunoblotting with anti-GFP antibody. 
Equal loading of proteins was confirmed by Ponceau staining. (B) HeLa cells were 
incubated with 100ng/mL EGF for 0, 1 or 2 hours after starvation in serum free media for 
3 hours. Endogenous EGFR was visualized by immunoblotting with anti-EGFR antibody. 
Equal loading of proteins was confirmed by Ponceau staining and immunoblotting for !-
tubulin. (C) TRex-HEK293;EGFR-GFP cells were incubated with 10ng/mL tetracycline 
overnight to induce EGFR-GFP expression. Cells were then stimulated with 100ng/mL 
EGF for 0min, 10min or 2 hours and analyzed by epifluorescence microscopy. Nuclei 
were visualized by DAPI staining while GFP signal was visualized without staining. 
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Images were taken under the same exposure time. (D) HeLa cells were incubated with 
200ng/mL of EGF conjugated with Alexa-555 fluorescent dye for 30min on ice. After 
washing unbound ligands, cells were transferred to 37ºC and incubated for 15min or 5 
hours. Cells were stained with DAPI and analyzed by epifluorescence microscopy. 
Images were taken under the same exposure time.  
 
Figure 4-4 EGFR degradation is inhibited by manipulating the ESCRT pathway.  
(A) HeLa cells transfected with GFP or VPS4B(E235Q)-GFP were stimulated with 
100ng/mL EGF for 0, 1 and 2 hours after starvation for 3 hours. Endogenous EGFR was 
visualized by immunoblotting with anti-EGFR antibody. Equal loading of proteins was 
confirmed by Ponceau staining, and expression of GFP and VPS4B(E235Q)-GFP was 
determined by immunoblotting with anti-GFP antibody. (B) HeLa cells transfected with 
20nM Tsg101 siRNA were simulated with EGF and analyzed as described above. Equal 
loading of proteins was confirmed by immunoblotting for !-tubulin. Knockdown efficiency 
of Tsg101 is shown in Figure 4-2(B).  
 
Figure 4-5 Trafficking and degradation of DOR upon agonist treatment.  
(A) HEK293 cells stably expressing FLAG-DOR (HEK293;FLAG-DOR) were stimulated 
with 10"M DADLE for 0, 2 or 4 hours and analyzed by immunoblotting with anti-FLAG 
antibody. (B) HeLa cells stably expressing FLAG-DOR (HeLa;FLAG-DOR) were 
stimulated with DADLE and analyzed as described above. (A-B) Equal loading of protein 
was confirmed by immunoblotting for !-tubulin. (C) HEK293;FLAG-DOR cells stimulated 
with 10"M DADLE for 0min, 30min or 4 hours were immunostained for FLAG-DOR and 
EEA1 (early endosomal marker), and analyzed by confocal microscopy. Images were 
taken under the same confocal setting.  
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Figure 4-6 Internalized DOR transits through late endosomes.  
HEK293;FLAG-DOR cells stimulated with 10!M DADLE for 30min were immunostained 
for FLAG-DOR and CD63, a marker for late endosomes/MVBs, and subsequently 
analyzed by confocal microscopy. FLAG-DOR and CD63 are shown in green and red 
respectively. DIC image is shown in gray.  
 
Figure 4-7 Dominant negative mutant VPS4 inhibits degradation of DOR.  
(A) HEK293;FLAG-DOR cells transfected with VPS4B-GFP (wild type or mutant 
(E235Q)) were incubated with 10!M DADLE for 0, 2 and 4 hours and analyzed by 
immunoblotting with anti-FLAG antibody. (B) TRex-HEK293 cells stably expressing 
VPS4B-GFP (wild type or mutant (E235Q)) in addition to FLAG-DOR were stimulated 
with DADLE and analyzed as described above. Expression of VPS4B was induced by 
treatment of 1!g/mL tetracycline overnight. (A and B) Equal loading of proteins and 
expression of VPS4 proteins were confirmed by immunoblotting with anti-"-tubulin 
antibody and anti-GFP antibody. (C) TRex-HEK293 cell line expressing both FLAG-DOR 
and VPS4(E235Q)-GFP was stimulated with 10!M DADLE for 1 hour, immunostained 
with anti-FLAG antibody and subsequently analyzed by confocal microscopy. Expression 
of VPS4B was induced by treatment of 1!g/mL tetracycline for 6 hours. GFP signal 
visualized without staining is shown in green and FLAG-DOR shown in red.  
 
Figure 4-8 Knockdown of VPS4 inhibits degradation of DOR.   
HEK293;FLAG-DOR (A) and HeLa;FLAG-DOR (B) cell lines transfected with 30nM 
control or VPS4 siRNAs (15nM/each) were stimulated with 10!M DADLE for 0, 2 and 4 
hours and analyzed by immunoblotting with anti-FLAG antibody. Knockdown efficiency 
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for VPS4A and VPS4B was determined by immunoblotting for VPS4A and VPS4B 
respectively. Equal loading of proteins was confirmed by immunoblotting for !-tubulin.  
 
Figure 4-9 Dominant negative ESCRT-III proteins inhibit degradation of DOR.  
(A) HEK293;FLAG-DOR cells were transfected with FLAG-CHMP2A full-length or 1-180 
(dominant negative mutant). Next day, cells were treated with 10"M DADLE for 0, 2 and 
4 hours and analyzed by immunoblotting with anti-FLAG antibody. (B) TREx-HEK293 
cells stably expressing Myc-CHMP2A (wild type or 1-180) in addition to FLAG-DOR 
were stimulated with DADLE and analyzed as described above. Expression of CHMP2A 
proteins was induced by treatment of 1"g/mL tetracycline overnight. (A - B) Equal 
loading of proteins and expression of CHMP2A proteins were confirmed by 
immunoblotting with anti-!-tubulin antibody and anti-FLAG antibody. (C) TREx-HEK293 
cell line expressing both FLAG-DOR and Myc-CHMP2A (1-180) was stimulated with 
10"M DADLE for 1 hour, immunostained with anti-FLAG antibody, and subsequently 
analyzed by confocal microscopy. Expression of CHMP2A 1-180 was induced by 
treatment of 1"g/mL tetracycline for 6 hours. GFP signal visualized without staining is 
shown in green and FLAG-DOR shown in red.  
 
Figure 4-10 Knockdown of Tsg101 inhibits degradation of DOR.  
HEK293;FLAG-DOR (A) and HeLa;FLAG-DOR (B) cell lines transfected with 20nM 
control or Tsg101 siRNA were stimulated with 10"M DADLE for 0, 2 or 4 hours and the 
level of DOR was visualized by immunoblotting with anti-FLAG antibody. Knockdown 
efficiency of Tsg101 and equal loading of proteins were confirmed by immunoblotting for 
Tsg101 and !-tubulin respectively.   
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Antigen Source  conc. 
Detection of 
endogenous 
protein 
by IB 
Detection of 
endogenous 
proteins 
by IF 
comments 
CHMP1A 
Abcam 
ab55536 
mouse 
monoclonal 
1µg/µL 1-2µg/mL 
cannot detect 
endogenous 
protein 
  
CHMP2A 
Proteintech 
group BC-2 
10477-1 
rabbit 
polyclonal 
0.55µg/µL 1-2µg/mL 
cannot detect 
endogenous 
protein 
not cross-react 
with CHMP2B  
CHMP2B 
Abcam 
ab33174 
rabbit 
polyclonal 
0.7µg/µL 1 - 1.5 µg/mL  3-5 µg/mL  
not cross-react 
with CHMP2A 
CHMP2 
Santa Cruz 
sc-49905 
goat 
polyclonal 
0.2µg/µL 
cannot detect 
endogenous 
protein/ 1µg/mL 
for overexpressed 
CHMP2A 
not determined 
not cross-react 
with CHMP2B / 
use PVDF for 
blotting  
CHMP3 
Hanson lab, 
affinity 
purified by LK 
rabbit 
polyclonal 
N/A 1:40 
cannot detect 
endogenous 
protein 
not stable 
CHMP4A 
Hanson lab, 
affinity 
purified by LK 
rabbit 
polyclonal 
N/A 1:50 1:20 - 1:50 
not cross-react 
with CHMP4B or 
CHMP4C 
CHMP4B 
Shiels lab # 
0485  
rabbit 
polyclonal, 
affinity 
purified 
N/A 1:2000 1:100 - 1:250 
not cross-react 
with CHMP4A or 
CHMP4C 
CHMP4B 
Shiels lab # 
0518  
rabbit 
polyclonal, 
affinity 
purified 
N/A 1:2000 1:100 - 1:250 
not cross-react 
with CHMP4A or 
CHMP4C 
CHMP5 
Everst 
EB06716 
goat 
polyclonal 
0.5µg/µL 2µg/mL 
cannot detect 
endogenous 
protein 
  
CHMP6 
Santa Cruz 
sc-49922 
goat 
polyclonal 
0.2µg/µL 
cannot detect the 
endogenous 
protein  
not determined   
CHMP6 
Sundquist 
Lab 
rabbit 
polyclonal 
serum 
N/A 1:500 1:300   
VPS4A 
Sundquist 
Lab 
rabbit 
polyclonal 
serum 
N/A 1:1000 not determined 
generally specific 
to VPS4A but 
cross-react little 
bit with VPS4B 
VPS4B/SKD1 
Hanson lab, 
affinity 
purified by YL 
rabbit 
polyclonal, 
affinity 
purified 
N/A 1:200 not determined 
not cross-react 
with VPS4A 
LIP5 Kaplan lab 
rabbit 
polyclonal, 
serum 
N/A 1:500 
cannot detect 
endogenous 
protein 
block in TBST 
containing 5% 
milk and 1% BSA 
for blotting 
Tsg101 
GeneTex, 
MS-TSG10-
PX 
mouse 
monoclonal 
1µg/µL 2µg/µL 
cannot detect 
endogenous 
protein 
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Target 
protein 
Type targeting sequence source comment 
LacZ shRNA CTACGCATAGAAGCCGGGATT TRC1 A4  
CHMP2A shRNA GCAGGCAGAGATCATGGATAT TRC1 C6  
CHMP2B shRNA GCAGCTTTAGAGAAACAAGAA TRC1 C2  
CHMP3 shRNA GTGAAACGATCTGTGAAAGAT TRC1 D4  
CHMP6 shRNA GCGCAATCACTCAGGAACAAA TRC1 E1  
CHMP6 shRNA GCTGCTCAAGAAGAAGCGATA TRC1 E2  
LIP5 shRNA CCTTCTATACTGCAAGTCTTT TRC1 B9  
Tsg101 shRNA GCAGAGCTCAATGCCTTGAAA TRC1 A10  
Tsg101 siRNA CCUCCAGUCUUCUCUCGUC Dharmacon dTdT to 3' end added 
VPS4A siRNA CCGAGAAGCUGAAGGAUUA Dharmacon dTdT to 3' end added 
VPS4B siRNA CCAAAGAAGCACUGAAAGA Dharmacon dTdT to 3' end added 
0    1    2 100ng EGF (hours)
EGFR
Ponceau 
?-tubulin
0    1    2 100ng EGF (hours)
EGFR-GFP
Ponceau 
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CHAPTER FIVE 
 
DISCUSSION AND FUTURE DIRECTIONS 
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1. Summary  
The studies described in this thesis focus on studying the regulation of ESCRT-III 
proteins and their functions in multivesicular body biogenesis. The work in Chapter 2 
identified a common autoinhibitory domain in ESCRT-III proteins which controls the 
conformational states of these proteins. This solidified the model that ESCRT-III 
operates by switching between closed and open states, and confirmed the self-
propagating property of ESCRT-III polymers. The work in Chapter 3 discovered an 
unexpected link between these ESCRT-III proteins and LIP5, a cofactor of VPS4. In 
Chapter 4, I described the study of the roles of endogenous ESCRT-III proteins in ILV 
formation and cargo sorting into ILVs. In this chapter, I discuss my current thinking about 
the role and regulation of ESCRT-III and remaining questions. I also describe some 
pieces of data and suggestions that may contribute to future studies.  
 
2. Discussion 
The ESCRT machinery has clearly established roles in cargo sorting to the MVB 
and creating intralumenal vesicles. A flurry of studies over the past several years has 
provided structural and mechanistic insight into the assembly and disassembly of 
ESCRTs and recruitment of cargo to the MVB. In particular, the molecular architecture of 
ESCRT-0, I and II and their roles in directing ubiquitinated cargo to the MVB have 
become fairly clear (1). One of the major challenges remaining in the ESCRT field is to 
understand how ESCRT-III assembles on the endosomal membrane and what roles it 
plays in generating ILVs (2, 3).  
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ESCRT-III polymers 
Thanks to several recent reports, the molecular architecture of ESCRT-III 
polymers is beginning to come to light (4-8). Although the precise stoichiometry and 
structure of ESCRT-III polymers is still unclear, ESCRT-III polymers seem to be highly 
organized and membrane-associated structures that contain different ESCRT-III proteins. 
Snf7/CHMP4 is likely to be a main constituent of the polymers because Snf7 is a main 
protein present in ESCRT-III isolated from yeast (5). Furthermore, circular 
homopolymers formed by CHMP4 proteins in mammalian cells are able to induce 
membrane deformation (4).  
 
Regulation of ESCRT-III polymer assembly  
From the work of the past several years, including mine, it is quite clear that 
ESCRT-III proteins in the cytoplasm are maintained in a closed conformation by the C-
terminal autoinhibitory domain (8-12). When ESCRT-III proteins are relieved from 
autoinhibition (or opened), they assemble on the endosomal membrane. There are two 
important steps in regulating ESCRT-III assembly. One is opening ESCRT-III proteins to 
expose their ability to associate with the membrane and form polymers. ESCRT-III 
proteins in an open conformation likely promote the opening of other ESCRT-III proteins, 
allowing propagation of ESCRT-III polymer assembly (9, 10). It has been proposed that 
there are cellular factors that bind to the autoinhibitory domain and help control 
conformational changes of ESCRT-III proteins (9-11). The other important step is 
targeting ESCRT-III proteins in the cytoplasm to the specific endosomal membrane. 
Many cytosolic proteins including components of upstream ESCRTs are recruited to the 
endosomal membrane by their interactions with specific phospholipids on endosomes 
(13, 14). I will discuss possible mechanisms for endosomal targeting of ESCRT-III 
proteins in Section 3.  
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VPS4 mediated ESCRT-III polymer disassembly 
Several recent reports have shown that different variations of ESCRT-III 
polymers could be disassembled by VPS4 in the presence of ATP, confirming that VPS4 
is indeed the disassembly machinery for ESCRT-III (6-8, 15). Whether or not VPS4 is 
directly involved in ILV formation remains to be determined. Nevertheless, it is clear that 
VPS4 mediated disassembly is a critical process for MVB biogenesis (16-19). Thanks to 
advances in structural biology, the structure of VPS4 and its interaction with ESCRT-III 
proteins have been fairly well characterized (20-22). However, the mechanistic basis for 
VPS4 mediated disassembly of ESCRT-III polymers is far from clear. One of the 
questions to be answered regarding VPS4 mediated disassembly is how VPS4 acts on a 
core of ESCRT-III polymers - CHMP4/Snf7, and I will discuss this issue in Section 3.    
 
Regulators of ESCRT-III polymer disassembly  
Given the importance of VPS4 in MVB biogenesis, it is not surprising that many 
proteins identified as regulators of the ESCRT pathway are proposed to control VPS4 
mediated disassembly directly or indirectly. Such regulatory proteins include Vta1/LIP5, 
Ist1/IST1, Did2/CHMP1 and Vps60/CHMP5 (23-30). Although mutants of these 
regulators in yeast exhibit only mild phenotypes, knocking out CHMP5 in mice leads to 
embryonic lethality (24-26, 30). This suggests that roles of these proteins may be 
underappreciated. Furthermore, the regulators can interact with each other and are 
thought to function cooperatively or antagonistically. How exactly these proteins fine-
tune VPS4 mediated disassembly, and thereby MVB biogenesis, is not clear yet. In 
Section 3, I will discuss one of these regulators, CHMP5, which may negatively regulate 
the ESCRT pathway via its interaction with LIP5, a proposed cofactor of VPS4.   
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Mechanisms for ILV formation by ESCRT-III polymers 
Although we have begun to learn about the characteristics of ESCRT-III 
polymers and their ability to deform membranes, our current knowledge is not enough to 
understand the precise relationship between ESCRT-III polymers and ILV formation. The 
current speculative model is that ESCRT-III polymers may form circular filaments around 
concentrated cargo, push membranes into the lumen to form a vesicle and finally cut the 
neck of the vesicle (3, 4, 8, 15). Based on the currently available data, ESCRT-III 
proteins are not likely to be incorporated into ILVs; thus, ESCRT-III polymers could not 
provide a platform inside of a vesicle to deform the membrane. Instead, they might form 
a circular ‘fence’ inside the neck of a nascent vesicle (3, 4, 8, 12, 15).  
Whether and how ESCRT-III polymers initiate the negative membrane curvature 
from a flat membrane remains enigmatic. Interestingly, this seems to be less problematic 
in other topologically related budding processes. In the case of HIV and other retroviral 
budding, Gag proteins comprising the core of a virus particle may provide a scaffold to 
deform the membrane (31, 32). Supporting this, when a late domain of a virus which 
recruits ESCRT machinery is mutated, viral budding is shown to be arrested at a late 
stage (33, 34). ESCRT machinery also plays a role in the final step of cytokinesis after 
the cleavage furrow is formed by actomyosin-based contraction (35-37). Therefore, it is 
conceivable that generating the initial membrane curvature for ILV formation may require 
help from other factors such as upstream ESCRTs, concentrated cargo proteins, and/or 
lipids. Alternatively and not exclusively, budding processes for viral budding and 
cytokinesis may require only part of the ESCRT-III machinery for a late stage of vesicle 
formation – perhaps narrowing and closing the neck of the vesicles.  
Whether and how VPS4 contributes to the budding process also remains unclear. 
VPS4 might help ESCRT-III polymers contract the neck of a vesicle by inducing 
conformational changes in ESCRT-III proteins and/or disassembly of ESCRT-III 
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polymers concomitant with assembly (3, 4, 12). Alternatively, VPS4 might contribute to 
membrane scission analogous to dynamin, a GTPase functioning in endocytic vesicle 
formation (38). A recent in vitro reconstitution study using giant unilamellar vesicles, 
however, suggests that Vps20, Snf7 and Vps24 are sufficient for creating and detaching 
ILVs and the role of VPS4 mediated disassembly may be limited to the recycling of 
machinery (15). It should be noted that a significant number of vesicles were formed 
spontaneously in this reaction, implying that the synthetic membranes used in the assay 
might be prone to form vesicles. Therefore, it is necessary to determine exactly when 
and how ESCRT-III and VPS4 act on the ILV formation in a more physiological reaction, 
which is a goal of the work described in Chapter 4.  
 
3. Preliminary data and future directions 
Determine how ESCRT-III proteins are selectively targeted to the endosomal 
membrane  
To gain insight into regulation of ESCRT-III, it will be critical to determine the 
molecular mechanisms governing ESCRT-III targeting to the endosomal membrane. 
Components of upstream ESCRTs contain phosphoinositide-3-phosphate (PI3P) binding 
domains, such as the FYVE and GLUE domains, which help them localize to the 
endosomal membrane; however, how ESCRT-III is targeted to the endosome is less 
clear (39-44). In the current model, ESCRT-III is thought to be targeted to the endosomal 
membrane by the interaction of CHMP6/Vps20 with a component of ESCRT-II 
(Eap20/Vps25). However, the data from my cell based experiments suggest that 
ESCRT-III proteins may have the ability to target themselves to the endosomal 
membrane (10). First, individual ESCRT-III proteins interact with the endosomal 
membrane when their C-terminal autoinhibitory domain is removed (Figure 2-2). 
Because each protein was highly overexpressed in cells, its interaction with membranes 
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is not likely to be mediated by association with endogenous proteins. Some ESCRT-III 
proteins like CHMP3 and CHMP4A were shown to have weak specificity to 
phosphoinositide-3,5-bisphosphate (PI(3,5)P2), a phospholipid found in the endosome (9, 
45). Additionally, C-terminally truncated CHMP2A co-localized well with the FYVE 
domain in cells cotransfected with CHMP2A 1-180 and 2x FYVE domain, suggesting 
that the ESCRT-III protein may have specificity to PI3P (Fig. 5-1). Furthermore, the 
crystal structure of CHMP3 suggests that an ESCRT-III protein contains a basic N-
terminal helical core which could bind to acidic phosphoinositides concentrating on 
endosomal membranes (46). Taken together, I hypothesize that individual ESCRT-III 
proteins have an intrinsic ability to bind to endosomal membranes, and that this property 
contributes to restricting ESCRT-III assembly to these membranes.  
CHMP2A may be a good ESCRT-III protein for testing this hypothesis. First, less 
is known about membrane binding and endosomal targeting of CHMP2/Vps2 compared 
to other core ESCRT-III proteins, and therefore it deserves more attention. Additionally, 
the striking difference between full-length (soluble) and !1-!5 (membrane-bound) 
proteins should make it possible to better understand how the interaction of the protein 
with membranes is regulated (Fig. 2-2 and 2-3). To test the direct interaction of CHMP2A 
with membranes and its lipid specificity, I would carry out an in vitro liposome binding 
assay with recombinant CHMP2A proteins (comparing full-length and !1-!5 mutant (1-
180)) and liposomes containing different phosphoinositides. To distinguish lipid 
specificity from nonspecific electrostatic interactions between the basic surface of 
CHMP2A and acidic phosphoinositides, the interaction with other acidic lipids should be 
tested. If CHMP2A binds specifically to certain phosphoinositide(s), it would be 
interesting to define the domain responsible for this lipid specificity. In my cell based 
experiments, !1-!5 mutant CHMP2A was localized on the endosome while CHMP2A 
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with a deletion from the end of !4 (!1-!4 mutant; CHMP2A 1-144) was not found 
primarily on the endosome (Fig. 2-2). Similar trends were seen with other ESCRT-III 
proteins. Supporting this, the helical bundle formed by !1-!4 in the CHMP3 crystal 
structure does not have a notable feature that might provide lipid specificity (46) . 
Together, a specific determinant for targeting may lie within the region around helix 5 of 
an ESCRT-III protein. If deleting !5 changes lipid specificity, one could carry out alanine 
scanning within the !5 region to identify residues critical for endosomal targeting. The 
proposed work will provide insight into the molecular basis for endosomal targeting of 
ESCRT-III proteins, and also help set up systems to screen cellular factors to control 
ESCRT-III assembly on the endosomal membrane.  
 
Determine mechanisms to disassemble the core of ESCRT-III polymers - 
interaction of VPS4 with CHMP4  
ESCRT-III is disassembled by the AAA ATPase VPS4. A subset of ESCRT-III 
proteins contain the MIT domain interacting motif1 (MIM1) at their extreme C-termini (!6 
region) while CHMP6/Vps20 has the MIM2 within the linker between !5 and !6 (20, 21, 
47). It is less clear how CHMP4/Snf7 interacts with VPS4 although CHMP4/Snf7 is 
thought to be a main component of ESCRT-III polymers (5). It has been suggested that 
CHMP4 also has the MIM2 similar to CHMP6; however, binding affinity between the 
MIM2 and the MIT domain is very weak (47). In detail, the dissociation constants (Kd) for 
CHMP1B MIM1 and CHMP6 MIM2 to the VPS4A MIT domain are 5- 20"M, while Kd for 
CHMP4A MIM2 to the VPS4A MIT domain is about 250"M (47).  
Interestingly, my preliminary data points to a more internal region than the MIM2 
in CHMP4 as a potential VPS4 binding site. When the dominant negative mutant VPS4 
(VPS4B(E235Q)) was coexpressed with CHMP4A 1-181 (!1-!5, lacking both MIM1 and 
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MIM2), the mutant VPS4B accumulated on the rim of the enlarged endosomal vesicles 
delineated by CHMP4A 1-181 (Fig. 5-2A). VPS4B(E235Q), however, was not recruited 
by CHMP4A 1-147 (!1-!4). The mutant VPS4B also co-localized well with CHMP4A 20-
181 but not with 20-147 (Fig. 5-2A). Because the localization of CHMP4A 20-181 differs 
strikingly from that of 1-181 and from that of VPS4B(E235Q) expressed by itself, the 
colocalization of 20-181 and VPS4 must reflect an interaction between them (9). The 
interaction of CHMP4A 1-181 with VPS4B(E235Q) seen by light microscopy was further 
confirmed by deep-etch electron microscopy (data not shown). Interestingly, a sequence 
alignment of Snf7/CHMP4 from different species suggests that the !5 region is one of 
the most highly conserved regions, and contains a MIM-like motif (Fig. 5-2B). Finally, 
this helix in the CHMP3 crystal structure is packed perpendicular to the core of the 
protein in what seems likely to be an accessible and regulatory region (46). Together, 
the predicted !5 appears to be a likely candidate VPS4 binding site.  
To define the VPS4 binding site, I would carry out site-directed mutagenesis 
within the !5 region of CHMP4A. The effects of mutations on CHMP4A binding to VPS4 
can be determined by binding assays. I have attempted to carry out a GST pull down 
assay using bacterially expressed GST-CHMP4A proteins and VPS4B(E235Q). 
However, the binding between these proteins was too weak to detect their interaction 
under my assay conditions. One possible change to make would be using VPS4A rather 
than VPS4B because the binding affinity for CHMP4 to the VPS4A MIT domain is higher 
than that to the VPS4B MIT domain (47). Alternatively, I could use immunofluorescence 
analysis similar to that shown in Fig. 5-2A. I would introduce mutations in 20-181 
constructs and examine the disruption of co-localization between mutant VPS4 and 
CHMP4A 20-181 by various mutations in !5 region of CHMP4A 20-181. Finally, The 
ATPase activity of VPS4 stimulated by different constructs of CHMP4A could be used as 
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an indicator of the interaction between VPS4 and CHMP4A. Sam Merrill, another student 
in our lab, has established an in vitro VPS4 ATPase assay and showed that CHMP4 
could stimulate ATPase activity of VPS4. Characterizing the interaction between VPS4 
and CHMP4, a main component of ESCRT-III polymers, will help us understand the 
precise mechanisms for VPS4 mediated ESCRT-III polymer disassembly.   
 
Determine the role of CHMP5, a regulator in the ESCRT pathway 
CHMP5/Vps60 is an ESCRT-III-like protein and proposed to be a regulator of the 
ESCRT pathway (24, 26, 27, 29, 30). Precisely how CHMP5/Vps60 regulates the 
ESCRT pathway is not clear. Because it tightly interacts with LIP5/Vta1,  it has been 
suggested that CHMP5/Vps60 acts through LIP5/Vta1 (24, 26, 27, 29, 30, 48-50). 
Interestingly, cells from CHMP5 knockout mice have enlarged MVBs filled with a number 
of ILVs such that ILV formation seems to be almost facilitated without CHMP5 (25). 
Based on my work and from elsewhere, LIP5 interacts preferentially with soluble CHMP5 
over polymerized CHMP5 (Fig. 3-8) (29, 48, 50). Together, I hypothesize that CHMP5 
sequesters LIP5, a positive regulator of VPS4 in the cytoplasm and thereby functions as 
a negative regulator of the ESCRT pathway.  
To test this hypothesis, I would first determine whether endogenous CHMP5 and 
LIP5 form a stable complex in the cytoplasm by chemical cross-linking and sucrose 
gradient analysis. I have characterized antibodies for CHMP5 and LIP5 which are 
necessary for the experiments (Fig. 4-1 and Table 4-1). To test whether CHMP5 
functions via its interaction with LIP5, the specific interaction between CHMP5 and LIP5 
should be characterized. In Chapter 3, I found that CHMP5 interacts with the N-terminus 
of LIP5 via its !5 region (Fig. 3-8) (48). In fact, a small fragment of CHMP5 (27 amino 
acids) was sufficient for LIP5 binding (Fig. 3-8C). Additionally, a recent crystal structure 
of Vta1, the yeast ortholog of LIP5, showed that there are two MIT domains at the N-
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terminus of Vta1 (51). Thus, I tested the contribution of these MIT domains to 
interactions with two MIM1 containing ESCRT-III proteins (CHMP1B and CHMP2A) and 
CHMP5, and found that the MIT1 domain is important for interaction with MIM1 
containing ESCRT-III proteins while the MIT2 domain is required for binding to CHMP5 
(Fig. 5-3A-C). Interestingly, CHMP5 also contains an MIM-like motif within its !5 region, 
suggesting that CHMP5 interaction with LIP5 is a variation of MIT-MIM interaction (Fig. 
5-3D). To further define the LIP5 binding site in CHMP5, I would examine the interaction 
of LIP5 with CHMP5 after mutating residues in the MIM-like motif of CHMP5 by site-
directed mutagenesis.  
To disrupt the interaction between CHMP5 and LIP5 specifically, I would treat 
cells with a peptide (27 amino acids) from the CHMP5 !5 region sufficient for LIP5 
binding or express CHMP5 with mutations within its MIM-like motif in cells. Furthermore, 
because the MIT2 domain is important for the interaction with CHMP5 but not for binding 
to other ESCRT-III proteins, I would express LIP5 with mutations in the MIT2 domain in 
cells. I would then examine the effects of these manipulations on the ESCRT pathway 
with the various functional assays described in Chapters 2 and 4. I would also analyze 
the morphology of MVBs after disrupting the interaction of CHMP5 and LIP5, and 
compare the results to published data showing the effects of knockout of CHMP5 (25). 
Finally, one could also establish an ESCRT-III disassembly assay and test how CHMP5 
affects VPS4 mediated disassembly in the presence of LIP5. Overall, this work will 
provide insight into the intricate regulation of the ESCRT pathway.  
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FIGURE LEGENDS 
 
Figure 5-1 Co-localization of FYVE domain with C-terminally truncated CHMP2A.  
COS7 cells transfected with 2x FYVE-GFP alone or cotransfected with 2xFYVE-GFP 
and FLAG-CHMP2A 1-180 (!1-!5) were immunostained with anti-FLAG antibody and 
analyzed by epifluorescence microscopy. GFP signal was visualized without staining. 
Subcellular localization 2x FYVE and CHMP2A are shown in the left (green) and middle 
(red) panel respectively. Merge image is shown in the right panel.   
 
Figure 5-2 VPS4 binding site in CHMP4A.  
(A) COS-7 cells co-transfected with VPS4B(EQ)-GFP and indicated FLAG-CHMP4A 
constructs were immunostained with anti-FLAG antibody and viewed by epifluorescence 
microscopy. GFP signal was visualized without staining. Subcellular localization of 
VPS4B(E235Q)-GFP and CHMP4A are shown in the left (green) and middle (red) panel 
respectively. Merged images are shown in the right panel. (B) Sequence alignment of !5 
region of CHMP4/Snf7 from different species.  
 
Figure 5-3 Differential contribution of two MIT domains in LIP5 to interaction of 
ESCRT-III proteins.  
(A-B) Interaction of MIM1 containing ESCRT-III proteins (CHMP2A and CHMP1B) with 
LIP5 MIT domains. Shown is GST pull down with purified GST-CHMP2A C-terminal half 
(residue 117-222) or GST-CHMP1B C-terminal half (residue 106-199) and HEK293T cell 
lysate containing GFP-LIP5. Critical residues in MIT1 and MIT2 domains in LIP5 were 
mutated into alanine (Met64 in MIT1 domain, Lys148 in MIT2 domain). (C) Interaction of 
CHMP5 with LIP5 MIT domains. GFP-LIP5 was immunoprecipitated from soluble lysate 
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of HEK293T cells cotransfected with FLAG-CHMP5 and GFP-LIP5. Bound proteins and 
lysate were analyzed by immunoblotting. (D) Sequence alignment of !5 region of human 
CHMP5 and yeast Vps60.  
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CHMP4B, a novel gene for autosomal 
dominant cataracts linked to chromosome 
20q (Am J. Hum. Genet., 2007 81(3):596-606). 
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CHMP4B, a Novel Gene for Autosomal Dominant Cataracts Linked
to Chromosome 20q
Alan Shiels, Thomas M. Bennett, Harry L. S. Knopf, Koki Yamada, Koh-ichiro Yoshiura,
Norio Niikawa, Soomin Shim, and Phyllis I. Hanson
Cataracts are a clinically diverse and genetically heterogeneous disorder of the crystalline lens and a leading cause of
visual impairment. Here we report linkage of autosomal dominant “progressive childhood posterior subcapsular” cataracts
segregating in a white family to short tandem repeat (STR) markersD20S847 (LOD score [Z] 5.50 at recombination fraction
[v] 0.0) and D20S195 ( at ) on 20q, and identify a refined disease interval (rs2057262–(3.8Mb)–rs1291139)Zp 3.65 vp 0.0
by use of single-nucleotide polymorphism (SNP) markers. Mutation profiling of positional-candidate genes detected a
heterozygous transversion (c.386ArT) in exon 3 of the gene for chromatin modifying protein-4B (CHMP4B) that was
predicted to result in the nonconservative substitution of a valine residue for a phylogenetically conserved aspartic acid
residue at codon 129 (p.D129V). In addition, we have detected a heterozygous transition (c.481GrA) in exon 3 ofCHMP4B
cosegregating with autosomal dominant posterior polar cataracts in a Japanese family that was predicted to result in the
missense substitution of lysine for a conserved glutamic acid residue at codon 161 (p.E161K). Transfection studies of
cultured cells revealed that a truncated form of recombinant D129V-CHMP4B had a different subcellular distribution
than wild type and an increased capacity to inhibit release of virus-like particles from the cell surface, consistent with
deleterious gain-of-function effects. These data provide the first evidence that CHMP4B, which encodes a key component
of the endosome sorting complex required for the transport-III (ESCRT-III) system of mammalian cells, plays a vital role
in the maintenance of lens transparency.
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Hereditary forms of cataracts are usually diagnosed at
birth (congenital), during infancy, or during childhood
and are clinically important as a cause of impaired form
vision development.1 In addition to being found in 150
genetic syndromes involving other ocular defects (e.g.,mi-
crophthalmia [MIM 212550]) and systemic abnormalities
(e.g., galactokinase deficiency [MIM 230200]), cataracts
may be inherited as an isolated lens phenotype, most
frequently by autosomal dominant transmission.2 So far,
genetic linkage studies of 160 families worldwide have
mapped at least 25 independent loci for clinically diverse
forms of nonsyndromic cataracts on 15 human chromo-
somes, involving some 17 lens-abundant genes.2 The
majority of associated mutations have been identified in
10 crystallin genes (CRYAA [MIM 123580], CRYAB [MIM
123590], CRYBB1 [MIM 600929], CRYBB2 [MIM 123620],
CRYBB3 [MIM 123630], CRYBA1 [MIM 123610], CRYBA4
[MIM 123631], CRYGC [MIM 123680], CRYGD [MIM
123690], and CRYGS [MIM 123730]),3–11 which encode the
major “refractive” proteins of the lens. The remainingmu-
tations have been identified in seven functionally diverse
genes, including those coding for gap-junction connexin
proteins (GJA3 [MIM 121015], GJA8 [MIM 600897]),12,13
a heat-shock transcription factor (HSF4 [MIM 602438]),14
an aquaporin water channel (MIP [MIM 154050])15 a clau-
din-like cell-junction protein (LIM2 [MIM 154045]),16 and
intermediate-filament-like cytoskeletal proteins (BFSP1
[MIM 603307], BFSP2 [MIM 603212]).17,18 In addition to
the known genes, at least 10 novel genes for autosomal
dominant or recessive forms of nonsyndromic cataracts
remain to be identified at loci on chromosomes 1 (CCV
[MIM 115665], CTPP1 [MIM 116600]), 2 (PCC [MIM
601286], CCNP [MIM 607304, MIM 115800]), 3 (CATC2
[MIM 610019]), 9 (CAAR [MIM 605749]), 15 (CCSSO
[MIM 605728]), 17 (CTAA2 [MIM 601202], CCA1 [MIM
115660]), 19 (CATCN1 [MIM 609376]), and 20 (CPP3
[MIM 605387]).19–32 Here we have fine-mapped a locus for
autosomal dominant cataracts on chromosome 20q and,
subsequently, have identified underlying missense muta-
tions in the gene for chromatin modifying protein-4B
(CHMP4B [MIM 610897]), also known as charged multi-
vesicular body protein-4B, which has not previously been
associated with human disease.
Linkage studies.—We investigated a six-generationwhite
family from the United States (family Sk) segregating au-
tosomal dominant progressive childhood posterior sub-
capsular cataracts (PCPSC) in the absence of other ocular
or systemic abnormalities (fig. 1A). Ophthalmic records
indicated that the cataracts presented in both eyes as disc-
shaped posterior subcapsular opacities, progressing with
age to affect the nucleus and anterior subcapsular regions
of the lens (fig. 1B). The age at diagnosis varied from 4 to
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20 years, and the age at surgery ranged from 4 to 40 years.
Postsurgical corrected visual acuity varied from 20/20 to
20/200 in the better eye. Blood samples were obtained
from 27 family members, and leukocyte genomic DNA
was purified and quantified using standard techniques
(Qiagen). Ethical approval for this study was obtained
from the Washington University Human Research Protec-
tion Office, and written informed consent was provided
by all participants prior to enrollment, in accordance with
the tenets of the Declaration of Helsinki.
For linkage analysis, 15 affected individuals, 8 unaf-
fected individuals, and 4 spouses from family Sk were ge-
notyped using STRmarkers from the combinedGe´ne´thon,
Marshfield, and deCODE genetic linkage maps (National
Center for Biotechnology Information [NCBI]), as de-
scribed elsewhere.33 Following exclusion of linkage to
known loci for autosomal dominant cataracts on chro-
mosomes 1–3, 10–13, 15–17, 19, 21, and 22 (table 1), we
obtained significant evidence of linkage (table 2) formark-
ersD20S847 ( and ),D20S195 ( andZp 5.50 vp 0 Zp 3.65
), and D20S870 ( and ).vp 0 Zp 3.11 vp 0
Haplotype analysis detected seven recombinant indi-
viduals within the Sk pedigree (fig. 1A). First, two affected
females, VI:4 and VI:6, were obligate recombinants, prox-
imally at D20S885 and distally at D20S855, respectively.
Second, three affected females (IV:1, IV:4, and V:3) and
one affected male (VI:1) were obligate recombinants dis-
tally at D20S834. Third, one affected female (V:3) and her
affected son (VI:1) were obligate recombinants proximally
at D20S837. However, with the exception of individual V:
5 (see below), no further recombinant individuals were
detected at four other intervening STR markers, suggest-
ing that the cataract locus lay in the physical interval,
D20S837–(4.7 Mb)–D20S834.
At the time of our study, individual V:5 was 17 years of
age and phenotypically unaffected; however, he inherited
the complete disease haplotype (fig. 1A), suggesting that
he was either nonpenetrant or presymptomatic for cata-
racts. The two-point LOD scores shown in table 2 were
calculated with the assumption of unaffected status for
individual V:5 and 95% penetrance in family Sk; however,
even when 100% penetrance was assumed, we still re-
tained significant evidence of linkage proximally at
D20S195 ( at ) and distally atZ p 4.31 v p 0.04max max
D20S847 ( at ). Conversely, if in-Z p 5.08 v p 0.04max max
dividual V:5 developed cataracts later in life, perhaps ex-
tending the age-at-onset range in family Sk, and was in-
cluded with the assumption of preaffected status and
100% penetrance, we would obtain enhanced evidence
for linkage (D20S195, at ; D20S847,Z p 5.12 v p 0.0max max
at ). However, regardless of whetherZ p 6.97 v p 0.0max max
individual V:5 was included or excluded, we found no
evidence of linkage at other candidate genes or loci for
autosomal dominant cataracts (table 1).
To further refine the disease interval, we genotyped fam-
ily Sk with biallelic SNP markers (NCBI) located within
the STR interval using conventional dye-terminator cycle-
sequencing chemistry (Applied Biosystems). Critical af-
fected individuals IV:1, IV:4, and V:3 were also found to
be recombinant at SNPmarker rs1291139 (A/T), which lies
∼0.5 Mb centromeric to D20S834. Similarly, critical af-
fected individuals V:3, and VI:1 were also recombinant at
marker rs2057262 (A/C) located ∼0.4 Mb telomeric to
D20S837 (fig. 1A). However, individual V:5 excepted, no
further recombination events were detected at intervening
SNP markers, indicating that the cataract locus lay in the
reduced (∼0.9 Mb) physical interval, rs2057262–(3.8Mb)–
rs1291139 (fig. 1C).
Mutation analysis.—The refined SNP interval contained
∼80 positional-candidate genes, none of which were ob-
vious functional candidates for cataracts in family Sk
(NCBI Map Viewer). We prioritized genes for mutation
analysis of exons and intron boundaries (splice sites) on
the basis of three main criteria.
1. NCBI reference sequence status, with those genes des-
ignated “reviewed” or “provisional” selected over
those designated “model” or “pseudogene.”
2. Evidence of expression in (fetal) eye, from the
UniGene EST database.
3. Number of exons or amplicons required for coverage
of the coding region, starting with smaller genes first.
Resequencing analysis of individuals IV:5, V:6, V:10, and
VI:6 from the Sk pedigree (fig. 1A) excluded the presence
of coding or splice-site mutations in eight genes (data
not shown), including EPB41L1 (MIM 602879), E2F1
(MIM 189971), ZNF341, PXMP4, ITGB4BP (MIM 602912),
APBA2BP, SCAND1 (MIM 610416), and DYNLRB1 (MIM
607167). However, resequencing of a 5-exon gene sym-
bolized CHMP4B (GeneID: 128866) identified a hetero-
zygous c.386ArT transversion in exon 3 that was not pre-
sent in wild type (fig. 2B). This single-nucleotide change
did not result in the gain or loss of a convenient restriction
site; therefore, we designed allele-specific (A/T) PCR anal-
ysis to confirm that the mutant “T” allele cosegregated
with affected but not unaffected members of family Sk,
with the exception of individual V:5 (fig. 2C). Further-
more, when we tested the c.386ArT transversion as a bial-
lelic marker, with a notional allelic frequency of 1%, in a
two-point LOD score analysis of the cataract locus (table
2) we obtained further compelling evidence of linkage
( at ). In addition, we confirmed that theZp 6.52 vp 0
c.386ArT transversion was not listed in the NCBI SNP
database (dbSNP), and we excluded it as a SNP in a panel
of 192 normal, unrelated individuals (i.e., 384 chromo-
somes), using the allele-specific PCR analysis described in
fig. 2C (data not shown). Although it is possible that an
undetected mutation lay elsewhere within the disease-
haplotype interval (3.8 Mb), our genotype data strongly
suggested that the c.386ArT transversion in exon 3 of
CHMP4B represented a causative mutation rather than a
benign SNP in linkage disequilibrium with the cataract
phenotype.
To verify that the c.386ArT transversion in CHMP4B

www.ajhg.org The American Journal of Human Genetics Volume 81 September 2007 599
Figure 1. Autosomal dominant PCPSC in a six-generation family (Sk). A, Pedigree and haplotype analysis showing segregation of
eight STR markers and two SNP markers on 20q, listed in descending order from the centromere. Squares and circles denote males and
females, respectively. Filled symbols and bars denote affected status and haplotypes, respectively. Individual V:5 is marked with a
question mark (?) to denote unknown status. Pedigree and haplotype data were managed using Cyrillic 2.1 software (FamilyGenetix).
B, Slit-lamp image of lens from affected female V:12 (age 40 years) showing posterior subcapsular, nuclear, and anterior subcapsular
opacities. C, Ideogram of chromosome 20, comparing the cytogenetic location of SNP markers defining the PCPSC locus in this study
(red) with those of STR markers defining loci for CPP3 and PCZNC.31,32
was present at the RNA transcript level in family Sk, we
performed allele-specific RT-PCR analysis of peripheral
blood leukocytes (PBLs), which have been shown to ex-
press CHMP4B.35 PCR primers (table 3) were designed to
amplify the entire coding region of CHMP4B (codons 1–
224) in the presence of a nested mutant (T allele) primer
to detect heterozygosity in three consenting relatives, in-
cluding individual V:5 (fig. 3A). The affected father (IV:5)
and his son (V:5) were heterozygous for the wild-type (A
allele) and mutant (T allele) transcripts, whereas his un-
affected daughter (V:6) was homozygous for the wild-type
(A allele) transcript. To gain a more accurate comparison
of wild-type versus mutant CHMP4B transcript levels in
PBL RNA, we then performed quantitative (q)RT-PCRwith
SYBR Green-1 in real time (fig. 3B), using a sense anchor
primer paired with either a mutant (T allele) or wild-type
(A allele) primer (table 3).When standardized against tran-
script levels for the midabundance ribosomal protein-L19
(RPL19), the ratio of wild-type to mutant CHMP4B tran-
scripts was estimated to be 60(A):40(T), suggesting de-
creased expression and/or increased turnover of the
mutant transcript in affected individuals. Overall, the
transcript and genotype data are consistent for these in-
dividuals (fig. 1A and fig. 3A) and support the view that
the clinically unaffected son (V:5) is either presymptom-
atic or nonpenetrant for the cataract phenotype. More-
over, the ability to amplify the intact coding region of
CHMP4B transcripts from affected individuals was con-
sistent with correct mRNA splicing, suggesting that the
c.386ArT transversion, which is located near the begin-
ning of exon 3, did not activate a cryptic splice site.36
Finally, we also confirmed that the intact coding region
of CHMP4B transcripts could be amplified from human
and mouse post mortem lenses (fig. 3C), consistent with
a functional role for CHMP4B in lens biology.
CHMP4B is cytogenetically distinct from BFSP1 and an
interval on 20p (fig. 1C) that was linked recently with
autosomal dominant progressive congenital zonular nu-
clear cataract (PCZNC) segregating in a Chinese family.32
However, CHMP4B is located within a much larger region
spanning 20p12–20q12 that was previously linked with
autosomal dominant posterior polar cataract (CPP3 [MIM
605387]) segregating in a Japanese family.31 Like the cat-
aracts in family Sk, CPP3 was characterized by a juvenile
onset and progressive disc-shaped posterior subcapsular
opacities along with some cortical opacification.37 To in-
vestigate the possibility of allelism, we performed a similar
mutation screen of CHMP4B in the CPP3 family and iden-
tified a heterozygous c.481GrA transition in exon 3 that
was not present in wild type (fig. 4A and 4B) or in the
SNP database. This single-nucleotide change removed an
adjacentMnl1 restriction enzyme-site, and restriction frag-
ment length analysis confirmed that the heterozygous A
allele cosegregated with affected members of the CPP3
family but was not present in unaffected relatives or our
control panel (fig. 4C and data not shown). The identi-
fication of a second coding nucleotide change in a geo-
graphically and ethnically distinct family provided strong
supporting evidence for CHMP4B as the causative gene for
cataracts linked to 20q. In addition, the locus for lens
opacity-4 (Lop4)38 has been linked to a region of murine
chromosome 2 that is syntenic with human 20q11.2 rais-
ing the possibility of a mouse model for the cataracts de-
scribed here.
CHMP4B encodes a highly charged helical protein (∼25
kDa) with N-terminal basic and C-terminal acidic halves
(fig. 5B). The c.386ArT transversion in exon 3 occurred
at the second base of codon 129 (GATrGTT), and is pre-
dicted to result in the missense substitution of aspartic
acid to valine (p.D129V) at the level of translation. Sim-
ilarly, the c.481GrA transition occurred at the first base
of codon 161 (GAGrAAG) of exon 3, and is predicted to
translate as a missense substitution of glutamic acid to
lysine (p.E161K). Cross-species alignment of the amino
acid sequences for CHMP4B present in the Entrez Pro-
tein database, performed by means of ClustalW, revealed
that p.D129 and p.E161 are phylogenetically conserved
from yeast to man (fig. 5C). Moreover, the predicted
p.D129V and p.E161K substitutions represented noncon-
servative amino acid changes, with the acidic side-group
(!CH2COOH) of aspartic acid replaced by the neutral, hy-
drophobic side-group (!CH!C2H6) of valine, and the
acidic side-group (!C2H4COOH) of glutamic acid replaced
by the basic side-group (!C4H8NH2) of lysine, respectively,
suggestive of functional consequences.
Functional expression studies.—Eleven CHMP genes have
been identified in the human genome and, on the basis
of phylogenetic analyses, have been divided into seven
subfamilies, some with multiple members.39,40 CHMP4B is
one of three human orthologs of yeast Snf7/Vps32 (su-
crose non-fermenting-7 or vacuolar protein sorting-32),
which functions in protein sorting and transport in the
endosome-lysosome pathway.39 In the current model,
CHMP4B is a core subunit of the endosomal-sorting com-
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Table 1. Two-point LOD scores (Z) Showing Exclusion of
Linkage between the Autosomal Dominant Cataract Locus
and STR Markers near Candidate Genes or Loci on
Chromosomes Other Than 20
Marker Za v Chromosome Gene/Locus
D1S243 !2.77 .10 1p36 CCV, CPP1
D1S214 !2.93 .10
D1S2748 !2.14 .20 1p32 FOXE3[MIM 601094]
D1S305 !2.01 .20 1q21 GJA8
D2S2333 !2.35 .20 2p12 CCNP
D2S128 !3.19 .05 2q32-q36 CRYGC, CRYGD, CRYBA2
D2S2248 !2.75 .20
D3S1768 !" .00 3p21.1-p21.3 CATC2
D3S3564 !2.34 .05
D3S1292 !1.76 .05 3q22.1 BFSP2
D3S3686 !4.04 .10 3q27.2 CRYGS
D5S2014 !2.05 .05 5q33.1 SPARC [MIM 182120]
D6S1710 !2.37 .05 6q12 GLULD1
D9S303 !1.31 .05 9q21.31 CAAR
D9S1120 !1.28 .05
D10S566 !2.94 .10 10q24-q25 PITX3[MIM 602669]
D10S1697 !3.01 .10
D11S4154 !2.63 .05 11p13 PAX6 [MIM 607108]
D11S4192 !2.55 .10 11q23.1 CRYAB
D11S1347 !3.28 .05
D12S368 !1.94 .10 12q13.3 MIP
D13S175 !2.34 .05 13q11 GJA3
D14S1047 !2.12 .05 14q24.3 CHX10[MIM 142993]
D15S209 !3.14 .05 15q21-q22 CCSSO
D15S1036 !2.41 .20
D16S412 !2.51 .10 16p12.3 CRYM[MIM 123740]
D16S3095 !2.99 .10 16q22.1 HSF4
D17S1840 !2.45 .05 17p13 CTAA2
D17S796 !2.13 .10
D17S799 !1.79 .05 17q11.2 CRYBA1
D17S798 !1.18 .05
D17S785 !2.14 .10 17q24 GALK1[MIM 604313]
D17S802 !1.91 .05 17q24 CCA1
D17S784 !2.67 .10
D19S412 !2.41 .15 19q13 LIM2
D20S112 2.58 .08 20p11.23 BFSP1
D20S885 2.71 .10 20p12–20q12 CPP3
D20S847 5.08 .04
D21S1259 !2.78 .10 21q22.3 CRYAA
D21S1885 !.81 .00
D22S1154 !2.20 .15 22q11.23-q21.1 CRYBA4, CRYBB1-4
a A gene frequency of 0.0001 and a penetrance of 100% were assumed
for the disease locus.
Figure 2. Mutation analysis of CHMP4B in family Sk. A, Sequence
trace of the wild-type allele, showing translation of aspartic-acid
(D) at codon 129 (GAT). B, Sequence trace of the mutant allele,
showing the heterozygous c.386ArT transversion (denoted as W
by the International Union of Pure and Applied Chemistry [IUPAC]
code) that is predicted to result in the missense substitution of
valine (GTT) for aspartate at codon 129 (p.D129V). Exons and
flanking intron regions were amplified with gene-specific primers
(M13-tailed) by use of the AmpliTaq PCR Master Mix in a GeneAmp
9700 thermal-cycler (Applied Biosystems). Resulting amplicons
were purified using the QIAquick gel-extraction kit (Qiagen) and
then direct sequenced in both directions with M13-primers and
the BigDye Terminator (v.3.1) cycle sequencing kit on a 3130xl
genetic analyzer running SeqScape mutation-profiling software
(Applied Biosystems). C, Allele-specific PCR analysis using the
three primers (table 3) indicated by arrows in the schematic di-
agram; exon 3 was amplified as above with the sense (anchor)
primer located in intron 2 (Ex3F), the anti-sense primer located
in intron 3 (Ex3R), and the nested mutant primer specific for the
T allele in codon 129 (T-alleleR). PCR products were visualized
(302 nm) on 2% agarose gels stained with ethidium bromide
(EtBr). Note that only affected members of family Sk are hetero-
zygous for the T allele (171 bp), with the exception of individual
V:5, who is believed to be presymptomatic or nonpenetrant for
cataracts.
plex required for transport-III (ESCRT-III), which facilitates
the biogenesis of multivesicular bodies (MVBs).39 The only
CHMP gene so far implicated in human disease isCHMP2B
(yeast ortholog Vps2/Did4 [MIM 609512]), which has
been reported to harbormutations infrequently associated
with frontotemporal dementia (FTD [MIM 600795]) and
amyotropic lateral sclerosis (ALS [MIM 609512]).41–43
CHMP4B is found diffusely throughout the cytoplasm
and/or in association with endosome-like compartments
when expressed in cultured mammalian cells.44,45 To de-
termine the effect of the p.D129V substitution on the sub-
cellular distribution of CHMP4B, we transfected African
green monkey kidney (COS-7) cells with expression plas-
mids46 encoding either wild-type or mutant forms of
CHMP4B tagged at the N-terminus with the FLAG epitope.
Immunofluorescence microscopy with FLAG antibody re-
vealed that full-length wild-type (FLAG-CHMP4B) and
mutant protein (FLAG-D129V-CHMP4B) were diffusely
distributed (fig. 6A and 6B). At higher expression levels,
both were associated with endosome-like compartments
(data not shown). Overall, there were no notable differ-
ences in the subcellular localization of wild type and
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Table 2. Two-Point LOD Scores (Z) for Linkage between the Cataract Locus and
Markers on Chromosome 20q Listed in Physical Order (Mb) from the Short-Arm
Telomere (p-tel)
Marker
Distance
from p-tel Za at v p
Zmax vmaxcM Mb .00 .05 .10 .20 .30 .40
D20S885 39.9 17.91 !7.79 2.51 2.72 2.35 1.60 .74 2.72 .10
D20S111 49.2 29.94 !2.82 1.14 1.17 .91 .54 .19 1.18 .08
D20S837 50.7 30.73 !.81 4.15 3.98 3.18 2.14 1.01 4.15 .05
rs2057262 31.15 !4.03 !.02 .14 .16 .09 .03 .17 .15
D20S195 50.2 31.29 3.65 4.17 3.88 2.96 1.90 .87 4.20 .03
CHMP4B
(A1T)
31.90 6.24 5.87 5.37 4.19 2.82 1.36 6.24 .00
D20S909 50.7 33.92 1.89 1.88 1.72 1.25 .73 .33 1.91 .02
D20S896 50.2 34.16 2.88 2.60 2.30 1.68 1.05 .46 2.88 .00
D20S870 50.7 34.16 3.11 2.93 2.63 1.94 1.23 .59 3.11 .00
D20S847 50.2 34.32 5.50 5.18 4.72 3.60 2.33 1.05 5.50 .00
rs1291139 34.95 !1.85 .99 1.10 .96 .66 .30 1.10 .11
D20S834 50.7 35.43 !1.08 2.07 1.91 1.30 .65 .19 2.07 .05
D20S607 54.9 38.23 !1.61 1.85 2.02 1.81 1.30 .66 2.03 .11
D20S855 56.0 39.08 !.29 3.26 3.19 2.58 1.71 .77 3.27 .06
NOTE.—STR marker allele frequencies used for linkage analysis were those calculated by Ge´ne´-
thon/Marshfield/deCODE. A gene frequency of .0001 and a penetrance of 95% were assumed for
the disease locus.
a Z values were calculated using the MLINK subprogram from the LINKAGE (5.1) package of
programs.34
Table 3. PCR Primers for Mutation Screening and
Transcript Analysis of CHMP4B
Primer Location Strand Sequence (5′r3′)a
Ex1F Exon 1 Sense gtagtcagtggcgcgttg
Ex1R Intron 1 Antisense aggcgagtctgatgaaggtg
Ex2F Intron 1 Sense cactagaacctcaccctgtgc
Ex2R Intron 2 Antisense aaacaaactcaggtgctcgaa
Ex3F Intron 2 Sense tcacagggagtcattgcaggg
Ex3R Intron 3 Antisense cccaccctggaaaggtgcag
Ex3R2 Intron 3 Antisense agggacagcctcagggtatcattt
Ex4F Intron 3 Sense cacagggtctggaacctggaa
Ex4R Intron 4 Antisense tgggcaagctcaggacacaga
Ex5F1 Intron 4 Sense aacatgttgaacgcaccagtc
Ex5R1 Exon 5 Antisense AGGTCATTTCAACTGCAACCA
Ex5F2 Exon 5 Sense CGCTGACTCCACTGCTGAATCC
Ex5R2 Exon 5 Antisense ctggaaagggtcagctcccg
StartF Exon 1 Sense caccATGTCGGTGTTCGGGAAGCT
EndR Exon 5 Antisense CATGGATCCAGCCCAGTTCTCCAA
A-alleleR Exon 3 Antisense CAGCAATGTCCTGCATTAACTCAT
T-alleleR Exon 3 Antisense CAGCAATGTCCTGCATTAACTCAA
a Noncoding sequence is shown in lowercase, coding sequence
in uppercase.
p.D129V mutant protein. In contrast, similar expression
studies of a splicingmutation inCHMP2B underlying FTD,
which resulted in truncation (36 amino acids) and mis-
coding (29 amino acids) at the C-terminus of the full-
length protein (residues 1–213), has been associated with
redistribution of CHMP2B and the formation of dys-
morphic organelles of the late endosomal pathway.41
The p.D129V missense substitution was predicted to be
located centrally in CHMP4B and to result in the net loss
of a negatively charged residue (fig. 5B). Domain expres-
sion studies have revealed that the N-terminal half of
CHMP4A (MIM 610051), an isoform of CHMP4B, is re-
sponsible for self-association into polymers and binding
to membrane phospholipids.46 To better appreciate the ef-
fects of the p.D129V substitution, we compared the sub-
cellular localization of wild-type and mutant N-terminal
fragments of CHMP4B (residues 1–150) comparable to
those previously studied.46,47 As expected, the distribution
of the truncated wild-type fragment (FLAG-CHMP4B1–150)
differed from that of the full-length wild-type protein; the
former appeared to be in large polymers and sometimes
associated with vacuolar structures (fig. 6C), whereas the
latter was diffuse (fig. 6A). Similarly, the truncatedmutant
fragment (FLAG-D129V-CHMP4B1–150) differed from the
full-length mutant protein; the former was concentrated
on a punctate perinuclear structure (fig. 6D), and the latter
was again diffuse (fig. 6B). Consistently, however, the trun-
cated mutant fragment (fig. 6D) displayed a different sub-
cellular distribution pattern from that of the truncated
wild-type fragment (fig. 6C).
In addition to MVB formation, CHMP4B is thought to
participate in the budding of a number of RNA viruses,
including human immunodeficiency virus type-1 (HIV-1),
from the surface of infected cells.45 To further investigate
the effect of the p.D129V substitution on CHMP4B activ-
ity in a functional assay, we compared the effect of ex-
pressing wild-type and mutant protein on release of HIV-
1 virus-like-particles (VLPs). To monitor VLP production,
human embryonic kidney (HEK 293T) cells were cotrans-
fected with a plasmid encoding the HIV-1Gag polyprotein
(Pr55) and a plasmid encoding wild-type or mutant
CHMP4B. HIV-1 Gag forms VLPs in the absence of other
viral proteins,48 and expression of Gag and CHMP4B
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Figure 3. RT-PCR analysis of CHMP4B transcripts in peripheral
blood leukocytes (PBLs) and eye lens. A, Agarose-gel electropho-
resis showing nested amplification products of CHMP4B transcripts
in PBL RNA from family Sk, confirming that individuals IV:5 and
V:5 are heterozygous for the mutant T allele (413 bp), whereas
individual V:6 is homozygous for the wild-type A allele (676 bp).
PBL RNA was purified using the Versagene kit (Gentra), reverse
transcribed with the iScript cDNA synthesis kit (Bio-Rad), and PCR
amplified as above with three primers (StartF, nested T-alleleR,
and EndR) (table 3). B, Quantitative amplification of CHMP4B tran-
scripts from PBL RNA with allele-specific primers (StartF ! A-
alleleR, or StartF ! T-alleleR) (table 3) showing the relative levels
of wild-type (A allele) and mutant (T allele) transcripts in indi-
viduals IV:5, V:5, and V:6 from family Sk. RT-PCR products were
amplified in a 10-fold dilution series (in triplicate) by use of the
iQ SYBR Green Supermix in an iCycler fitted with a MyiQ single-
color real-time PCR detection system (Bio-Rad). Allele-specific
CHMP4B transcripts were detected by melt-curve analysis and stan-
dardization against control RPL19 transcript, which was amplified
separately in a similar 10-fold dilution series of the same PBL RT-
PCR products by use of RPL19 forward (5′-catccgcaagcctgtgac-3′)
and reverse (5′-gtgaccttctctggcattcg-3′) primers. C, Agarose-gel
electrophoresis showing amplicons containing the entire coding
region (codons 1–224) of CHMP4B transcripts (676 bp) from human
(Hs) lens (∼30 years old), mouse (Mm) lens (postnatal day 6),
and HEK 293 cells. Post mortem human lenses were obtained from
the Lions Eye Bank of Oregon, and RNA was extracted using TRIzol
reagent (Invitrogen). Following euthanasia (CO2 gas), mouse
lenses were dissected into RNAlater tissue preservative, and RNA
was extracted using the RNAqueous kit (Ambion). RNA was ex-
tracted from cultured HEK 293 cells as for mouse lenses. RT-PCR
of lens and HEK 293 RNA was performed as for PBL RNA above,
with use of StartF and EndR primers (table 3), and the resulting
amplicons were verified by sequencing.
Figure 4. Mutation analysis of CHMP4B in the CPP3 family. A,
Sequence trace of the wild-type allele showing translation of glu-
tamic-acid (E) at codon 161 (GAG). B, Sequence trace of the mutant
allele showing the heterozygous c.481GrA transition (denoted R
by the IUPAC code) that is predicted to result in the missense
substitution of lysine (AAG) for glutamate at codon 161 (p.E161K).
C, Restriction-fragment–length analysis showing loss of an Mnl1
site (3′-GGAGN6) that cosegregates only with affected individuals
from the Japanese family31 heterozygous for the c.481GrA trans-
version (103 bp). Exon 3 was amplified with PCR primers (table
3) shown in the schematic diagram and resulting amplicons (326
bp) digested (at 37!C for 1 h) with Mnl1 (5 U; New England
BioLabs). Restriction fragments (175 bp) were visualized on 2%
agarose-EtBr gels.
within cells and release of Gag into the media as VLPs was
detected by immunoblotting (fig. 6E). As expected on the
basis of previous results,49 expression of the truncated
wild-type fragment (FLAG-CHMP4B1–150) inhibited VLP re-
lease. Interestingly, the truncatedmutant fragment (FLAG-
D129V-CHMP4B1–150) was a more potent inhibitor than
truncated wild type allowing release of only 53% " 7%
(average " SD) as much Gag in VLPs. Correspondingly,
the level of Gag expression in cells expressing the mutant
fragment was 1.4 " 0.3 times that of cells expressing the
wild-type fragment. In contrast, neither the wild type nor
the mutant forms of full-length CHMP4B significantly in-
hibited Gag production or VLP release (data not shown).
Precisely how the p.D129V substitution affects the func-
tion of CHMP4B is unclear. In this study, we found that
the p.D129V substitution changed the subcellular distri-
bution and effects of CHMP4B on VLP release when the
protein’s acidic C-terminus was removed. Previous studies
suggest that the acidic C-termini of CHMPs are regulatory
domains that interact specifically with their cognate N-
terminal basic domains in an auto-inhibitory manner.46,
49,50 Thus, it is possible that when CHMP4B is relieved
from auto-inhibition (mimicked here by truncation), the
p.D129V substitution is exposed resulting in deleterious
gain-of-function effects. On the basis of expression anal-
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Figure 5. Gene structure and protein domains of CHMP4B. A, Exon organization and mutation profile of CHMP4B. Intron sizes are
indicated (kb), and codons are numbered above each exon. B, Amino acid sequence of CHMP4B, showing the conserved SNF7 domain
(underlined) of this protein family (Conserved Domain Databse, pfam03357) containing at least four predicted helical domains (grey).
The proposed p.D129V and p.E161K substitutions are predicted to be located in the C-terminal acidic half of the protein, near the start
of adjacent helices within the SNF7 domain. Charged amino acids (!, ") and the translation stop codon (*) are also indicated. C,
Amino acid sequence alignment of human CHMP4B and orthologs from other species, showing phylogenetic conservation of D129 and
E161.
ysis of the N-terminal region of CHMP4A,46 we speculate
that, once unmasked, the p.D129V substitution alters
the polymerization and/or membrane-binding properties
of CHMP4B; however, other mechanisms cannot be
excluded. Further work will be required to understand
how the p.D129V change affects the behavior of intact
CHMP4B. Functional expression studies are also under-
way to determine how the p.E161K substitution affects
CHMP4B. Although little is known about the role of
CHMP proteins in lens development, endosome-like
compartments have been observed in the newborn
mouse lens.51 Further characterization of endosomal path-
ways in the lens should provide insight into the patho-
genetic mechanisms linking CHMP4B dysfunction with
cataractogenesis.
In conclusion, our data identify the first mutations
(p.D129V, p.E161K) in a novel gene (CHMP4B) for inher-
ited cataracts linked to 20q, and they suggest that gain-
of-function defects in an endosome-sorting complex
(ESCRT-III) subunit triggers loss of lens transparency.
Figure 6. Transient expression of CHMP4B in cultured cells. A–D, Subcellular localization of CHMP4B proteins in COS-7 cells, visualized
by immunostaining with FLAG antibody and epifluorescence microscopy. A, Full-length wild-type FLAG-CHMP4B. B, Full-length mutant
FLAG-D129V-CHMP4B. C, Truncated wild-type FLAG-CHMP4B1–150. D, Truncated mutant FLAG-D129V-CHMP4B1–150. For full-length constructs,
the coding sequence (codons 1–224) of human CHMP4B was PCR amplified from HeLa cDNA (Clontech) with forward (5′-gtagatctatgtcggtgt-
tcgggaagctgttcgg-3′) and reverse (5′-cactcgagttacatggatccagcccagttctcc-3′) primers and then subcloned into the BamHI and XhoI re-
striction sites in the poly-linker of pcDNA3.1-FLAG.46 The D129V substitution was generated using the QuickChange mutagenesis kit
(Stratagene). For truncated CHMP4B constructs, amplicons corresponding to codons 1–150 were amplified using the full-length constructs
as templates and were subcloned into pcDNA3.1-FLAG as above. Plasmid DNA was prepared using the QIAprep spin kit (Qiagen), and
inserts were verified by sequencing using the T7 primer. For transient expression, cells were cultured in Dulbecco’s modified Eagle’s
medium (Gibco-BRL) containing 5% fetal bovine serum (Gibco-BRL), 5% supplemented calf serum (Hyclone Laboratories), and 2 mM
glutamine. Cells were transfected with expression plasmids by use of Lipofectamine 2000 reagent (Invitrogen). At 18–24 h after
transfection, COS-7 cells grown on glass cover slips were fixed in 3.5% paraformaldehyde, permeabilized in 0.2% Triton X-100, and
immunostained with rabbit FLAG antibody (Sigma) followed by Alexa Fluor 488 goat anti-rabbit IgG (Molecular Probes). Cell nuclei were
counterstained (blue) with DAPI (4′,6-Diamidino-2-phenylindole [Molecular Probes]). E, Immunoblot analysis of VLPs produced by HEK
293T cells cotransfected with plasmids encoding Gag (p24 antibody) and CHMP4B1–150 (FLAG antibody). Top blot shows Gag recovered
in VLPs, and middle blot shows Gag in cell lysates. Bottom blot shows that the levels of CHMP4B1–150 were similar in cell lysates;
however, the D129V substitution increased the electrophoretic mobility of the mutant fragment on SDS (sodium dodecyl sulfate)
polyacrylamide gels compared with its wild-type counterpart. For VLPs, HEK 293T cells were transfected with 4 mg pCMV55 encoding
HIV Gag, alone or together with 1mg of the indicated CHMP4B construct. At 18–24 h after transfection, media containing VLPs was
harvested and clarified by passing through a 0.45 mm filter. VLPs were pelleted by centrifugation (3 h) through a 20% sucrose cushion
at 26,000 rpm in SW41 Ti rotor (Beckman Coulter). VLPs and cell lysates were resuspended in sodium dodecyl sulfate (SDS) sample
buffer, were separated by SDS-polyacrylamide gel electrophoresis, and then were analyzed by immunoblotting using rabbit antibody
against p24, the capsid domain of HIV Gag, horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG, and the SuperSignal West
Pico chemiluminescence detection kit (Pierce). Immunoblot signals were quantified using the Odyssey Infrared Imaging System (Li-Cor
Bioscience).
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Appendix 2 
 
List of plasmids 
 
Name of plasmid  Key word Expression type
Antibioti
cs
Orignal DNA Source Primers (Fwd/Rev) Restriction enzyme (5'/3') backbone vector
pET11a Alix 1-716 Alix bacterial Amp Sundquist lab N/A N/A pET11a
pET11a Alix 1-868 Alix bacterial Amp Sundquist lab N/A N/A pET11a
pET11a Alix 1-876 Alix bacterial Amp Sundquist lab N/A N/A pET11a
pCI FLAG Alix 1-868 Alix mammalian Amp Sundquist lab N/A N/A pCI
pCI FLAG Alix 1-868 Alix mammalian Amp Sundquist lab N/A N/A pCI
AMSH GFP AMSH mammalian Kan Stahl Lab N/A N/A N/A
pGEX CHMP1B 106-136 CHMP1B bacterial Amp Cloned by SS PHA903/PHA899 BamHI/XhoI pGEX 4T1
pGEX CHMP1B 106-168  CHMP1B bacterial Amp Cloned by SS PHA903/PHA900 BamHI/XhoI pGEX 4T1
pGEX CHMP1B 106-181 CHMP1B bacterial Amp Cloned by SS PHA903/PHA901 BamHI/XhoI pGEX 4T1
pGEX CHMP1B 106-199 (C-term half) CHMP1B bacterial Amp Cloned by SS PHA903/PHA820 BamHI/XhoI pGEX 4T1
pGEX CHMP1B 1-168 CHMP1B bacterial Amp Cloned by SS PHA898/PHA900 BamHI/XhoI pGEX 4T1
pGEX CHMP1B 1-181 CHMP1B bacterial Amp Cloned by SS PHA898/PHA901 BamHI/XhoI pGEX 4T1
pcDNA3.1 FLAG CHMP1B CHMP1B mammalian Amp Cloned by SS PHA819/PHA820 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG CHMP1B 1-105 CHMP1B mammalian Amp Cloned by SS PHA898/PHA902 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG CHMP1B 1-136 CHMP1B mammalian Amp Cloned by SS PHA898/PHA899 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG CHMP1B 1-168 CHMP1B mammalian Amp Cloned by SS PHA898/PHA900 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG CHMP1B 1-181 CHMP1B mammalian Amp Cloned by SS PHA898/PHA901 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG CHMP1B 1-181 DE158,159AA CHMP1B mammalian Amp Quickchanged by TN/SS PHA928/PHA929 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG CHMP1B FL DE158,159AA CHMP1B mammalian Amp Quickchanged by TN/SS PHA928/PHA929 BamHI/XhoI pcDNA3.1 FLAG
pcDNA4TO CHMP1B myc CHMP1B mammalian Amp Cloned by SS PHA819/PHA886 BamHI/XhoI pcDNA4TO myc
pcDNA4TO Vps2-1(CHMP2A) 1-206 myc CHMP2A bacterial Amp Cloned by SS PHA802/PHA836 BamHI/XhoI pGEX 4T1
pET28a Vps2-1(CHMP2A) 1-144 CHMP2A bacterial Kan Cloned by SS cut and paste BamHI/XhoI pET28a
pET28a Vps2-1(CHMP2A) 1-180 CHMP2A bacterial Kan Cloned by SS cut and paste BamHI/XhoI pET28a
pET28a Vps2-1(CHMP2A) FL CHMP2A bacterial Kan Cloned by SS PHA802/PHA792 BamHI/XhoI pET28a
pGEX Vps2-1(CHMP2A) 1-144 CHMP2A bacterial Amp Cloned by SS cut and paste BamHI/XhoI pGEX 4T1
pGEX Vps2-1(CHMP2A) 1-144 CHMP2A bacterial Amp Cloned by SS cut and paste BamHI/XhoI pGEX 4T1
pGEX Vps2-1(CHMP2A) 1-180 CHMP2A bacterial Amp Cloned by SS cut and paste BamHI/XhoI pGEX 4T1
pGEX Vps2-1(CHMP2A) 1-193 CHMP2A bacterial Amp Cloned by SS PHA802/PHA833 BamHI/XhoI pGEX 4T1
pGEX Vps2-1(CHMP2A) 1-203 CHMP2A bacterial Amp Cloned by SS PHA802/PHA851 BamHI/XhoI pGEX 4T1
pGEX Vps2-1(CHMP2A) 1-206 CHMP2A bacterial Amp Cloned by SS PHA802/PHA837 BamHI/XhoI pcDNA3.1 FLAG
pGEX Vps2-1(CHMP2A) 1-216 CHMP2A bacterial Amp Cloned by SS PHA802/PHA852 BamHI/XhoI pGEX 4T1
pGEX Vps2-1(CHMP2A) 1-219 CHMP2A bacterial Amp Cloned by SS PHA802/PHA837 BamHI/XhoI pGEX 4T1
pGEX Vps2-1(CHMP2A) 56-144 CHMP2A bacterial Amp Cloned by SS PHA791/ PHA792 BamHI/XhoI pGEX 4T1
pGEX Vps2-1(CHMP2A) 56-180 CHMP2A bacterial Amp Cloned by SS PHA791/ PHA772 BamHI/XhoI pGEX 4T1
pGEX Vps2-1(CHMP2A) 56-222 CHMP2A bacterial Amp Cloned by SS PHA791/ PHA773 BamHI/XhoI pGEX 4T1
pGEX Vps2-1(CHMP2A) C-half (117-222) CHMP2A bacterial Amp Cloned by SS PHA792/PHA904 BamHI/XhoI pGEX 4T1
pGEX Vps2-1(CHMP2A) FL CHMP2A bacterial Amp Cloned by SS cut and paste BamHI/XhoI pGEX 4T1
pGEX Vps2-1(CHMP2A) L216A CHMP2A bacterial Amp Cloned by SS PHA802/PHA792 BamHI/XhoI pGEX 4T1
pGEX Vps2-1(CHMP2A) S203A CHMP2A bacterial Amp Cloned by SS PHA802/PHA792 BamHI/XhoI pGEX 4T1
Lenti CHMP2A shRNA C6 CHMP2A mammalian Amp TRC1 N/A N/A pLKO
Lenti CHMP2A shRNA C8 CHMP2A mammalian Amp TRC1 N/A N/A pLKO
pcDNA3.1 FLAG Vps2-1(CHMP2A) C-half (117-222) CHMP2A mammalian Amp Cloned by SS PHA792/PHA904 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG Vps2-1(CHMP2A) 1-116 CHMP2A mammalian Amp Cloned by SS PHA730/PHA771 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG Vps2-1(CHMP2A) 1-144 CHMP2A mammalian Amp Cloned by SS PHA730/PHA772 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG Vps2-1(CHMP2A) 1-180 CHMP2A mammalian Amp Cloned by SS PHA730/PHA773 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG Vps2-1(CHMP2A) 1-193 CHMP2A mammalian Amp Cloned by SS PHA802/PHA833 BamHI/XhoI pGEX 4T1
pcDNA3.1 FLAG Vps2-1(CHMP2A) 1-206 CHMP2A mammalian Amp Cloned by SS PHA802/PHA835 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG Vps2-1(CHMP2A) 1-206 DE153,154AACHMP2A mammalian Amp Quickchanged by TN/SS PHA930/PHA931 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG Vps2-1(CHMP2A) 1-206 DE169,170 AACHMP2A mammalian Amp Quickchanged by SS PHA825/PHA826 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG Vps2-1(CHMP2A) 1-206 DE177,178AA CHMP2A mammalian Amp Quickchanged by TN/SS PHA932/PHA933 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG Vps2-1(CHMP2A) 1-219 CHMP2A mammalian Amp Cloned by SS PHA802/PHA837 BamHI/XhoI pcDNA3.1 FLAG
pcDNA31. FLAG Vps2-1(CHMP2A) 56-180 CHMP2A mammalian Amp Cloned by SS PHA791/PHA773 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG Vps2-1(CHMP2A) 56-203 CHMP2A mammalian Amp Cloned by SS PHA791/PHA851 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG Vps2-1(CHMP2A) 56-222 CHMP2A mammalian Amp Cloned by SS PHA791/PHA792 BamHI/XhoI pcDNA4TO myc
pcDNA3.1 FLAG Vps2-1(CHMP2A) FL CHMP2A mammalian Amp Cloned by SS cut and paste BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG Vps2-1(CHMP2A) FL DE169,170 AA CHMP2A mammalian Amp Quickchanged by SS PHA825/PHA826 BamHI/XhoI pcDNA3.1 FLAG
pcDNA4TO FLAG Vps2-1(CHMP2A) 1-180 CHMP2A mammalian Amp cloned by SS cut and paste HindIII-FLAG-BamHI-cDNA-XhoI pcDNA4TO
pcDNA4TO FLAG Vps2-1(CHMP2A) FL CHMP2A mammalian Amp cloned by SS cut and paste HindIII-FLAG-BamHI-cDNA-XhoI pcDNA4TO
pcDNA4TO N-myc CHMP2A 1-180 CHMP2A mammalian Amp Cloned by SS cut and paste BamHI/XhoI pcDNA4TO N-myc
pcDNA4TO N-myc CHMP2A FL CHMP2A mammalian Amp Cloned by SS cut and paste BamHI/XhoI pcDNA4TO N-myc
pcDNA4TO Vps2-1(CHMP2A)  myc 1-144 CHMP2A mammalian Amp Cloned by SS PHA802/PHA804 BamHI/XhoI pcDNA4 TO myc
pcDNA4TO Vps2-1(CHMP2A)  myc 1-180 CHMP2A mammalian Amp Cloned by SS PHA802/PHA803 BamHI/XhoI pcDNA4 TO myc
pcDNA4TO Vps2-1(CHMP2A) myc FL CHMP2A mammalian Amp Cloned by SS PHA802/PHA793 BamHI/XhoI pcDNA4 TO myc
pcDNA4TO Vps2-1(CHMP2A) myc FL(DE169,170AA) CHMP2A mammalian Amp Quickchanged by TN/SS PHA825/PHA826 BamHI/XhoI pcDNA4 TO myc
pcDNA4TO Vps2-1(CHMP2A) myc FL(L216A) CHMP2A mammalian Amp Quickchanged by TN/SS PHA831/PHA832 BamHI/XhoI pcDNA4 TO myc
pcDNA4TO Vps2-1(CHMP2A) myc FL(S203A) CHMP2A mammalian Amp Quickchanged by TN/SS PHA827/PHA828 BamHI/XhoI pcDNA4 TO myc
pcDNA4TO Vps2-1(CHMP2A) myc FL(S203D) CHMP2A mammalian Amp Quickchanged by TN/SS PHA829/PHA830 BamHI/XhoI pcDNA4 TO myc
pCR blunt Vps2-1(CHMP2A) FL CHMP2A mammalian N/A Cloned by LK N/A N/A pCR blunt
Lenti CHMP2B shRNA C2 CHMP2B mammalian Amp TRC1 N/A N/A pLKO
Lenti CHMP2B shRNA C4 CHMP2B mammalian Amp TRC1 N/A N/A pLKO
pcDNA3.1 FLAG CHMP2B CHMP2B mammalian Amp Cloned by SS PHA950/PHA951 EcoRV/XhoI pcDNA3.1 FLAG
pcDNA4TO CHMP2B myc CHMP2B mammalian Amp Cloned by SS PHA944/PHA945 Blunt (BamHI-BglI)/XhoI pcDNA4TO myc
pcDNA4TO N-myc CHMP2B 1-179 CHMP2B mammalian Amp Cloned by SS cut and paste BamHI/XhoI pcDNA4TO N-myc
pcDNA4TO N-myc CHMP2B FL CHMP2B mammalian Amp Cloned by SS cut and paste Blunt (BamHI-BglI)/XhoI pcDNA4TO N-myc
pcDNA4TO N-myc CHMP2B intron5 CHMP2B mammalian Amp Cloned by SS cut and paste BamHI/XhoI pcDNA4TO N-myc
pET28a hVps24(CHMP3) FL (with PCR mutations) CHMP3 bacterial Kan Cloned before 2005 N/A N/A pET28a
pGEX Vps24(CHMP3) FL (mutations corrected) CHMP3 bacterial Amp Cloned by SS PHA805/PHA806 BamHI/XhoI pGEX 4T1
pGEX hVps24(CHMP3) FL (with PCR mutations) CHMP3 bacterial Amp Cloned before 2005 N/A N/A pGEX 4T1
hVps24(CHMP3)-GFP CHMP3 mammalian Kan Cloned before 2005 N/A N/A N/A
hVps24(CHMP3)-GFP N half CHMP3 mammalian Kan Cloned before 2005 N/A N/A N/A
hVps24(CHMP3)-myc (PCR mutations) CHMP3 mammalian Amp Cloned before 2005 N/A N/A N/A
Lenti CHMP3 shRNA D4 CHMP3 mammalian Amp TRC1 N/A N/A pLKO
pcDNA3.1 hVps24(CHMP3) myc FL (G149E) CHMP3 mammalian Amp Quickchanged by TN/SS PHA798/PHA799 HindIII/XbaI pcDNA3.1(-) myc his 
pcDNA3.1 hVps24(CHMP3) myc FL (WT, no mutations)CHMP3 mammalian Amp Quickchanged by TN/SS PHA800/PHA801 XhoI/BamHI pcDNA3.1(-) myc his 
pcDNA4TO hVps24(CHMP3) myc 1-119 CHMP3 mammalian Amp Cloned by TN/SS PHA774/PHA775 BamHI/XhoI pcDNA4 TO myc 
pcDNA4TO hVps24(CHMP3) myc 1-150 CHMP3 mammalian Amp Cloned by TN/SS PHA774/PHA776 BamHI/XhoI pcDNA4 TO myc
pcDNA4TO hVps24(CHMP3) myc 1-178(WT; G149E) CHMP3 mammalian Amp Quickchanged by TN/SS PHA798/PHA799 BamHI/XhoI pcDNA4 TO myc
pET28a hSnf7-1(CHMP4A) FL CHMP4A bacterial Kan Cloned before 2005 N/A N/A pET28a
pET28a hSnf7-1(CHMP4A) C half CHMP4A bacterial Kan Cloned before 2005 N/A N/A pET28a
pET28a hSnf7-1(CHMP4A) N half CHMP4A bacterial Kan Cloned before 2005 N/A N/A pET28a
pGEX hSnf7-1(CHMP4A) FL CHMP4A bacterial Amp Cloned before 2005 N/A N/A pGEX 4T1
pGEX hSnf7-1(CHMP4A) C half CHMP4A bacterial Amp Cloned before 2005 N/A N/A pGEX 4T1
pGEX hSnf7-1(CHMP4A) N half CHMP4A bacterial Amp Cloned before 2005 N/A N/A pGEX 4T1
pGEX Snf7-1(CHMP4A) 60-147 CHMP4A bacterial Amp Cloned by SS cut and paste BamHI/XhoI pGEX 4T1
pGEX Snf7-1(CHMP4A) 60-181 CHMP4A bacterial Amp Cloned by SS cut and paste BamHI/XhoI pGEX 4T1
pGEX Snf7-1(CHMP4A) 60-222 CHMP4A bacterial Amp Cloned by SS cut and paste BamHI/XhoI pGEX 4T1
hSnf7-1(CHMP4A)  N half monoGFP CHMP4A mammalian N/A Cloned before 2005 N/A N/A N/A
hSnf7-1(CHMP4A) monoGFP CHMP4A mammalian N/A Cloned before 2005 N/A N/A N/A
hSnf7-1(CHMP4A) myc CHMP4A mammalian N/A Cloned before 2005 N/A N/A N/A
hSnf7-1(CHMP4A) myc CHMP4A mammalian N/A Cloned before 2005 N/A N/A N/A
hSnf7-1(CHMP4A) no Tag CHMP4A mammalian N/A Cloned before 2005 N/A N/A N/A
hSnf7-1(CHMP4A) no Tag CHMP4A mammalian N/A Cloned before 2005 N/A N/A N/A
hSnf7-1(CHMP4A)-GFP CHMP4A mammalian N/A Cloned before 2005 N/A N/A N/A
hSnf7-1(CHMP4A)-monoGFP CHMP4A mammalian N/A Cloned before 2005 N/A N/A N/A
pCAF FLAG hSnf7-1(CHMP4A) CHMP4A mammalian N/A N/A N/A N/A N/A
pcDNA 3.1 FLAG Snf7-1(CHMP4A) 1-147 CHMP4A mammalian Amp Cloned by SS PHA289/PHA711 BamHI/XhoI pcDNA3.1 FLAG
pcDNA 3.1 FLAG Snf7-1(CHMP4A) 1-181 CHMP4A mammalian Amp Cloned by SS PHA289/PHA712 BamHI/XhoI pcDNA3.1 FLAG
pcDNA 3.1 FLAG Snf7-1(CHMP4A) 1-209 CHMP4A mammalian Amp Cloned by SS PHA289/PHA713 BamHI/XhoI pcDNA3.1 FLAG
pcDNA 3.1 FLAG Snf7-1(CHMP4A) 1-48 CHMP4A mammalian Amp Cloned by SS PHA289/PHA708 BamHI/XhoI pcDNA3.1 FLAG
pcDNA 3.1 FLAG Snf7-1(CHMP4A) 1-58 CHMP4A mammalian Amp Cloned by SS PHA289/PHA709 BamHI/XhoI pcDNA3.1 FLAG
pcDNA 3.1 FLAG Snf7-1(CHMP4A) 1-80 CHMP4A mammalian Amp Cloned by SS PHA289/PHA710 BamHI/XhoI pcDNA3.1 FLAG
pcDNA 3.1 FLAG Snf7-1(CHMP4A) 20-116 CHMP4A mammalian Amp Cloned by SS PHA714/PHA634 BamHI/XhoI pcDNA3.1 FLAG
pcDNA 3.1 FLAG Snf7-1(CHMP4A) 20-147 CHMP4A mammalian Amp Cloned by SS PHA714/PHA711 BamHI/XhoI pcDNA3.1 FLAG
pcDNA 3.1 FLAG Snf7-1(CHMP4A) 20-181 CHMP4A mammalian Amp Cloned by SS PHA714/PHA712 BamHI/XhoI pcDNA3.1 FLAG
pcDNA 3.1 FLAG Snf7-1(CHMP4A) 20-222 CHMP4A mammalian Amp Cloned by SS PHA714/PHA290 BamHI/XhoI pcDNA3.1 FLAG
pcDNA 3.1 FLAG Snf7-1(CHMP4A) 60-116 CHMP4A mammalian Amp Cloned by SS PHA715/PHA634 BamHI/XhoI pcDNA3.1 FLAG
pcDNA 3.1 FLAG Snf7-1(CHMP4A) 60-147 CHMP4A mammalian Amp Cloned by SS PHA715/PHA711 BamHI/XhoI pcDNA3.1 FLAG
pcDNA 3.1 FLAG Snf7-1(CHMP4A) 60-181 CHMP4A mammalian Amp Cloned by SS PHA715/PHA712 BamHI/XhoI pcDNA3.1 FLAG
pcDNA 3.1 FLAG Snf7-1(CHMP4A) 60-222 CHMP4A mammalian Amp Cloned by SS PHA715/PHA290 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG hSnf7-1(CHMP4A) CHMP4A mammalian Amp Cloned before 2005 N/A N/A pcDNA3.1 FLAG
pcDNA3.1 FLAG hSnf7-1(CHMP4A) C half CHMP4A mammalian Amp Cloned before 2005 N/A N/A pcDNA3.1 FLAG
pcDNA3.1 FLAG hSnf7-1(CHMP4A) C half CHMP4A mammalian Amp Hanson lab N/A BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG hSnf7-1(CHMP4A) D126V CHMP4A mammalian Amp Quickchanged by SS PHA778/PHA781 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG hSnf7-1(CHMP4A) D126V 1-147 CHMP4A mammalian Amp Quickchanged by SS PHA778/PHA781 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG hSnf7-1(CHMP4A) FL CHMP4A mammalian Amp Cloned before 2005 N/A N/A pcDNA3.1 FLAG
pcDNA3.1 FLAG hSnf7-1(CHMP4A) N(S2C) CHMP4A mammalian Amp Cloned before 2005 N/A BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG hSnf7-1(CHMP4A) N(WT) CHMP4A mammalian Amp Quickchange by LK N/A BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG Snf7-1(CHMP4A) EE177,178AA CHMP4A mammalian Amp Quickchanged by TN/SS N/A BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 hSnf7-1(CHMP4A) myc-his D126V CHMP4A mammalian Amp Quickchanged by SS PHA778/PHA781 HindIII/XbaI pcDNA3.1(-) myc his
pcDNA3.1 N-myc hSnf7-1(CHMP4A) 1-181 CHMP4A mammalian Amp Cloned by SS cut and paste BamHI/XhoI pcDNA3.1 N-myc
pcDNA3.1 N-myc hSnf7-1(CHMP4A) 1-209 CHMP4A mammalian Amp Cloned by SS cut and paste BamHI/XhoI pcDNA3.1 N-myc
pcDNA3.1 N-myc hSnf7-1(CHMP4A) 20-222 CHMP4A mammalian Amp Cloned by SS cut and paste BamHI/XhoI pcDNA3.1 N-myc
pcDNA4TO N-myc hSnf7-1(CHMP4A) 1-181 CHMP4A mammalian Amp cloned by SS cut and paste HindIII-Myc-BamHI-cDNA-XhoI pcDNA4TO 
pcDNA4TO N-myc Snf7-1(CHMP4A) FL CHMP4A mammalian Amp cloned by SS cut and paste BamHI/XhoI pcDNA4TO N-myc
pcDNA3.1 FLAG hSnf7-2(CHMP4B) 1-150 CHMP4B mammalian Amp Cloned by SS PHA789/PHA790 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG hSnf7-2(CHMP4B) 1-150 CHMP4B mammalian Amp Cloned by SS PHA789/PHA790 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG hSnf7-2(CHMP4B) 1-185 DV CHMP4B mammalian Amp Cloned by SS PHA789/PHA797 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG hSnf7-2(CHMP4B) 1-185 WT CHMP4B mammalian Amp Cloned by SS PHA789/PHA797 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG hSnf7-2(CHMP4B) D129V CHMP4B mammalian Amp Quickchanged by SS PHA779/PHA782 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG hSnf7-2(CHMP4B) D129V 1-150 CHMP4B mammalian Amp Cloned by SS PHA789/PHA790 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG hSnf7-2(CHMP4B) D129V 1-150 CHMP4B mammalian Amp Cloned by SS PHA789/PHA790 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG hSnf7-2(CHMP4B) FL CHMP4B mammalian Amp Cloned before 2005 N/A N/A pcDNA3.1 FLAG
pCAF FLAG hSnf7-3(CHMP4C) CHMP4C mammalian N/A Cloned before 2005 N/A N/A pCAF FLAG
pGEX CHMP5 121-149 CHMP5 bacterial Amp Cloned by SS PHA870/PHA896 BamHI/XhoI pGEX 4T1
pGEX CHMP5 121-149 CHMP5 bacterial Amp Cloned by SS PHA870/PHA896 BamHI/XhoI pGEX 4T1
pGEX CHMP5 121-158 CHMP5 bacterial Amp Cloned by SS PHA870/PHA897 BamHI/XhoI pGEX 4T1
pGEX CHMP5 121-175 CHMP5 bacterial Amp Cloned by SS PHA870/PHA877 BamHI/XhoI pGEX 4T1
pGEX CHMP5 121-175 CHMP5 bacterial Amp Cloned by SS PHA870/PHA896 BamHI/XhoI pGEX 4T1
pGEX CHMP5 121-175 CHMP5 bacterial Amp Cloned by SS PHA870/PHA896 BamHI/XhoI pGEX 4T1
pGEX CHMP5 121-205 CHMP5 bacterial Amp Cloned by SS PHA870/PHA878 BamHI/XhoI pGEX 4T1
pGEX CHMP5 149-175 CHMP5 bacterial Amp Cloned by SS PHA905/PHA907 BamHI/XhoI pGEX 4T1
pGEX CHMP5 149-183 CHMP5 bacterial Amp Cloned by SS PHA905/PHA908 BamHI/XhoI pGEX 4T1
pcDNA3 mouse CHMP5-FLAG CHMP5 mammalian Amp Ghosh Lab N/A HindIII-cDNA-KpnI-FLAG-XhoI pcDNA3
pcDNA3.1 FLAG CHMP5 1-175 CHMP5 mammalian Amp Cloned by SS PHA817/PHA876 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG CHMP5 1-205 CHMP5 mammalian Amp Cloned by SS PHA817/PHA878 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG CHMP5 149-175 CHMP5 mammalian Amp Cloned by SS PHA905/PHA907 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG CHMP5 149-183 CHMP5 mammalian Amp Cloned by SS PHA905/PHA908 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 FLAG CHMP5 FL CHMP5 mammalian Amp Cloned by SS PHA817/PHA818 BamHI/XhoI pcDNA3.1 FLAG
pcDNA3.1 N-Myc CHMP5 121-149 CHMP5 mammalian Amp Cloned by SS PHA870/PHA896 BamHI/XhoI pcDNA3.1 N-myc
pcDNA3.1 N-Myc CHMP5 149-175 CHMP5 mammalian Amp Cloned by SS PHA905/PHA907 BamHI/XhoI pcDNA3.1 N-myc
pcDNA3.1 N-Myc CHMP5 149-183 CHMP5 mammalian Amp Cloned by SS PHA905/PHA908 BamHI/XhoI pcDNA3.1 N-myc
pcDNA4TO CHMP5 1-205 myc CHMP5 mammalian Amp Cloned by SS PHA817/PHA879 BamHI/XhoI pcDNA4TO myc
pcDNA4TO CHMP5 FL myc CHMP5 mammalian Amp Cloned by SS PHA817/PHA857 BamHI/XhoI pcDNA4TO myc
pGEX Vps20(CHMP6) CHMP6 bacterial Amp Cloned by SS PHA808/PHA809 EcoRIXhoI pGEX 4T1
pGEX Vps20(CHMP6) CHMP6 bacterial Amp Cloned by SS PHA808/PHA809 EcoRIXhoI pGEX 4T1
pcDNA4TO hVps20(CHMP6)-myc-his CHMP6 mammalian Amp Cloned by LK N/A N/A pcDNA4TO myc
pcDNA4TO hVps20(CHMP6)-myc-his 1-115 CHMP6 mammalian Amp Cloned by LK N/A N/A pcDNA4TO myc
pcDNA4TO hVps20(CHMP6)-myc-his 1-147 CHMP6 mammalian Amp Cloned by LK N/A N/A pcDNA4TO myc
pcDNA4TO hVps20(CHMP6)-myc-his 1-167 CHMP6 mammalian Amp Cloned by LK N/A N/A pcDNA4TO myc
pcDNA4TO Vps20(CHMP6) no tag T55S CHMP6 mammalian Amp Cloned by LK N/A N/A pcDNA4TO myc
pcDNA-Vps20(CHMP6)-myc (deltaQ26) CHMP6 mammalian Amp Burbelo lab N/A N/A pcDNA4TO myc
Clathrin-GFP clathrin mammalian N/A N/A N/A N/A pcDNA4TO myc
pcDNA3 FLAG-DOR 0K-HA (all lysine mutated) DOR mammalian Amp von Zastrow lab N/A N/A pcDNA3
pcDNA3 FLAG-DOR-HA DOR mammalian Amp von Zastrow lab N/A N/A pcDNA3
pcDNA3.0 FLAG-DOR DOR mammalian Amp von Zastrow lab N/A N/A pcDNA3.0
pEGFP N1 FLAG-DOR (FLAG-DOR-GFP) DOR mammalian Kan cloned by SS cut and paste HindIII/blunt (EcoRV-SmaI) pEGFP N1
pcDNA4TO EGFR-GFP EGFR mammalian Amp cloned by SS cut and paste Blunt/NotI pcDNA4/TO myc
pN1 EGFP-EGFR(EGFR-GFP) EGFR mammalian Kan From Pike lab N/A N/A pN1 EGFP
pCMV M1-10 (GAG) Gag mammalian Amp Ratner lab N/A N/A N/A
Hrs V5 His pcDNA Hrs mammalian Amp From Stahl Lab N/A N/A N/A
pSPORT6 human Ist1 Ist1 mammalian Amp purchased from ATCC N/A N/A pSPORT6
Lenti LacZ shRNA A4 LacZ mammalian Amp TRC1 N/A N/A pLKO
LC3-GFP LC3 mammalian Kan Weihl Lab N/A N/A N/A
pCMV 8.2 delta R (Lenti-packaging) Lenti mammalian Amp Stewart Lab N/A N/A pCMV
pCMV VSV-G Lenti mammalian Amp Stewart Lab N/A N/A pCMV
pRRL-GFP (Lenti-GFP) Lenti mammalian Amp Stewart Lab N/A N/A pRRL
pET16b LIP5 LIP5 bacterial Amp Kaplan Lab N/A BamHI/XhoI pET16b
pET28a LIP5 LIP5 bacterial Kan Cloned by SS N/A NdeI-XhoI/BamHI pET28a
Lenti LIP5 shRNA B10 LIP5 mammalian Amp TRC1 N/A N/A pLKO
Lenti LIP5 shRNA B9 LIP5 mammalian Amp TRC1 N/A N/A pLKO
Lenti LIP5 shRNA E10 LIP5 mammalian Amp TRC1 N/A N/A pLKO
pEGFP C1- LIP5 LIP5 mammalian Kan Kaplan Lab N/A BglII/KpnI pEGFP C1
pEGFP C1 LIP5 K148A LIP5 mammalian Kan Quickchanged by SS PHA942/PHA943 KpnI/BamHI pEGFP C1
pEGFP C1 LIP5 M64A LIP5 mammalian Kan Quickchanged by SS PHA940/PHA941 KpnI/BamHI pEGFP C1
pEGP C1 LIP5 delta C LIP5 mammalian Kan Cloned by SS PHA855/PHA856 BglII/HindIII pEGFP C1
pEGFP C1 Rab5 Q79L Rab5 mammalian Kan Stahl Lab N/A HindIII/XhoI pEGFP C1
STAM PM1WHA STAM mammalian N/A Stahl Lab N/A N/A N/A
Lenti Tsg101 shRNA A10 Tsg101 mammalian Amp TRC1 N/A N/A pLKO
Lenti Tsg101 shRNA A9 Tsg101 mammalian Amp TRC1 N/A N/A pLKO
pLLEXP Tsg101 FLAG -WT Tsg101 mammalian N/A Cohen lab N/A N/A pLLEXP
UBPY GFP UBPY mammalian Kan Stahl Lab N/A N/A N/A
pET28a vector bacterial Kan Hanson lab N/A N/A pET28a
pBS SK+ vector mammalian N/A Hanson Lab N/A N/A pBS SK+
pcDNA3.1 FLAG3NK3B (vector + insert) vector mammalian Amp Kornfeld Lab N/A N/A pcDNA3.1 FLAG
pcDNA3.1 Zeo (+) vector mammalian Amp Hanson Lab N/A N/A pcDNA3.1
pcDNA4TO-myc-his A vector mammalian Amp Hanson lab N/A N/A pcDNA4/TO myc
pEGFP N1 vector mammalian Kan Hanson lab N/A N/A pN1 EGFP
pEGFP C1 Vps4A VPA4A mammalian Kan Sundquist lab N/A EcoRI/BamHI pEGFP C1
pEGFP C1 VPS4A E258A VPS4A mammalian Kan Quickchanged by TN/SS PHA954/PHA955 EcoRI/BamHI pEGFP C1
pEGFP C1 VPS4A E228Q VPS4A mammalian Kan Quickchanged by TN/SS PHA823/PHA924 EcoRI/BamHI pEGFP C1
pEGFP C1 VPS4A L202A VPS4A mammalian Kan Quickchanged by TN/SS PHA952/PHA953 EcoRI/BamHI pEGFP C1
pEGFP C1 VPS4A R254A VPS4A mammalian Kan Quickchanged by TN/SS PHA927/PHA973 EcoRI/BamHI pEGFP C1
pEGFP C1 VPS4A E228Q, E258A VPS4A mammalian Kan Quickchanged by TN/SS PHA954/PHA955 EcoRI/BamHI pEGFP C1
pEGFP C1 VPS4A E228Q, L202A VPS4A mammalian Kan Quickchanged by TN/SS PHA952/PHA953 EcoRI/BamHI pEGFP C1
pEGFP C1 VPS4A E228Q, R254A VPS4A mammalian Kan Quickchanged by TN/SS PHA927/PHA973 EcoRI/BamHI pEGFP C1
pGEX VPS4B/SKD1EQ VPS4B bacterial Amp Cloned by SS N/A BamHI/XhoI pGEX 4T1
pGEX VPS4B/SKD1WT VPS4B bacterial Amp Cloned by SS N/A BamHI/XhoI pGEX 4T1
pHO 2d VPS4B/SKD1 WT VPS4B bacterial Amp Cloned before 2005 N/A NcoI/EcoRI pHO 2d
PHO 4d VPS4B/SKD1 EQ VPS4B bacterial Amp Cloned by SS N/A NcoI/EcoRI pHO 4d
pHO 4d VPS4B/SKD1 WT VPS4B bacterial Amp Cloned by SS N/A NcoI/EcoRI pHO 4d
pcDNA4 TO VPS4B/SKD1 EQ myc-his VPS4B mammalian Amp Cloned before 2005 N/A N/A pcDNA4TO myc
pcDNA4 TO VPS4B/SKD1 WT myc-his VPS4B mammalian Amp Cloned before 2005 N/A N/A pcDNA4TO myc
pcDNA4TO VPS4B/SKD1 EQ-GFP VPS4B mammalian Amp Cloned before 2005 N/A N/A pcDNA4TO
pcDNA4TO VPS4B/SKD1 WT-GFP VPS4B mammalian Amp Cloned before 2005 N/A N/A pcDNA4TO
pEGFP N1 VPS4B/SKD1 EQ VPS4B mammalian Kan Cloned before 2005 N/A N/A pEGFP N1
pEGFP N1 VPS4B/SKD1 WT VPS4B mammalian Kan Cloned before 2005 N/A N/A pEGFP N1
VPS4B/SKD1 EQ momeric GFP VPS4B mammalian Kan Quickchanged by LK N/A N/A N/A
VPS4B/SKD1 WT momeric GFP VPS4B mammalian Kan Quickchanged by LK N/A N/A N/A
N/A : information is not available
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